Palliative radiotherapy combined with stent insertion to reduce recurrent dysphagia in oesophageal cancer patients: the ROCS RCT by Adamson, Douglas et al.
                          Adamson, D., Blazeby, J. M., Porter, C., Hurt, C., Griffiths, G., Nelson,
A., Sewell, B., Jones, M., Svobodova, M., Fitzsimmons, D., Nixon, L.,
Fitzgibbon, J., Thomas, S., Millin, T., Crosby, T., Staffurth, J., & Byrne,
A. (2021). Palliative radiotherapy combined with stent insertion to
reduce recurrent dysphagia in oesophageal cancer patients: the
ROCS RCT. Health Technology Assessment, 25(31), 1-144.
https://doi.org/10.3310/hta25310
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.3310/hta25310
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via NIHR Journals
Library at 10.3310/hta25310. Please refer to any applicable terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the




Palliative radiotherapy combined with 
stent insertion to reduce recurrent 
dysphagia in oesophageal cancer 
patients: the ROCS RCT 
Douglas Adamson, Jane Blazeby, Catharine Porter, Christopher Hurt,  
Gareth Griffiths, Annmarie Nelson, Bernadette Sewell, Mari Jones,  
Martina Svobodova, Deborah Fitzsimmons, Lisette Nixon, Jim Fitzgibbon,  
Stephen Thomas, Anthony Millin, Tom Crosby, John Staffurth and Anthony Byrne
Health Technology Assessment
Volume 25 • Issue 31 • May 2021
ISSN 1366-5278

Palliative radiotherapy combined with stent
insertion to reduce recurrent dysphagia in
oesophageal cancer patients: the ROCS RCT
Douglas Adamson ,1 Jane Blazeby ,2
Catharine Porter ,3 Christopher Hurt ,3
Gareth Griffiths ,4 Annmarie Nelson ,5
Bernadette Sewell ,6 Mari Jones ,6
Martina Svobodova ,3 Deborah Fitzsimmons ,6
Lisette Nixon ,3 Jim Fitzgibbon ,7 Stephen Thomas ,7
Anthony Millin ,8 Tom Crosby ,8 John Staffurth 8
and Anthony Byrne 5,8*
1Tayside Cancer Centre, Ninewells Hospital, NHS Tayside, Dundee, UK
2Bristol Centre for Surgical Research, NIHR Bristol and Weston Biomedical Research
Centre, Bristol University, Bristol, UK
3Centre for Trials Research, Cardiff University, Cardiff, UK
4Southampton Clinical Trials Unit, University of Southampton, Southampton, UK
5Marie Curie Research Centre, Division of Population Medicine, Cardiff University,
Cardiff, UK
6Swansea Centre for Health Economics, Swansea University, Swansea, UK
7Lay research partners, Centre for Trials Research, Cardiff University, Cardiff, UK
8Velindre University NHS Trust, Cardiff, UK
*Corresponding author
Declared competing interests of authors: Douglas Adamson reports grants from Roche (F. Hoffman-La
Roche Ltd, Basel, Switzerland) and Boehringer Ingelheim (Ingelheim am Rhein, Germany) outside the
submitted work and has given advice to Roche on the development of multidisciplinary team software
but received no financial recompense for this. Jane Blazeby is a member of NIHR Clinical Trials Unit
(CTU) Standing Advisory Committee (2015–19). Deborah Fitzsimmons reports grants from NIHR
during the conduct of the study (PB-PG-0418-20044, RP-PG-1016-20008, RP-PG-0218-20002,
RP-PG-0618-20001) and is a member of the European Organisation for Research and Treatment of
Cancer Quality of Life Group (1996 to present). Stephen Thomas has received payment from NIHR
Health Technology Assessment (HTA) NETSCC Integrated Community Health and Social Care
Committee (A) outside the submitted work, and is a member of the NIHR HTA Prioritisation Committee
(May 2018 to July 2020). John Staffurth has received personal fees and non-financial support from
Janssen oncology (Janssen-Cilag Limited, High Wycombe, UK), non-financial support from Bayer, AG
(Leverkusen, Germany), and personal fees from Astellas Pharma Inc. (Tokyo, Japan), outside the
submitted work.
Disclaimer: This report contains transcripts of interviews conducted in the course of the research and




This report should be referenced as follows:
Adamson D, Blazeby J, Porter C, Hurt C, Griffiths G, Nelson A, et al. Palliative radiotherapy
combined with stent insertion to reduce recurrent dysphagia in oesophageal cancer patients:
the ROCS RCT. Health Technol Assess 2021;25(31).
Health Technology Assessment is indexed and abstracted in Index Medicus/MEDLINE, Excerpta







Health Technology Assessment is indexed in MEDLINE, CINAHL, EMBASE, the Cochrane Library and Clarivate Analytics
Science Citation Index.
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE)
(www.publicationethics.org/).
Editorial contact: journals.library@nihr.ac.uk
The full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be
purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk
Criteria for inclusion in the Health Technology Assessment journal
Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme,
and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.
Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis
methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.
HTA programme
Health Technology Assessment (HTA) research is undertaken where some evidence already exists to show that a technology can
be effective and this needs to be compared to the current standard intervention to see which works best. Research can evaluate
any intervention used in the treatment, prevention or diagnosis of disease, provided the study outcomes lead to findings that
have the potential to be of direct benefit to NHS patients. Technologies in this context mean any method used to promote
health; prevent and treat disease; and improve rehabilitation or long-term care. They are not confined to new drugs and include
any intervention used in the treatment, prevention or diagnosis of disease.
The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform
National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for
National Screening Committee (NSC) policy decisions.
This report
The research reported in this issue of the journal was funded by the HTA programme as project number 10/50/49. The
contractual start date was in March 2013. The draft report began editorial review in November 2019 and was accepted for
publication in June 2020. The authors have been wholly responsible for all data collection, analysis and interpretation, and for
writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to
thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages
or losses arising from material published in this report.
This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions
expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR,
NETSCC, the HTA programme or the Department of Health and Social Care. If there are verbatim quotations included in this
publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect
those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care.
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Adamson et al. under the terms of a
commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for
the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising.
Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health
Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park,
Southampton SO16 7NS, UK.
Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland
(www.prepress-projects.co.uk).
NIHR Journals Library Editor-in-Chief
NIHR Journals Library Editors
Professor Ken Stein   Professor of Public Health, University of Exeter Medical School, UK
Professor John Powell Chair of HTA and EME Editorial Board and Editor-in-Chief of HTA and EME journals.
Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK, and Professor of 
Digital Health Care, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK 
Professor Andrée Le May  Chair of NIHR Journals Library Editorial Group (HS&DR, PGfAR, PHR journals) and 
Editor-in-Chief of HS&DR, PGfAR, PHR journals
Professor Matthias Beck  Professor of Management, Cork University Business School, Department of Management
and Marketing, University College Cork, Ireland
Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK
Dr Eugenia Cronin   Senior Scientific Advisor, Wessex Institute, UK
Dr Peter Davidson   Consultant Advisor, Wessex Institute, University of Southampton, UK
Ms Tara Lamont   Senior Scientific Adviser (Evidence Use), Wessex Institute, University of Southampton, UK
Dr Catriona McDaid  Senior Research Fellow, York Trials Unit, Department of Health Sciences, University of York, UK
Professor William McGuire   Professor of Child Health, Hull York Medical School, University of York, UK
Professor Geoffrey Meads   Emeritus Professor of Wellbeing Research, University of Winchester, UK
Professor James Raftery   Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, 
University of Southampton, UK
Dr Rob Riemsma   Reviews Manager, Kleijnen Systematic Reviews Ltd, UK
Professor Helen Roberts   Professor of Child Health Research, UCL Great Ormond Street Institute of Child Health, UK
Professor Jonathan Ross  Professor of Sexual Health and HIV, University Hospital Birmingham, UK
Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, 
Swansea University, UK
Professor Ken Stein   Professor of Public Health, University of Exeter Medical School, UK
Professor Jim Thornton  Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, 
University of Nottingham, UK 
Please visit the website for a list of editors: www.journalslibrary.nihr.ac.uk/about/editors
Editorial contact:  journals.library@nihr.ac.uk
NIHR Journals Library www.journalslibrary.nihr.ac.uk
Abstract
Palliative radiotherapy combined with stent insertion to
reduce recurrent dysphagia in oesophageal cancer patients:
the ROCS RCT
Douglas Adamson ,1 Jane Blazeby ,2 Catharine Porter ,3
Christopher Hurt ,3 Gareth Griffiths ,4 Annmarie Nelson ,5
Bernadette Sewell ,6 Mari Jones ,6 Martina Svobodova ,3
Deborah Fitzsimmons ,6 Lisette Nixon ,3 Jim Fitzgibbon ,7
Stephen Thomas ,7 Anthony Millin ,8 Tom Crosby ,8 John Staffurth 8
and Anthony Byrne 5,8*
1Tayside Cancer Centre, Ninewells Hospital, NHS Tayside, Dundee, UK
2Bristol Centre for Surgical Research, NIHR Bristol and Weston Biomedical Research Centre, Bristol
University, Bristol, UK
3Centre for Trials Research, Cardiff University, Cardiff, UK
4Southampton Clinical Trials Unit, University of Southampton, Southampton, UK
5Marie Curie Research Centre, Division of Population Medicine, Cardiff University, Cardiff, UK
6Swansea Centre for Health Economics, Swansea University, Swansea, UK
7Lay research partners, Centre for Trials Research, Cardiff University, Cardiff, UK
8Velindre University NHS Trust, Cardiff, UK
*Corresponding author Anthony.Byrne2@wales.nhs.uk
Background: Most patients with oesophageal cancer present with incurable disease. For those with
advanced disease, the mean survival is 3–5 months. Treatment emphasis is therefore on effective
palliation, with the majority of patients requiring intervention for dysphagia. Insertion of a self-expanding
metal stent provides rapid relief but dysphagia may recur within 3 months owing to tumour progression.
Evidence reviews have called for trials of interventions combined with stenting to better maintain the
ability to swallow.
Objectives: The Radiotherapy after Oesophageal Cancer Stenting (ROCS) study examined the
effectiveness of palliative radiotherapy, combined with insertion of a stent, in maintaining the ability to
swallow. The trial also examined the impact that the ability to swallow had on quality of life, bleeding
events, survival and cost-effectiveness.
Design: A pragmatic, multicentre, randomised controlled trial with follow-up every 4 weeks for
12 months. An embedded qualitative study examined trial experiences in a participant subgroup.
Setting: Participants were recruited in secondary care, with all planned follow-up at home.
Participants: Patients who were referred for stent insertion as the primary management of dysphagia
related to incurable oesophageal cancer.
Interventions: Following stent insertion, the external beam radiotherapy arm received palliative
oesophageal radiotherapy at a dose of 20 Gy in five fractions or 30 Gy in 10 fractions.
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Main outcome measures: The primary outcome was the difference in the proportion of participants
with recurrent dysphagia, or death, at 12 weeks. Recurrent dysphagia was defined as deterioration of
≥ 11 points on the dysphagia scale of the European Organisation of Research and Treatment of Cancer
Quality of Life Questionnaire oesophago-gastric module questionnaire. Secondary outcomes included
quality of life, bleeding risk and survival.
Results: The study recruited 220 patients: 112 were randomised to the usual-care arm and 108 were
randomised to the external beam radiotherapy arm. There was no evidence that radiotherapy reduced
recurrence of dysphagia at 12 weeks (48.6% in the usual-care arm compared with 45.3% in the external
beam radiotherapy arm; adjusted odds ratio 0.82, 95% confidence interval 0.40 to 1.68; p = 0.587)
and it was less cost-effective than stent insertion alone. There was no difference in median survival or
key quality-of-life outcomes. There were fewer bleeding events in the external beam radiotherapy arm.
Exploration of patient experience prompted changes to trial processes. Participants in both trial arms
experienced difficulty in managing the physical and psychosocial aspects of eating restriction and
uncertainties of living with advanced oesophageal cancer.
Limitations: Change in timing of the primary outcome to 12 weeks may affect the ability to detect a
true intervention effect. However, consistency of results across sensitivity analyses is robust, including
secondary analysis of dysphagia deterioration-free survival.
Conclusions: Widely accessible palliative external beam radiotherapy in combination with stent
insertion does not reduce the risk of dysphagia recurrence at 12 weeks, does not have an impact on
survival and is less cost-effective than inserting a stent alone. Reductions in bleeding events should be
considered in the context of patient-described trade-offs of fatigue and burdens of attending hospital.
Trial design elements including at-home data capture, regular multicentre nurse meetings and qualitative
enquiry improved recruitment/data capture, and should be considered for future studies.
Future work: Further studies are required to identify interventions that improve stent efficacy and to
address the multidimensional challenges of eating and nutrition in this patient population.
Trial registration: Current Controlled Trials ISRCTN12376468 and Clinicaltrials.gov NCT01915693.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health
Technology Assessment programme and will be published in full in Health Technology Assessment;
Vol. 25, No. 31. See the NIHR Journals Library website for further project information.
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Most people are diagnosed with oesophageal (gullet) cancer when it is already at an advancedstage. Losing the ability to swallow food and even fluids is very common when patients are
approaching the last months of life.
Placing a flexible metal tube, or stent, in the gullet opens it up and improves the ability to swallow
quickly. Unfortunately this can fail after around 3 months because the cancer grows and presses on
the stent.
We designed this trial to see if giving a small dose of radiotherapy alongside insertion of the stent
would allow more people to remain swallowing well after 3 months. This could then improve their
quality of life and reduce hospitalisation towards the end of life. It may also reduce bleeding from the
gullet, as well as other symptoms.
We recruited 220 people across the UK, randomly assigning them to have the stent as usual or the stent
and a low dose of radiotherapy.We collected a lot of information from the participants at home on how
the cancer, the stent and the radiotherapy affected their ability to swallow and their quality of life.
Overall, the study showed that the radiotherapy did not improve the ability to swallow 3 months
following stent insertion and was less cost-effective than stent insertion alone. It seemed to reduce
the risk of bleeding from the tumour itself, but patients found that radiotherapy made them tired
and attending extra hospital visits could be troublesome. We also learned that, even after a stent
was inserted, patients still struggled with food and needed more support with managing daily life
with the stent.
The trial results are important. They show that, to answer questions such as these, studies should use
different ways of assessing what works, particularly focusing on patients’ and families’ viewpoints.
The results will guide doctors to not routinely give radiotherapy in this situation. The results also
suggest that, after the insertion of a stent, patients need extra help in managing their diet, their
worries about the stent and their worries about the future.
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The majority of oesophageal cancers occur in those aged ≥ 60 years. Most patients have advanced
disease at presentation, with an average survival of 3–5 months.
The focus of treatment is frequently on effective palliation, with many patients requiring intervention
for dysphagia. This single symptom has a profound impact on social and physical functioning and other
aspects of quality of life. Interventions to improve swallowing should aim to produce prompt and
lasting palliation while minimising the impact that the intervention has on other aspects of quality of
life, as well as reducing the need for late reinterventions and hospitalisation towards the end of life.
Systematic reviews have shown that the insertion of self-expanding metal stents is the quickest way
to restore the ability to swallow in severe dysphagia but patients who have a stent suffer from issues
with pain, poorer quality of life and recurrence of dysphagia in the 2–3 months prior to death. These
reviews have called for randomised trials of interventions combined with stents to address these
problems, and for such studies to include a robust assessment of quality of life and cost-effectiveness.
External beam radiotherapy is widely accessible to patients with advanced cancer and is frequently
used to palliate symptoms. By contrast, brachytherapy accounts for < 2% of palliative interventions
in this context in the UK. External beam radiotherapy may, therefore, represent an appropriate
intervention alongside stenting to maintain swallow and reduce symptom burden.
Objectives
The main objective of the study was to assess whether or not the addition of external beam
radiotherapy reduces the risk of recurrent dysphagia in oesophageal cancer patients receiving
insertion of a stent as the primary treatment. We also wanted to assess the impact that insertion
of a stent has on other aspects of quality of life and bleeding risk as well as assessing the cost-
effectiveness of adding external beam radiotherapy at the time of stent insertion. An embedded
qualitative study explored patient experience in relation to:
l trial involvement and study processes
l acceptability of the intervention and perceived trade-offs of burdens and benefits
l experiences of having a stent inserted and living with advanced oesophageal cancer.
Methods
We conducted a pragmatic, multicentre, randomised controlled trial comparing usual stent placement
with usual stent placement followed by palliative external beam radiotherapy at a dose of 20 Gy in five
fractions or, at clinician discretion, 30 Gy in 10 fractions. The randomisation ratio was 1 : 1 and was
stratified by centre, stage at diagnosis (I–III vs. IV), histology (squamous or other) and multidisciplinary
team intent to give chemotherapy (yes or no).
Participants were patients (and their carers for the qualitative study) with incurable oesophageal
carcinoma referred for a stent as palliation of dysphagia. They were recruited from 23 sites across the
UK and referred by members of the local upper gastrointestinal multidisciplinary team.
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The inclusion criteria were age ≥ 16 years, being referred for a stent as primary treatment of dysphagia,
being unsuitable for radical treatment, having an expected survival of at least 12 weeks and being
deemed clinically able to tolerate radiotherapy, having the ability to provide written informed consent,
and having completed, as a minimum, the baseline dysphagia questionnaire.
The primary outcome was recurrent dysphagia, or death, at 12 weeks. Dysphagia was defined as an
11-point deterioration in the European Organisation of Research and Treatment of Cancer-OG25
dysphagia score (or a dysphagia-related event consistent with such a deterioration). To detect a
reduction in this proportion from 40% to 20% required 164 participants (80% power, 5% alpha
two-sided), or 220 participants allowing for 25% loss to follow-up. Secondary outcomes included
other key health-related quality-of-life outcomes, bleeding events and cost-effectiveness. Patients were
followed up 4-weekly for 12 months, with additional 2-weekly in-between telephone calls to determine
dysphagia scores.
All follow-up assessments were planned to take place at home to minimise patient burden. Investment
in additional research nurse time and training was implemented to achieve this and to maximise data
capture. A subgroup of patients and their carers contributed to the in-depth qualitative interviews that
were analysed by thematic analysis.
Results
A total of 220 patients were randomised over 4.6 years. Eligibility was 43.6%, with a consent rate of
40%. Of those randomised, 112 were allocated to the usual-care arm and 108 were randomised to the
external beam radiotherapy arm. Twenty-one patients were excluded from the modified intention-to-
treat population (no stent inserted or no baseline dysphagia score), leaving 102 in the usual-care arm
and 97 in the external beam radiotherapy arm. Baseline characteristics were comparable between
arms. Assessment of adherence to radiotherapy showed that 15 out of 97 (15.4%) evaluable patients
either died or withdrew prior to radiotherapy. Data returns were very good up to week 12 (149 with
complete data sets to week 12) but reduced significantly after 12 weeks.
The primary analysis demonstrated that the addition of radiotherapy did not reduce the proportion of
primary events at 12 weeks (48.6% in the usual-care arm vs. 45.3% in the external beam radiotherapy arm;
adjusted odds ratio 0.82, 95% confidence interval 0.40 to 1.68; p = 0.587) and that it was less cost-
effective to this point. Sensitivity analyses did not alter the results. Dysphagia deterioration-free survival
was similar in both arms and median survival was 19.7 weeks in the usual-care arm and 18.9 weeks in
the external beam radiotherapy arm.
Those in the radiotherapy arm had significantly fewer bleeding events. Up to week 16, in the usual-
care arm 18.6% of patients had a bleeding related event, compared with 10.3% in the external beam
radiotherapy arm, giving a number needed to treat of 12. The effect persisted and increased over time,
and by 52 weeks 28.4% in the usual-care arm, compared with 16.5% in the radiotherapy arm, had an
event, giving a number needed to treat of eight.
Key secondary health-related quality-of-life outcomes were not different, but initial fatigue and
pain scores tended to be higher in the radiotherapy arm, and were recorded more often as
significant toxicities.
Qualitative enquiry indicated that some patients in the radiotherapy arm found the intervention tiring
and burdensome to attend. In the qualitative interviews, patients in both arms also described significant
challenges with eating restrictions and worries about nutrition. They adopted trial-and-error approaches
to daily life and sought to reframe their hope in relation to better quality of life rather than survival.
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Implications for health care
l We can conclude that patients with advanced oesophageal cancer requiring a self-expanding metal
stent to improve dysphagia will not benefit further from the addition of concurrent palliative
external beam radiotherapy, and are likely to find the trade-offs of fatigue and additional hospital
visits too burdensome. For those who have a longer prognosis and are considered to have an
increased risk of tumour bleeding, concurrent external beam radiotherapy may reduce bleeding risk
and associated interventions. However, when offering patients this intervention, information about
the impact on quality of life and trade-offs will be important to inform decision-making.
l Insertion of a stent for dysphagia does not address the experience of patients in relation to eating
concerns, symptoms and adapting to uncertainty. Patients and carers required timely and ongoing
support from multidisciplinary professionals with the important psychosocial and physical aspects of
nutrition and eating. They also require help in negotiating uncertainty and the reframing of hope
towards quality of life rather than survival.
Implications for future research
l Future studies will be important to define other interventions that may usefully be combined with
self-expanding metal stent to improve swallow outcomes. Such studies may benefit from insights
gained during the Radiotherapy after Oesophageal Cancer Stenting (ROCS) study on trial conduct in
this context. Investing in additional research practitioner time and training that allows follow-up
data collection at home, timing of randomisation after stent insertion to allow more time for patient
identification and trial consideration, and regular meetings of the multisite research practitioners to
share best practice can all improve trial conduct. Embedded qualitative methods can also ensure that
intervention combinations are properly assessed in terms of patient experience and perceptions of
trade-offs between treatment benefits and burdens.
l The ROCS study has highlighted significant unmet supportive and palliative care needs of patients
with advanced oesophageal cancer, including multifaceted aspects of eating and nutrition. Further
research is required to define the most effective elements of multidisciplinary supportive interventions,
specifically in relation to the multidimensional concerns around eating and nutritional intake, and the
triggers for timely multiprofessional involvement.
Trial registration
This trial is registered as ISRCTN12376468 and Clinicaltrials.gov NCT01915693.
Funding
This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 25, No. 31.
See the NIHR Journals Library website for further project information.
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There are > 9000 new cases of oesophageal cancer and 8000 oesophageal cancer deaths in the UK
each year.1 Oesophageal cancer is the seventh most common cause of cancer deaths (the fourth most
common in men) and accounts for 5% of the UK total. The majority of cases occur in those aged
≥ 60 years and overall prognosis is poor, with 5-year survival rates of only 15%.1 Worldwide there are
> 450,000 new cases of oesophageal cancer per year and > 400,000 deaths. Over 80% of new cases,
and deaths, occur in low- and middle-income nations.2
The majority of patients present with incurable disease and mean survival in advanced disease is
3–5 months.3 The emphasis of treatment for most patients is therefore on effective palliation. Between
70% and 90% will require intervention for dysphagia.4,5 This particular symptom has a profound impact
on physical independence, social functioning and other aspects of health-related quality of life.
Interventions to improve swallowing must, therefore, aim to produce prompt and lasting palliation of
dysphagia while minimising the need for late reinterventions and hospitalisation. Interventions should
produce these benefits without causing significant impairment of other aspects of quality of life and be
accessible at scale to this patient population.
Evidence base for palliation of dysphagia in advanced oesophageal cancer
Although the optimal palliative intervention remains to be established, oesophageal stenting using
self-expanding metal stents (SEMSs) is the most widely used treatment option for providing prompt
relief of severe dysphagia. Shenfine et al.’s6 2005 Health Technology Assessment (HTA) evidence
review and prospective study confirmed the efficacy of SEMS placement and also highlighted that
delayed complications are common and result in later reinterventions. The pragmatic randomised
controlled trial (RCT) randomised 215 patients between SEMS and a variety of non-SEMS treatments.7
It found that SEMS is an effective one-treatment strategy for palliation of dysphagia but highlighted
higher initial pain scores and lower quality of life in the SEMS-treated arm.
Notably, 35% (38/108) of SEMS patients in the study required reintervention, with the risk of stent-
related complications increasing over time. The analysis of survival data in Shenfine et al.’s7 study
suggested that there was longer survival in patients treated with non-stent therapies (median survival:
non-stent, 172 days; 18-mm SEMS, 86 days; 24-mm SEMS, 94 days; p = 0.04).
The study also confirmed the need for better evidence relating to combination therapies, survival –
particularly where treatment combinations are investigated – and more robust evidence on quality of
life. A literature review conducted as part of the Shenfine et al.7 report found that only 0.55% of
papers published since 1966 on oesophageal cancer considered quality-of-life issues, despite the
inherently palliative nature of treatment options for the majority of patients. It also highlighted that
the methodological quality of studies reporting quality-of-life data was very poor.
The two most recent Cochrane systematic reviews8,9 confirm the efficacy of SEMS in providing safe,
effective and quicker initial relief of dysphagia when compared with other intervention modalities, such
as rigid plastic tube insertion, endoscopic chemical and thermal ablation or external beam radiotherapy/
chemoradiotherapy. However, they too highlight a continuous decline in quality of life in SEMS-treated
patients, possibly related to poorer pain scores, and that non-stent modalities may be associated with
improved survival. Dai et al.’s9 updated review in 2014 included 3684 patients in 53 RCTs. It reported
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significant variability in the quality of evidence, with only 25% of studies graded as high quality.9
In general, studies recruited small numbers and used varied scales and outcomes – which precluded
meta-analysis – and few studies provided data on combined interventions. It also reported a lack
of well-designed studies containing robust assessment of health-related quality of life (HRQoL) or
costs. The conclusion of the review was that no absolute superiority of any intervention was shown,
but that combinations of different modalities might provide better treatment outcomes. Like Shenfine
et al.6 and Sreedharan et al.,8 Dai et al.9 called for high-quality RCTs of combination treatments,
particularly of SEMS with either brachytherapy or external beam radiotherapy (EBRT).
Dai et al.9 concluded that, of the non-stent interventions, high-dose intraluminal brachytherapy may be
considered an appropriate alternative to SEMS, particularly in patients with longer survival. This conclusion
was based on two studies comparing SEMS insertion with brachytherapy using validated patient-reported
measures of dysphagia and HRQoL.10,11 SEMS provided more rapid onset of relief. In Homs et al.’s10 larger
study of 209 patients, 18% of patients receiving brachytherapy alone had persistent problems with
dysphagia 2–4 weeks after the procedure, compared with none in the SEMS arm. However, dysphagia-free
survival was longer in the brachytherapy arm [median of 115 days, compared with 82 days with SEMS;
mean difference 33 days, 95% confidence interval (CI) 1 to 64 days; p < 0.05]. There was also evidence
in Homs et al.’s10 study that late upper gastrointestinal (GI) haemorrhage occurred significantly less
frequently in the brachytherapy arm than in the SEMS arm. In both studies, other aspects of HRQoL
appeared to be more stable in the brachytherapy arm over time.
More recently, Rosenblatt et al.12 reported a multicentre international RCT of EBRT at a dose of
30 Gy in 10 fractions combined with high-dose-rate intraluminal brachytherapy compared with high-
dose-rate intraluminal brachytherapy alone in 219 patients. The study reported an absolute difference
in dysphagia relief experience of 16% at 100 days and 18% at 200 days in favour of the combination
arm. There was no difference in survival between the two arms. Description of the toxicities was
limited, although this was reported as not significantly different between the arms. Importantly, only
patients with limited locoregional disease were eligible, limiting the relevance of the finding to the
broader population of patients who were receiving a stent.
There have been no large-scale trials combining stent plus brachytherapy. In a single-arm safety study
of brachytherapy followed by biodegradable stent placement, Hirdes et al.13 reported early termination
of the study as the safety threshold was exceeded, with 47% of patients suffering major complications.
By contrast, Amdal et al.14 have reported a RCT of brachytherapy following SEMS placement versus
brachytherapy alone. However, the trial was closed because of slow recruitment, with only 42 patients
randomised and insufficient statistical power to draw robust conclusions.
One prospective multicentre Chinese RCT combining endoluminal radiotherapy and stent in a single
modality has been reported by Zhu et al.15 Compared with conventional stenting (n = 75), patients
treated with 125I irradiation stents (n = 73) had longer survival (median 177 days vs. 147 days) and
consistently lower dysphagia scores over time, although recurrent dysphagia due to occlusion was not
different between arms (28% vs. 27%). No health economic analysis was included and the expertise
required for irradiation stent placement and care is not widely available. Tian et al.’s16 non-randomised
study in the same health-care economy suggested that the cost associated with irradiation stents is
almost four times that of conventional stents.
Implications for NHS practice
Therefore, the available evidence suggests that SEMS is an appropriate intervention for rapid
dysphagia relief in incurable oesophageal cancer, and is widely implemented as first-line management
of dysphagia in the NHS in this group.17
INTRODUCTION
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Brachytherapy represents an appropriate alternative to SEMS, particularly in those with longer
predicted survival, as, although the onset of dysphagia relief is slower, brachytherapy provides a longer
duration of dysphagia relief, improves quality of life over time and requires fewer reinterventions.
However, throughout the UK, experience of and access to brachytherapy is very limited. Indeed, only
2.5% of all cancer patients requiring radiotherapy,18 including those with oesophageal cancer, are
treated with brachytherapy. National Oesophago-Gastric Cancer Audits17,19 consistently report that
only 15% of English Cancer Alliances treating these patients have access to brachytherapy, with no
improvement over a 5-year period, and in the 2017 report17 < 30 brachytherapy episodes were
recorded compared with > 2000 stent insertions for palliation. Brachytherapy, therefore, does not
currently have a role in the routine palliation of oesophageal cancer dysphagia in NHS settings either
alone or as an option for combination with stenting.
The efficacy of SEMS alone, however, is limited by early problems with pain, decline in general aspects
of quality of life and later complications, such as haemorrhage and tumour overgrowth. Median time to
recurrent dysphagia in stent comparator studies20,21 and in Homs et al.’s10 SEMS versus brachytherapy
study is 11–12 weeks. Reinterventions not only impose a significant burden on NHS resources but also
decrease the quality of life and functioning of an unwell, predominantly elderly, population with a
median survival of 12–20 weeks. This is consistent with estimations that health-care costs in general in
the last year of life account for 20–30% of overall health-care budgets.22 This is also consistent with
data that demonstrate that, among cancer patients, patients with upper GI cancer have high rates of
health and social care usage in the last 12 months of life.23
Research rationale
In line with Cochrane Review research recommendations,8,9 the combination of SEMS with other
treatments might reduce costs and patient burden by reducing adverse events and reinterventions at a
time when patients are approaching the last weeks of life.
This study was developed in response to a National Institute for Health Research (NIHR) call for
research proposals into aspects of palliative care to address uncertainties in the evidence base for
interventions combined with SEMS.
In contrast with the lack of availability and higher cost of brachytherapy, EBRT is readily accessible by
patients at regional cancer centres across the UK, although its use in the immediate post-stent period
has not been rigorously studied.
Only one prospective RCT of EBRT in combination with SEMS versus SEMS alone has been reported.24
Javed et al.’s24 single-centre Indian study recruited 84 patients and reported more sustained dysphagia
relief in the SEMS plus EBRT group (7 months vs. 3 months) and longer survival (180 vs. 120 days).
However, there was no a priori statistical plan described, no power calculation and no reporting of
missing data, which resulted in low-quality evidence.
Study aim and objectives
This study aimed to assess whether or not the addition of EBRT reduces the risk of recurrent
dysphagia, improves quality of life and reduces health economic and personal burden in patients
undergoing SEMS placement.
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The Radiotherapy after Oesophageal Cancer Stenting (ROCS) study was funded by NIHR as part of its
HTA programme. The study was composed of:
l a RCT, with internal pilot, in which palliative radiotherapy at a dose of 20 Gy in five fractions
or 30 Gy in 10 fractions delivered following SEMS placement was compared with SEMS
placement alone
l an embedded qualitative study to explore patient and carer experience of participating in the
randomised study, of receiving the radiotherapy intervention, and of their lived experience of
advanced oesophageal cancer and dysphagia
l an evaluation of the cost-effectiveness of delivering the radiotherapy intervention, and of the
resource use associated with advanced oesophageal cancer.
Intervention development
The radiotherapy intervention was intended to reflect current practice in the centres recruiting to
this trial, rather than to be closely prescriptive. This would allow the findings to be readily and directly
applicable to current UK practice. EBRT is routinely available at regional cancer centres across the UK.
For palliation of oesophageal cancer, a radiotherapy course delivering a tumour-absorbed dose of
20 Gy in five fractions or 30 Gy in 10 fractions is generally recommended by the Royal College of
Radiologists.25 The study team suggested a dose of 20 Gy in five fractions, which was the most
commonly used dose across the UK at the time of study design,19 with the 30 Gy in 10 fraction dose
chosen at the discretion of the treating physician. Recent audit data suggest that both of these doses
remain the most commonly used palliative regimens in advanced oesophageal cancer in England,
accounting for 63% of palliative radiotherapy delivered.17
Self-expanding metal stents are the most common intervention used in the UK and internationally for
the palliation of malignant dysphagia. Audit data for 2014–16 confirm that they constituted 94.5%
of all stents placed for oesophageal cancer dysphagia in England.17 They can be placed at a single
endoscopic or radiological session. There are several designs with a variety of delivery devices and,
for this trial, SEMS insertion was undertaken in accordance with standard local protocols. Covered
or partially covered metal stents were permitted and the length, type and mode of stent placement
were selected by the treating clinician.
INTRODUCTION




The study was designed as a pragmatic RCT of EBRT in addition to stent insertions versus stent
insertion alone. Participants were those clinically assessed as requiring stent insertion for relief of
dysphagia caused by inoperable oesophageal cancer. An internal pilot was included to assess rates and
methods of recruitment as it was expected that the trial would be challenging in studying a palliative
population approaching the last months of life.
To ensure a multiperspective analysis of efficacy and address previously highlighted evidence gaps, the
trial also included an embedded qualitative study and a health economics component to interrogate
the cost-effectiveness of radiotherapy intervention, and to capture in detail health and social care
resource use across both arms of the trial.
A description of the trial protocol has previously been published.26 The trial schema is detailed in Figure 1.
A full summary of protocol amendments is included in Table 1.
Ethics approval and research governance
Ethics approval for the study was given by the Wales Research Ethics Committee 2 in October 2012
(reference number 12/WA/0230). Global Research and Development approval was given in January
2013. The trial was registered with the International Standard Randomised Controlled Trial Registry
(ISRCTN) under the reference number ISRCTN12376468 and also with Clinicaltrials.gov under the
reference number NCT01915693.
Participants
The study recruited patients referred for an oesophageal stent as primary palliation for advanced
oesophageal cancer dysphagia. Patients were recruited from 23 cancer centres and acute hospitals
across Scotland, England and Wales (see Appendix 1). Recruitment was limited to five sites in the first
18 months to allow for the embedded pilot phase and review.
Inclusion criteria
Patients were considered for inclusion if they:
l had oesophageal carcinoma with either of the following –
¢ histological confirmation (excluding small cell carcinoma)
¢ clinical and/or radiological evidence of invasive tumour [as agreed by multidisciplinary team
(MDT) consensus] and at least high-grade dysplasia of a non-small cell type on histology
l were not suitable for radical treatment (oesophagectomy or radical chemoradiotherapy) because of
either patient choice or medical reasons
l had dysphagia clinically assessed as needing a stent insertion as primary treatment of the dysphagia
l were aged ≥ 16 years
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l had a treatment decision made by discussion with an upper GI MDT for stent insertion
l were deemed suitable for radiotherapy
l had an expected survival of at least 12 weeks
l could provide written informed consent
l had completed baseline quality-of-life questionnaires (as a minimum patients had to have completed
the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life
Questionnaire (QLQ) oesophago-gastric module (OG25).
Follow-up post 1 year
Death CRF only
Radiotherapy
20Gy in 5 fractions or 30Gy in 10 fractions








Patients with oesophageal cancer requiring stent




Follow-up up to 1 year (or up to 3 months after the last patient is recruited, whichever comes first)
Telephone call 2 weeks after stent insertion and then 4-weekly thereafter (scheduled halfway
between the 4-weekly visits) to be carried out with patient’s consent. These will be brief and include
the three questions from the EORTC QLQ-OG25 that give the primary end point
Home visit 4 weeks after stent insertion and 4-weekly thereafter
Eligibility criteria met and consent obtained
Stent already inserted?
Consent for trial refused, but
consent to be interviewed given
Qualitative interview on reason
for refusal of trialYes No
Stent inserted
Collect 1-week post-stent data
FIGURE 1 Trial schema showing randomisation and follow-up. CRF, case report form; EORTC QLQ-OG25, European
Organisation for Research and Treatment of Cancer Quality of Life Questionnaire oesophago-gastric module;
MDT, multidisciplinary team.
METHODS
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Exclusion criteria
Patients were not considered for exclusion if they:
l had small-cell carcinoma
l had tumour length of > 12 cm
l had tumour growth within 2 cm of the upper oesophageal sphincter
l had endoscopic treatment of the tumour, other than dilatation, planned in the peri-stent period
TABLE 1 Summary of changes to the original ROCS protocol approved by Research Ethics Committee
Change to protocol Date
Exclusion criterion removed: planned endoscopic treatment of the tumour (e.g. laser) in the
immediate peri-stenting period
April 2013
Inclusion criterion added: patient has completed baseline QLQs added in the inclusion criteria April 2013
Companion PIS and consent form introduced in the qualitative study September 2014
Dedicated face-to-face follow-up specified as preferred to ensure optimum support for patients;
telephone or postal follow-up for questionnaire completion also permitted depending on
patient’s choice
September 2014
Additional level of withdrawal added: option for participants to stop home visits and questionnaires
but follow-up
September 2014
Qualitative study added interviews with research nurses responsible for recruiting patients to
the trial
September 2014
Randomisation allowed within 2 weeks after stent insertion, but preferably within 1 week of
stent insertion
April 2015
Baseline assessments for those patients consented following stent insertion, ideally baseline
assessments will occur within 1 week, but not > 2 weeks, following the procedure
April 2015
Clarification of time zero owing to consent also possible after stent insertion April 2015
Secondary outcome added: determine the haemostatic effect of radiotherapy on tumour bleeding March 2016
Inclusion criterion of oesophageal carcinoma widened to include clinical and/or radiological evidence
of invasive tumour (as agreed by MDT consensus) and at least high grade dysplasia of a non-small
cell type on histology
March 2016
Interim telephone calls introduced 2 weeks after stent insertion and 4-weekly thereafter to be
scheduled halfway between the 4-weekly assessment visits
March 2016
Dysphagia card was introduced with a list of questions asked during the telephone calls March 2016
Follow-up until death reduced to 1 year, follow-up post 1 year is death CRF only March 2016
Primary outcome amended: assess the impact that radiotherapy has in addition to stent placement
on time to progression of patient-reported dysphagia or other dysphagia-related event in a patient
population unable to undergo surgery
February 2017
Final accrual reduced from original 496 to 220 December 2017
Primary outcome amended: to assess the impact that radiotherapy has in addition to stent
placement on difference in event rate of patient-reported dysphagia or other dysphagia-related
event at 12 weeks following stent insertion in a patient population unable to undergo surgery
December 2017
Originally it was intended to perform a time-to-event analysis. However, in collaboration with the
IDMC in response to recruitment difficulties, the primary outcome analysis has been amended and
will now be based on proportion of events at week 12. An event is defined as a progression in
self-reported dysphagia (see above) or other dysphagia-related event
Follow-up for 1 year or up to 3 months after the last patient is recruited, whichever comes first December 2017
New secondary outcome – measure hospital admission rates December 2017
CRF, case report form; IDMC, Independent Data Monitoring Committee; MDT, multidisciplinary team; PIS, participant
information sheet; QLQ, quality of life questionnaire.
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l had a tracheo-oesophageal fistula
l had a pacemaker in proposed radiotherapy field
l had previous radiotherapy to the area of the proposed radiotherapy field
l were pregnant.
Recruitment procedure
Patients were identified in secondary care by their treating clinician or by members of the local upper
GI MDT. Patients were then approached prior to stent insertion by the local research nurse, who
introduced the ROCS study, provided them with a participant information sheet (PIS) and completed
eligibility checks. The research nurses received specific training on information provision to include the
radiotherapy intervention and the consent process.
Comprehensive screening log data were collected throughout the trial to track proportions of patients
who were eligible, approached and randomised. This was used to feed back to participating centres, the
Trial Management Group (TMG), the Independent Data Monitoring Committee (IDMC) and the funding
body throughout the duration of the study.
During the trial pilot phase, screening logs demonstrated that the number of patients requiring stent
insertion was as predicted by the trial team and that the 64% acceptance rate was above the 50%
initially predicted. However, eligibility was 33% compared with the 70% predicted. The reasons for
ineligibility included previous radiotherapy and capacity to consent issues. The screening data also
highlighted that a significant number of patients were being stented before trial teams became aware
(14%). Data from the qualitative study additionally identified individual patient distress at being
approached prior to stenting. Together these data resulted in a protocol amendment to allow randomisation
up to 2 weeks after stent insertion, and eventually 66% of the overall 220 patients were randomised
post stent insertion. Following review of the comprehensive pilot data, the funder approved trial
continuation and the number of centres was increased.
Informed consent
Once trial eligibility was confirmed, informed written consent was obtained after a full explanation
had been given and further questions answered. The consent was taken by an appropriately trained
research nurse or delegate. The original signed and dated consent forms were held securely as part
of the trial site file, with a copy provided to the participant. Patients and informal caregivers were
consented separately for the embedded qualitative study by the qualitative researcher.
Patients were also asked to consent to NHS Information Centre flagging so that the date and cause
of death could be collected without longer-term follow-up. This was optional and additional to the
standard informed consent.
Randomisation and concealment
Eligible and consenting participants were randomised centrally via the Wales Cancer Trials Unit
[now the Centre for Trials Research (CTR), Cardiff University] randomisation telephone line using an
online trial management database with a manual backup available. The outcome of the randomisation
procedure was communicated to the participant by the research nurse together with details of the
allocated treatment. As indicated, the initial protocol stipulated randomisation prior to stent insertion,
but was amended to allow post-stent randomisation after the pilot phase.
Participants were randomised to a trial arm using the method of minimisation with a random element
(80 : 20). Minimisation was stratified to ensure balanced allocation for a number of potential
confounding factors: centre, stage at diagnosis (I–III vs. IV), histology (squamous or other) and MDT
intent to give chemotherapy (yes or no). Randomisation was carried out using a 1 : 1 allocation ratio.
METHODS
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Study interventions
Self-expanding metal stents: both arms
Following the decision by the MDT to proceed with stenting as the primary treatment for oesophageal
cancer-related dysphagia, stent insertion was performed as per the standard procedures of the treating
centre. The length and type were determined and recorded by the treating clinician. It was advised that,
where possible, the length of stent should be chosen to ensure that at least 2 cm of normal oesophagus
was covered by the stent above and below the tumour stricture. The following were also recorded:
whether the stent was inserted under sedation or general anaesthetic, whether dilatation was required
before or after stent insertion and whether or not radiological imaging was used.
Patients who were offered any endoscopic treatment of the tumour, other than oesophageal dilatation
used as part of the centre’s normal procedure for stent insertion, were excluded from the study, unless
an emergency required such procedure. Use of such procedures was recorded on the case report form
(CRF). Patients in whom brachytherapy or EBRT was planned routinely for after stent insertion were
also excluded.
External beam radiotherapy trial arm: intervention
The study protocol mandated that the radiotherapy begin within 4 weeks of stent insertion and preferably
within 2 weeks. Radiotherapy treatment was delivered to the primary tumour and significant treatable
lymphadenopathy, as defined by the treating oncologist. Treatment dose was either 20 Gy in five fractions
over 1 week or 30 Gy in 10 fractions over 2 weeks using daily fractionation and the centre’s normal
radiotherapy treatment procedures. The 20 Gy in five fractions regimen was the preferred option but the
dose and fractionation schedule were chosen by the treating clinical oncologist.
Patients were withdrawn from the trial if they missed > 7 consecutive calendar days during
radiotherapy treatment and any further treatment given was at their treating clinician’s discretion.
In the unlikely event of radiotherapy side effects severe enough to interfere with treatment delivery,
the treating clinician had the option to temporarily stop treatment and allow a break of no more than
7 calendar days prior to recommencement.
Radiotherapy quality assurance
Radiotherapy quality assurance was carried out by the Cardiff National Cancer Research Institute
(NCRI) Radiotherapy Trial Quality Assurance (RTTQA) Group. The ROCS radiotherapy quality assurance
group consisted of a radiation oncologist and radiotherapy physicist from the Cardiff NCRI RTTQA
Group, who gave information and guidance regarding implementation of the protocol, monitored
compliance with the protocol and, where necessary, provided feedback on the radiotherapy quality
assurance accreditation.
Pre-trial quality assurance
A process document containing information on set-up, verification and beam arrangement was required
from all radiotherapy sites prior to being opened to recruitment. This was reviewed by the ROCS
radiotherapy quality assurance group.
On-trial quality assurance
Following entry of the first patient into the trial at each radiotherapy treatment site, a set of
computerised tomography (CT) images or simulator images, together with information concerning the
treatment fields (Digital Imaging and Communications in Medicine-RadioTherapy file or hard copy)
and treated volumes, were requested to ensure compliance.
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Data collection and management
Pre-stent and 1 week post stent insertion
Patients randomised prior to stent insertion were seen before stenting for a pre-stent assessment at
which the following data were collected: World Health Organization (WHO) performance status,
questionnaires, EORTC QLQ-C30, EORTC QLQ-OG25, EuroQol-5 Dimensions, three-level version
(EQ-5D-3L), Common Terminology Criteria for Adverse Events (CTCAE) v4.03. See Appendix 2 for
the QLQs.
All patients, including those randomised post stent insertion, were seen 1 week post stent insertion,
when the above data were collected, in addition to stent morbidity data, bleeding and transfusion
episodes, and resource use. This formed the baseline against which future deterioration was measured.
Follow-up
Every 4 weeks after the 1-week post-stent insertion assessment, and until death, the following
assessments were conducted and data were collected: WHO performance status, questionnaires
(EORTC QLQ-C30, EORTC QLQ-OG25, EQ-5D-3L), toxicity assessment (CTCAE), stent morbidity data,
bleeding and transfusion episodes, and resource use. Serious adverse events (SAEs) were monitored
in real time.
The funded study included costs for additional research nurse time to allow all follow-up visits to occur
in the home setting, or place of patient choice. The aim was to minimise the burden of study processes
for patients and their families and to maximise data capture in participants who were at an advanced
stage of illness. The challenges of capturing self-reported health data from patients with poor health
and life expectancy are well documented,27 with recommendations for dedicated research staff
collecting the quality-of-life (QoL) data via home visits where possible.10 Face-to-face follow-up was
preferred in our trial to ensure optimum support for patients in completing assessments and to
minimise disruption for them; however, where patients specifically declined face-to-face follow-up
visits but expressed a preference to have telephone or postal follow-up for questionnaire completion,
follow-up assessments were undertaken in this way.
Information was captured in the CRFs on whether or not patients required support from research
practitioners or family members/informal carers to complete patient-reported outcome questionnaires
and reasons for missing data were also recorded.
As part of their regular data reviews, the IDMC highlighted that, despite excellent CRF returns, there
were missing data owing to participants becoming too frail to complete questionnaires or dying without
the ROCS primary outcome data being collected. Subsequently, the study protocol was amended in
consultation with the research nurse teams to introduce interim telephone calls to participants scheduled
halfway between the 4-weekly follow-up visits, aiming to ensure that dysphagia deterioration was
assessed more frequently and that data were available in all patients. The telephone call assessments
were brief and included the specific OG25 dysphagia questions only. For ease of call administration,
participants were given a dysphagia card with details of the three questions that they were expected
to answer.
Trial and data management
Paper-based CRFs were completed at sites within 4 weeks of the follow-up visit and a copy sent to the
CTR for clinical database entry in MACRO Electronic Data Capture (InferMed, London, UK) version 4.9.
A range of data validation checks were carried out to minimise erroneous and missing data throughout
the trial. These consisted of checks programmed into MACRO Electronic Data Capture and more complex
consistency checks (central monitoring) programmed in Stata® (StataCorp LP, College Station, TX, USA)
METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
10
version 16 (e.g. comparing toxicities reported on CRFs with toxicities reported through the SAE
pharmacovigilance system). Data cleaning was an ongoing process and central monitoring was conducted
prior to IDMC meetings and to commencing the final data analysis. Where central monitoring highlighted
concerns at particular centres, site monitoring could be triggered and source data verification performed.
The TMG met once every 3 months to review screening and recruitment data and trials processes and
receive Trial Steering Committee (TSC) and IDMC reports and advice. They oversaw all reporting and
governance responsibilities and advised on all amendments to the protocol. The TSC and IDMC met
once every 6 months to review trial progress and safety.
Investigator meetings were planned on a 6-monthly basis to facilitate peer support and motivate
recruitment among principal investigators and particularly research nurses. The meetings allowed
identification of both generic and site-specific trial process issues, sharing of good practice, and feedback
from the qualitative researcher on patient experiences of being approached, informed about and
consented into the trial. The knowledge and experience of the research nurses and the qualitative patient
feedback resulted in real-time changes to, and improvements in, the protocol and data capture including:
l changes to CRF design and content
l changes to the wording of the PIS and description of the intervention by research nurses
l changes to the timing of randomisation to include after stent placement
l the inclusion of ‘between-visit’ telephone calls to capture primary outcome data
l an additional level of withdrawal to allow ongoing case note data capture
l the inclusion of research nurse interviews regarding non-consent.
Outcome measures
Primary outcome
The primary outcome in this trial was a revised binary measure of deterioration in dysphagia
symptoms, or death, by 12 weeks.
Patient-reported dysphagia was measured at each time point using the EORTC QLQ-OG25,28 which
amalgamates the widely used EORTC scales to assess HRQoL in patients with oesophageal and gastric
cancer.29,30 In the earlier EORTC scales, problems with the validity of the dysphagia scale were noted,
with patients finding the response categories confusing. The EORTC QLQ-OG25 resolved this issue
and combined both oesophageal and gastric modules to ensure that HRQoL issues relevant to both
groups of patients and that patients with oesophagogastric (junctional) tumours were included.
The questionnaire has six scales; the dysphagia scale is scored from 0 to 100 and a change of
10–15 points in mean score is considered to be clinically significant.31
Relief of dysphagia is expected in the majority of participants following stent insertion so the dysphagia
score taken 1 week after stent insertion (prior to EBRT in treatment arm) formed the time zero
measurement for the main end point of the study. A worsening in score of 11 compared with time
zero at any subsequent time point was taken as deterioration. However, it is possible that patients
undergoing radiotherapy may have a temporary worsening of dysphagia secondary to radiation-induced
oesophagitis and other temporary changes may occur. To ensure that EBRT did not bias the primary
outcome, definitive deterioration in dysphagia was defined as an 11-point change on two consecutive
occasions, with the first being taken as the event time point.
To ensure that all primary events were captured, all CRF data related to toxicities and SAEs were
reviewed to identify any additional dysphagia-related primary events that may have occurred
between assessments. These events were reviewed blindly by the two co-chief investigators and
by a gastroenterologist independent of the study (see Primary analysis).
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Notification of death was collected and overall survival (OS) was calculated from the date of stent
insertion to the date of death from any cause.
Dysphagia deterioration-free survival
Dysphagia deterioration-free survival (DDFS) was calculated from the date of stent insertion to the
date of deterioration in dysphagia symptoms (as per the primary outcome definition).
Health-related quality of life
Quality of life was measured using the EORTC QLQ-C30, EORTC QLQ-OG25 and EQ-5D-3L at the
specified assessment time points.
Health-related quality of life was assessed using generic instruments: the EORTC QLQ-C-30, which
assesses global QoL, functional domains (physical, emotional, social, role and cognitive) and symptoms
(fatigue, nausea and vomiting, pain, dyspnoea, insomnia, appetite loss, constipation, diarrhoea and
financial difficulty) that commonly occur in patients with cancer; and the EORTC QLQ-OG25. Both
tools (the EORTC QLQ-C30 and the EORTC QLQ-OG25) were employed, as validation of the EORTC
QLQ-OG25 demonstrated that it measures separate HRQoL issues and it is likely that dysphagia
accounts for only a proportion of the impact on QoL.32 All of the scales and single-item measures range
in score from 0 to 100; a higher score represents a higher (‘better’) level of functioning, or a higher
(‘worse’) level of symptoms.
The prespecified main patient-reported outcome items that were identified a priori to be of
relevance were the global health score from the EORTC QLQ-C30 and four scales from the EORTC
QLQ OG25 questionnaire: odynophagia, pain/discomfort, eating restrictions and eating in front
of others.
Toxicity
Toxicity data were scored using the National Cancer Institute CTCAE at baseline, during treatment and
at the prespecified time points during follow-up.
Morbidity
Tumour bleeding
Upper GI bleed events were confirmed by the chief investigators, who were blinded to the study arm,
and reviewed by an independent gastroenterologist. These included blood transfusion, haematemesis,
upper GI haemorrhage or bleed, melaena and interventions related to bleeding (e.g. argon plasma
coagulation or additional radiotherapy). If there was no clinical evidence that anaemia was due to a
bleed, then it was not considered.
Dysphagia-related stent complications and reinterventions
Stent complications were defined as re-stenting, repeat endoscopy, overgrowth of stent, undergrowth
of stent, stent blockage, stent fracture and stent slippage. Reinterventions were defined as additional
stent insertion, stent removal, endoscopic intervention (including laser therapy and alcohol injection)
and other palliative radiotherapy (including brachytherapy and additional EBRT for dysphagia).
Stent-related pain
A stent-related pain event was defined as grade 2+ stent-related pain reported on the toxicity CRF.
METHODS
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Cost-effectiveness
The economic valuation was in the form of a cost–utility analysis (CUA) assessing total costs against
differences in health outcome expressed as quality-adjusted-life-years (QALYs), with utilities derived
from the EQ-5D-3L questionnaire responses.33–35 EQ-5D-3L has been used previously on patients
with inoperable oesophageal cancer.7 CUA is the health economic method preferred by the National
Institute for Health and Care Excellence (NICE).33 In line with NICE guidance, the analysis was
undertaken from an NHS and Personal Social Services perspective. Details of the health economic
evaluation are reported in Chapter 5.
Patient perspectives
The embedded qualitative study was designed to explore the feasibility of patients’ recruitment
to the trial by examining their experience of consent and recruitment, to highlight the reasons for
non-consent and to examine patients’ motivation to accept randomisation to an intervention that
may include extra radiotherapy. It also provided the opportunity to understand patients’ experience
of living with advanced oesophageal cancer and dysphagia and how they negotiated interventions –
particularly in terms of trade-offs between perceived burdens and benefits. The qualitative methodology
is described in detail in Chapter 4.
Sample size
Original sample size justification based on time to event
In a population with a median survival of approximately 4 months, an increase in median time to
deterioration in self-reported dysphagia of 4 weeks was considered clinically meaningful. This was
based on previous results10 and expert multidisciplinary clinical and service user opinion. Sample size
was therefore originally calculated, based on a time-to-event analysis, to detect an increase in median
time to deterioration in self-reported dysphagia of 4 weeks: from 12 to 16 weeks [equivalent to a
hazard ratio (HR) of 0.75 and a difference in 12-week event rate of 50% vs. 60%]. For 80% power with
alpha = 0.05 based on a two-sided log-rank test, 198 patients per arm would be required: 396 in total,
which is a total of 384 events. Assuming 20% attrition, a total of 496 participants would be required.
Time to event would be calculated from the time of stent insertion to the time of deterioration or
death. Patients who did not achieve an improvement from the pre-stent measure of at least 11 points31
on the OG25 dysphagia subscale at the first week assessment after stent insertion (time zero) would
be included and followed up but assumed to have failed at time zero. Those who were deterioration
free and alive would be censored at the time last seen.
Revised sample size justification based on proportions of events at 12 weeks post stent
In view of the challenging nature of the study in recruiting a palliative population towards the end of
life, the IDMC undertook 6-monthly reviews of recruitment and data returns. Although the consent
rate continued to approach the predicted rate of 50%, the proportion of eligible patients remained
significantly lower than originally predicted (43.6% vs. the 70% predicted). Missing data also increased
significantly beyond 12 weeks, despite high CRF returns, reflecting the increasing frailty of the patient
population. In view of these combined issues the IDMC recommended a revised sample size calculation
based on comparison of proportions with a dysphagia event at week 12. To reduce this proportion
from 40% to 20% required 164 patients (80% power, 5% alpha two-sided). This difference in proportions
is in line with the difference sought in other studies of stent or non-stent interventions for malignant
dysphagia.9,12,36 To allow for a 25% loss to follow-up required 220 patients to be randomised. This is
equivalent to the largest sample size recruited into intervention RCTs for advanced oesophageal cancer
dysphagia. The changes were approved by the independent TSC and ratified by the funder following
independent review.
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Statistical analysis
Analysis and reporting of this trial were undertaken in accordance with Consolidated Standards of
Reporting Trials (CONSORT) guidelines.37 All statistical analyses were performed using Stata following
a predefined statistical analysis plan agreed with the IDMC. The modified intention-to-treat (ITT)
population was defined as all patients who had a stent inserted and returned a baseline EORTC
QLQ-OG25 (OG25) questionnaire. The per-protocol population was defined as the subgroup of the
modified ITT population that was alive and who had not withdrawn from trial treatment at 4 weeks
post stent insertion, that was not found to be ineligible, had no protocol deviation or other reason for
exclusion and (in the radiotherapy arm) received at least one fraction of radiotherapy.
Primary analysis
Analysis of the primary binary end points of deterioration in dysphagia symptoms by 12 weeks was
primarily conducted in the modified ITT population with complete-case data. Complete cases were
defined as having complete data for the dysphagia subscale of the EORTC QLQ-OG25 questionnaire at
time 0, week 4, week 8 and week 12 or having died with complete data prior to week 12. Single missing
time points were permitted under the rules described below.
Primary end point events were based on:
l Two consecutive deteriorations in patient-reported dysphagia score.
l One deterioration and no more data possible (i.e. patient withdrew completely or died before
next visit).
l One deterioration, missing next visit; withdrew or died within 4 weeks of missing visit.
l Additional dysphagia-related primary events (additional stent insertion, dysphagia on clinical
assessment or documented as reason for hospital admission, overgrowth or undergrowth of stent,
grade 3+ dysphagia on toxicity form or SAE or additional radiotherapy to oesophagus/stent region).
All additional primary events were assessed blindly and confirmed by the chief investigators and
reviewed by an independent gastroenterologist, as a dysphagia-related event.
l Death prior to week 12.
In the absence of a documented dysphagia-related event, missing dysphagia scores between two
non-event dysphagia scores were assumed to be no event.
Multivariate logistic regression was used to adjust for randomisation stratification factors and the
adjusted odds ratio (OR) was presented along with 95% CIs and p-values for the primary analysis
and all sensitivity analyses. Where there were fewer than five patients per centre, these patients
were combined into a new centre to ensure that all patients’ data were used in the adjusted model.
Three sensitivity analyses were performed:
1. using the same complete-case population but treating death by 12 weeks without prior
deterioration as no deterioration
2. imputing missing data using a best-case scenario that assumed no deterioration in a missing OG25
form immediately prior to an OG25 form that showed deterioration (or additional primary event
confirmed by the chief investigator), or missing OG25 data immediately prior to death
3. imputing missing data using a worst-case scenario that assumed deterioration in a missing OG25
form immediately prior to an OG25 form that showed deterioration (or additional primary event
confirmed by the chief investigator), or missing OG25 data immediately prior to death.
Additional sensitivity analyses of the main results and the three sensitivity analyses above were
performed in the per-protocol population.
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Secondary analyses
Overall survival, follow-up and dysphagia deterioration-free survival
Overall survival and DDFS were analysed by time-to-event methods (Kaplan–Meier curves and Cox
regression), with those without events being censored at time last seen. The Cox regressions were
adjusted for randomisation stratification factors with treating centre also included as a shared frailty.
For those with uncensored data, the reverse Kaplan–Meier approach was used to present follow-up
post-stent insertion in each arm. DDFS events were calculated as per the method used for the primary
end point above. As a sensitivity analysis, the DDFS analysis was repeated, but data were censored at
death with no prior dysphagia event.
Quality of life and World Health Organization performance status
All EORTC QLQ-C30 items were scored for each patient according to the EORTC QLQ-C30 scoring
manual.38 Data were imputed according to EORTC guidance if fewer than half of the items in a scale
were missing. Where data were missing from more than half of the items in any scale, these scales
were excluded from the analyses. When a complete questionnaire was missing, the reason for the
missing questionnaire was ascertained and categorised. The same methods were used for analysing
the QoL data and the WHO performance status scores.
The distribution of the baseline scores was tested for normality using kernel density plots, normal
probability plots, normal quantile plots and the Shapiro–Wilk test to determine which graphical method
to use to display scores over time [median and interquartile range (IQR) if not normal, mean and 95% CIs
if normal]. Questionnaires that were returned within 2 weeks (plus or minus a specified time point)
were selected for each time point measure.
Linear mixed models were used to compare differences between trial arms for each subscale or single
item. Time was included as a categorical covariate using the week of observation from 0 (time zero)
to 16, after which the proportion of missing data became too high. If an intermediate value was
missing, the corresponding time was skipped. Covariates included trial arm, age, time zero score and
randomisation stratification factors. For each subscale or single item, the interaction of treatment by
time of assessment was tested.
To assess goodness of fit of the linear mixed models, the fixed effects for determining the selection of
linear mixed model for each subscale or item were evaluated using Akaike information criterion (AIC)
and Bayesian information criterion (BIC) and the model with the lowest AIC and BIC is presented.
Morbidity
The same analytical method was used for the following morbidity events:
l upper GI bleed events
l dysphagia-related stent complications and reinterventions
l additional stent insertion
l repeat endoscopy
l overgrowth or undergrowth of stent
l stent-related pain.
Time to first morbidity event was compared between trial arms using competing risks regression, with
death as a competing risk, adjusted for randomisation stratification factors and cumulative incidence
functions plotted by trial arm.
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Missing data
The potential for missing data was significant in this trial given the study population. Plans to reduce
the number and impact of missing data centred on:
l maximising data capture
l handling of missing data
l analysis and reporting.
Significant efforts were made to reduce the number of missing data. As described, they included
additional research nurse time to collect all follow-up data at home, multidisciplinary input to trial
and CRF design to optimise the type and number of data captured and reasons for missing data,
implementation of between-visit telephone calls, and an additional level of withdrawal to allow
continued case note data capture.
The handling and investigation of the potential influence of missing data through sensitivity analyses
are described in Primary analysis and in Chapter 3.
Patient and public involvement
Aim
The involvement of patients and members of the public as research partners was underpinned by a
comprehensive strategy within the CTR and the Marie Curie Research Centre (MCRC) at Cardiff
University, which was responsible for the conduct of the main trial and the embedded qualitative
component. The ROCS study had research partner involvement from the initial concept and outline
design phase, through study delivery as part of the TMG and as a core component of the dissemination
phase. There were specific objectives in relation to:
l research partner advertisement and recruitment onto the TMG by interview
l research partner training and integration in to the trial team and TMG
l ongoing support and assessment of impact of the contribution of the research partners
l involvement in publications and dissemination plan.
Methods
One member of the public, Jim Fitzgibbon, had a lead role for development of patient and public
involvement (PPI) strategy in the CTR alongside Annmarie Nelson as academic lead for PPI. Together
they developed the strategy for PPI in the trial. They developed a role description and bespoke
recruitment and training plans. An additional member, Stephen Thomas, was appointed following
successful grant capture and set-up of the TMG.
Support
Research partners were introduced to, and integrated into, the trial team. Both research partners
became familiar with the trial unit environment, and trial staff received training on the importance of
the research partner role and specific aspects of support. Reimbursement of expenses was offered,
as were honoraria for their time, in keeping with the local strategy for research partner support.
Impact
Both lay members of the TMG were fully involved as the trial progressed. Particular areas where they
had an impact were:
l Jim Fitzgibbon was involved in initial trial design and grant submission as co-applicant, as well as the
protocol publication.
l Jim Fitzgibbon and Stephen Thomas directly influenced protocol design and subsequent
amendments, particularly in relation to patient-reported outcomes and recruitment strategy.
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l Jim Fitzgibbon and Stephen Thomas directly supported development of trial materials, particularly
the PIS and consent form, and the formatting and content of CRFs.
l They made sure that the trial was conducted in a participant-friendly and ethically acceptable way,
which included changes in timing of consent, the introduction of a patient card containing the
primary outcome dysphagia questions in support of telephone data capture, and introduction of
additional 2-weekly telephone assessments between the scheduled 4-weekly face-to-face assessments.
l They were involved in the interpretation and reporting of the trial results for this monograph.
It is anticipated that they will also be involved in:
l disseminating results through publication, UK and international presentations, and knowledge
transfer through national and regional clinical and academic organisations and patient groups.
Conclusions and reflections
The involvement of our lay research partners was core to the successful development and implementation
of the ROCS study. Their inputs have had an impact throughout the trial and have supported wider
integration of research partners in the trials unit environment. Although the involvement predates the
NIHR standards, we followed forefront processes in recruitment, training and support. Although it has
been possible to describe and list some of the impact that research partners have had, we recognise the
need in future to utilise more considered and timely ways of recording it and to undertake a ‘study within
the study’ of how best to capture and describe research partner impact. Work is proceeding in the CTR to
develop a practical system and tool to enable this to happen.
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A total of 220 participants were recruited to the ROCS study by 23 centres (see Appendix 1) between
16 December 2013 and 24 August 2018. In total, 112 participants were allocated to the usual-care
arm and 108 participants were allocated to the EBRT arm.
Flow of participants through the trial
The CONSORT flow diagram is shown in Figure 2 and summarises patient flow from eligibility screening
and randomisation to stent insertion (either before or after randomisation) and inclusion in the ITT and
per-protocol populations. Unless otherwise stated, all analyses are for the modified ITT population.
In total, 43.6% (546/1252) of screened patients were eligible and, of those, 40.3% (220/546) gave consent.
Characteristics of the study sample
Baseline characteristics
Baseline characteristics are shown in Tables 2 and 3. The randomisation stratification factors of tumour
type, stage at diagnosis and intended chemotherapy after stent insertion were well balanced between
trial arms, as were other baseline characteristics.
Allocation of treatments
Treatment adherence
Table 4 shows a summary of stent insertion, including clinical characteristics and complications. There
were no reports of oesophageal or other GI tract perforation. Radiotherapy administration is shown
in Table 5 for those randomised to stent plus radiotherapy. Of the 97 patients randomised to receive
radiotherapy, 15 died or withdrew before radiotherapy treatment could be given. One participant
chose a reduction to the planned radiotherapy, from 30 Gy in 10 fractions to 15 Gy in five fractions.
All remaining participants received the planned radiotherapy except one participant who received
8 Gy in one dose, as this was the local practice. This was classified by the TMG as a minor deviation
as this is an appropriate palliative dose and this patient was kept in the per-protocol population.
Missing data, compliance with follow-up and return of European Organisation
for Research and Treatment of Cancer Quality of Life Questionnaire C30 and
OG25 questionnaires
The return of EORTC QLQ-OG25 and C30 questionnaires over time, including missing reasons where
known, is shown in Table 6 and Appendix 3, Table 28, respectively. Although there was very good
questionnaire return in early visits, missing questionnaire data substantially increased over time.
Sensitivity analyses were used to take account of missing primary end-point data, and these are detailed in
the primary outcome analysis below. Around 50% of participants required help to complete questionnaires,
and this stayed fairly constant over time. Fewer participants needed a carer to complete the questionnaire
for them (0–8% prior to week 32). The main reasons for missing questionnaires in both arms were that the
patient was too ill, refused or withdrew consent, or the patient took the questionnaire away and did not
return it. However, for many of the missing questionnaires no reason is given.
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Not eligible, n = 706
• Previous radiotherapy to proposed field,
     n = 113
• Poor performance status or not expected
    to survive 12 weeks, n = 38
• Histology, n = 22
• Other clinical reason, n = 100
• Other treatment given, n = 200
• Unable to provide consent, n = 51
• Other reason (not given), n = 182
Eligible, n = 326
• Patient choice, n = 208
• Clinician choice, n = 29
• Site issues, n = 4
• Entered another study, n = 10
• Died, n = 3











Excluded from per protocol
(n = 12)
• Died, n = 8, or completely
    withdrawn, n = 4, within 4 weeks
    of stent insertion (the number
    of weeks before radiotherapy
    should have been started)
• Found to be ineligible, n = 0
Excluded from ITT
(n = 10)
• No stent inserted, n = 2
• No baseline QLQ-OG25
    assessment, n = 8
Excluded from ITT
(n = 11)
• No stent inserted, n = 3
• No baseline QLQ-OG25
    assessment, n = 8
Excluded from per protocol
(n = 15)
• Did not start radiotherapy, n = 15
    • Died before radiotherapy, n = 7
    • Completely withdrawn before
         radiotherapy, n = 8
• Found to be ineligible, n = 0
Per-protocol population
(n = 82)
FIGURE 2 The CONSORT flow diagram.
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TABLE 2 Baseline characteristics by trial arm
Characteristic Usual care (N= 102) EBRT (N= 97)
Age (years), median (IQR), n 73.5 (65.4–81.5), 102 72.0 (65.3–79.9), 97
Randomisation time point, n (%)
Before stent 39 (38.2) 36 (37.1)
After stent 63 (61.8) 61 (62.9)
WHO performance status, n (%)
0 10 (9.8) 10 (10.3)
1 61 (59.8) 59 (60.8)
2 27 (26.5) 27 (27.8)
3 4 (3.9) 1 (1.0)
4 0 (0.0) 0 (0.0)
Tumour type, n (%)
Adenocarcinoma 68 (66.7) 61 (62.9)
Squamous 33 (32.4) 34 (35.1)
Undifferentiated/other 1 (1.0) 2 (2.1)
Overall length of primary tumour (endoscopic assessment), median (IQR), n
Measured length (cm) 5.0 (4.0–7.0), 64 6.0 (4.0–8.0), 57
Estimated length (cm) 6.0 (4.5–8.0), 28 7.0 (5.0–8.0), 33
Measured/estimated length (cm) 5.9 (4.0–7.0), 92 6.0 (4.5–8.0), 90
Missing 10 (9.8) 7 (7.2)
Alternative method for assessing length, n (%)
PET 5 (4.9) 7 (7.2)
CT 23 (22.5) 23 (23.7)
Barium 0 (0.0) 0 (0.0)
Other 1 (1.0) 0 (0.0)
None 1 (1.0) 0 (0.0)
Site of predominant tumour, n (%)
Upper 3 (2.9) 3 (3.1)
Middle 24 (23.5) 25 (25.8)
Lower 75 (73.5) 68 (70.1)
If lower, involvement of GOJ 38 (37.3) 38 (39.2)
Unknown 0 (0.0) 1 (1.0)
Extension across GOJ (if involvement of GOJ), n (%)
Siewert type 1 21 (20.6) 20 (20.6)
Siewert type 2 15 (14.7) 13 (13.4)
Missing 2 (2.0) 5 (5.2)
T stage
0 1 (1.0) 0 (0.0)
1 1 (1.0) 1 (1.0)
2 4 (3.9) 7 (7.2)
3 61 (59.8) 54 (55.7)
continued
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TABLE 2 Baseline characteristics by trial arm (continued )
Characteristic Usual care (N= 102) EBRT (N= 97)
4 29 (28.4) 31 (32.0)
Unknown 2 (2.0) 2 (2.1)
Missing 4 (3.9) 2 (2.1)
N stage, n (%)
0 17 (16.7) 10 (10.3)
1 46 (45.1) 46 (47.4)
2 20 (19.6) 20 (20.6)
3 15 (14.7) 17 (17.5)
Unknown 1 (1.0) 2 (2.1)
Missing 3 (2.9) 2 (2.1)
M stage, n (%)
0 46 (45.1) 41 (42.3)
1 49 (48.0) 50 (51.5)
Unknown 2 (2.0) 1 (1.0)
Missing 5 (4.9) 5 (5.2)
Overall stage, n (%)
1–3 51 (50.0) 46 (47.4)
4 51 (50.0) 51 (52.6)
GOJ, oesophagogastric junction; PET, positron emission tomography.
TABLE 3 Baseline prior and intended chemotherapy by trial arm
Chemotherapy Usual care (N= 102) EBRT (N= 97)
Previous chemotherapy given, n (%)
No 87 (85.3) 74 (76.3)
Yes 15 (14.7) 23 (23.7)
EOX 6 (5.9) 7 (6.9)
ECX 4 (3.9) 3 (2.9)
Cisplatin + capecitabine 1 (1.0) 3 (2.9)
CX; OxCap 0 (0.0) 2 (2.0)
OxCap 2 (2.0) 0 (0.0)
Carboplatin + capecitabine + epirubicin 0 (0.0) 1 (1.0)
Carboplatin + paclitaxel 0 (0.0) 1 (1.0)
Cisplatin; 5FU 0 (0.0) 1 (1.0)
Cisplatin + epirubicin 0 (0.0) 1 (1.0)
CX 1 (1.0) 0 (0.0)
CX + herceptin; docetaxel 0 (0.0) 1 (1.0)
Docetaxel; irinotecan 0 (0.0) 1 (1.0)
ECF 0 (0.0) 1 (1.0)
ECX neoadjuvant; EOX 0 (0.0) 1 (1.0)
EOX; docetaxel 1 (1.0) 0 (0.0)
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TABLE 3 Baseline prior and intended chemotherapy by trial arm (continued )
Chemotherapy Usual care (N= 102) EBRT (N= 97)
If had prior chemotherapy, intended number of cycles,
median (IQR), n
6.0 (4.0–8.0), 15 4.0 (3.0–6.0), 21
Intended number of cycles missing, n (%) 0 (0.0) 2 (8.7)
Number of prior chemotherapy cycles given, median
(IQR), n
3.0 (2.0–6.0), 15 4.0 (3.0–6.0), 23
MDT intended chemotherapy after stent? n (%)
Yes 36 (35.3) 34 (35.1)
No 66 (64.7) 63 (64.9)
CX, capecitabine chemotherapy; ECF, epirubicin, cisplatin, 5-fluorouracil chemotherapy; ECX, epirubicin, cisplatin,
capecitabine chemotherapy; EOX, epirubicin, oxaliplatin, capecitabine chemotherapy.
TABLE 4 Stent insertion by trial arm
Stent characteristic Usual care (N= 102) EBRT (N= 97)
Type of stent, n (%)
Fully covered stent 31 (30.4) 24 (24.7)
Covered stent with anti-reflux valve 5 (4.9) 3 (3.1)
Partially covered stent 55 (53.9) 58 (59.8)
Partially covered stent with anti-reflux valve 0 (0.0) 1 (1.0)
Uncovered 9 (8.8) 9 (9.3)
Missing 2 (2.0) 2 (2.1)
Length of stent (cm), median (IQR), n 10.2 (8.0–13.0), 100 10.3 (8.0–13.0), 92
Dilatation required, n (%)
Before stent insertion 4 (3.9) 10 (10.3)
After stent insertion 0 (0.0) 2 (2.1)
Not required 95 (93.1) 80 (82.5)
Missing 3 (2.9) 5 (5.2)
Radiological imaging used, n (%)
Yes 69 (67.6) 46 (47.4)
No 33 (32.4) 48 (49.5)
Missing 0 (0.0) 3 (3.1)
Post-insertion oesophagogram performed, n (%)
Yes 10 (9.8) 13 (13.4)
No 92 (90.2) 84 (86.6)
If yes, any stent slippage, n (%)
Yes 0 (0.0) 3 (23.1)
No 10 (100.0) 10 (76.9)
Number of nights in hospital post stent, median (IQR), n 1.0 (0.0–2.0), 102 1.0 (0.0–2.0), 95
Acute airway compression, n (%)
Yes 0 (0.0) 0 (0.0)
No 99 (97.1) 96 (99.0)
Missing 3 (2.9) 1 (1.0)
continued
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TABLE 4 Stent insertion by trial arm (continued )
Stent characteristic Usual care (N= 102) EBRT (N= 97)
Oesophageal or other GI tract perforation, n (%)
Yes 0 (0.0) 0 (0.0)
No 101 (99.0) 97 (100.0)
Missing 1 (1.0) 0 (0.0)
CT scan performed post stent insertion, n (%)
Yes 3 (2.9) 7 (7.2)
No 99 (97.1) 90 (92.8)
Chest X-ray performed post stent insertion, n (%)
Yes 23 (22.5) 21 (21.6)
No 79 (77.5) 76 (78.4)
TABLE 5 Compliance with radiotherapy in EBRT arm
Radiotherapy compliance EBRT (N= 97)
Number of patients receiving radiotherapy, n (%) 82 (84.5)
Reasons if radiotherapy not received, n (%)
Withdrew before radiotherapy 7 (7.2)
Died before radiotherapy 8 (8.2)
Planned dose 20 Gy in five fractions 64 (78.0)
Planned dose 30 Gy in 10 fractions 17 (20.7)
Planned dose 8 Gy in one fraction 1 (1.2)
Reduction to planned dose 1 (1.2)
Radiotherapy delays 10 (12.2)
Toxicity 1 (10.0)
Patient choice 1 (10.0)
Logistical/machine breakdown 3 (30.0)
Other 5 (50.0)
Been hospitalised hydration 1 (10.0)
Felt ill 1 (10.0)
Weekend break 1 (10.0)
Bank holidays 1 (10.0)
Not known 1 (10.0)
Average number of days delayed, median (IQR; range), n 2.0 (1.0–2.0; 1.0–5.0), 10
Field size (cm), median (IQR), n
X 12.0 (10.0–14.0), 81
Y 11.4 (8.3–14.0), 81
Field definition, n (%)
CT simulator 77 (93.9)
Conventional simulator 5 (6.1)
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TABLE 5 Compliance with radiotherapy in EBRT arm (continued )
Radiotherapy compliance EBRT (N= 97)
Field arrangement, n (%)
Parallel pair (anteroposterior, posteroanterior) 76 (92.7)
Other 5 (6.1)
3D conformal radiotherapy 2 (40.0)
4 – field 1 (20.0)
5 – field 1 (20.0)
Conformal ‘4’ field box 1 (20.0)
Missing 1 (1.2)
Number of beams, median (IQR), n 2.0 (2.0–2.0), 82
















Contrast applied, n (%)
Yes 17 (20.7)
No 65 (79.3)




First calculation check done in RADCALC (Computer) 1 (50.0)
OMP planning system 1 (50.0)
Inhomogeneity correction used, n (%)
Yes 18 (22.0)
No 64 (78.0)
3D, three-dimensional; TPS, Treatment Planning Systems.
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TABLE 6 The QLQ-OG25 questionnaire return and missing reason by trial arm
Time point






















Baseline 0 102 102 (100.0) 46 (45.1) 5 (4.9) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
1 week post
stent insertion
0 39 39 (100.0) 21 (53.8) 6 (15.4) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
4 weeks post
stent insertion
11 91 78 (85.7) 36 (46.2) 3 (3.8) 0 (0.0) 3 (23.1) 0 (0.0) 10 (76.9)
8 weeks post
stent insertion
23 79 61 (77.2) 32 (52.5) 2 (3.3) 2 (11.1) 2 (11.1) 0 (0.0) 14 (77.8)
12 weeks post
stent insertion
37 65 46 (70.8) 18 (39.1) 0 (0.0) 3 (15.8) 2 (10.5) 0 (0.0) 14 (73.7)
16 weeks post
stent insertion
49 53 41 (77.4) 24 (58.5) 1 (2.4) 2 (16.7) 2 (16.7) 0 (0.0) 8 (66.7)
20 weeks post
stent insertion
57 45 34 (75.6) 19 (55.9) 0 (0.0) 3 (27.3) 0 (0.0) 0 (0.0) 8 (72.7)
24 weeks post
stent insertion
58 44 27 (61.4) 14 (51.9) 1 (3.7) 3 (17.6) 0 (0.0) 0 (0.0) 14 (82.4)
28 weeks post
stent insertion
65 37 21 (56.8) 11 (52.4) 1 (4.8) 3 (18.8) 0 (0.0) 0 (0.0) 13 (81.3)
32 weeks post
stent insertion
72 30 14 (46.7) 9 (64.3) 0 (0.0) 6 (37.5) 0 (0.0) 0 (0.0) 10 (62.5)
36 weeks post
stent insertion
76 26 13 (50.0) 7 (53.8) 0 (0.0) 1 (7.7) 0 (0.0) 0 (0.0) 12 (92.3)
40 weeks post
stent insertion
79 23 12 (52.2) 5 (41.7) 0 (0.0) 5 (45.5) 0 (0.0) 0 (0.0) 6 (54.5)
44 weeks post
stent insertion
85 17 6 (35.3) 3 (50.0) 0 (0.0) 2 (18.2) 0 (0.0) 0 (0.0) 9 (81.8)
48 weeks post
stent insertion
84 18 7 (38.9) 4 (57.1) 0 (0.0) 2 (18.2) 0 (0.0) 0 (0.0) 9 (81.8)
52 weeks post
stent insertion
86 16 4 (25.0) 2 (50.0) 0 (0.0) 2 (16.7) 0 (0.0) 0 (0.0) 10 (83.3)
a Withdrew/died before form expected.






















0 97 97 (100.0) 38 (39.2) 7 (7.2) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
0 36 36 (100.0) 11 (30.6) 2 (5.6) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
6 91 75 (82.4) 28 (37.3) 3 (4.0) 2 (12.5) 1 (6.3) 1 (6.3) 12 (75.0)
17 80 62 (77.5) 27 (43.5) 4 (6.5) 3 (16.7) 1 (5.6) 0 (0.0) 14 (77.8)
34 63 49 (77.8) 21 (42.9) 3 (6.1) 2 (14.3) 1 (7.1) 0 (0.0) 11 (78.6)
45 52 40 (76.9) 20 (50.0) 3 (7.5) 1 (8.3) 2 (16.7) 0 (0.0) 9 (75.0)
55 42 35 (83.3) 15 (42.9) 2 (5.7) 0 (0.0) 0 (0.0) 0 (0.0) 7 (100.0)
58 39 26 (66.7) 11 (42.3) 1 (3.8) 1 (7.7) 0 (0.0) 0 (0.0) 12 (92.3)
70 27 19 (70.4) 10 (52.6) 1 (5.3) 1 (12.5) 0 (0.0) 0 (0.0) 7 (87.5)
76 21 12 (57.1) 6 (50.0) 2 (16.7) 0 (0.0) 0 (0.0) 0 (0.0) 9 (100.0)
81 16 10 (62.5) 7 (70.0) 1 (10.0) 0 (0.0) 0 (0.0) 0 (0.0) 6 (100.0)
82 15 8 (53.3) 5 (62.5) 1 (12.5) 0 (0.0) 0 (0.0) 0 (0.0) 7 (100.0)
83 14 7 (50.0) 4 (57.1) 1 (14.3) 0 (0.0) 0 (0.0) 0 (0.0) 7 (100.0)
84 13 5 (38.5) 3 (60.0) 0 (0.0) 1 (12.5) 0 (0.0) 0 (0.0) 7 (87.5)
85 12 5 (41.7) 2 (40.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 7 (100.0)
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Baseline characteristics of participants missing versus not missing primary end-point data
Baseline characteristics of those participants missing and those not missing primary end-point data
were reasonably well balanced, as shown in Table 7 and in Appendix 3, Table 29.
TABLE 7 Baseline characteristics of participants missing vs. not missing primary end-point data
Characteristic
Complete data up to week 12
(N= 149)
Missing data up to week 12
(N= 50)
Age (years), median (IQR), n 72.2 (64.8–80.2), 149 75.0 (68.4–83.3), 50
Randomisation time point, n (%)
Before stent 59 (39.6) 16 (32.0)
After stent 90 (60.4) 34 (68.0)
WHO performance status, n (%)
0 17 (11.4) 3 (6.0)
1 93 (62.4) 27 (54.0)
2 37 (24.8) 17 (34.0)
3 2 (1.3) 3 (6.0)
Tumour type, n (%)
Adenocarcinoma 96 (64.4) 33 (66.0)
Squamous 51 (34.2) 16 (32.0)
Undifferentiated/other 2 (1.3) 1 (2.0)
Overall length of primary tumour (endoscopic assessment)
Measured length (cm), median (IQR), n 5.0 (4.0–7.0), 93 5.3 (4.3–7.0), 28
Estimated length (cm), median (IQR), n 6.0 (5.0–8.0), 42 7.0 (5.5–9.0), 19
Measured/estimated length (cm),
median (IQR), n
6.0 (4.0–8.0), 135 6.0 (5.0–8.0), 47
Missing, n (%) 14 (9.4) 3 (6.0)
Alternative method for assessing length, n (%)
PET 9 (6.0) 3 (6.0)
CT 33 (22.1) 13 (26.0)
Barium 0 (0.0) 0 (0.0)
Other 1 (0.7) 0 (0.0)
None 1 (0.7) 0 (0.0)
Site of predominant tumour, n (%)
Upper 5 (3.4) 1 (2.0)
Middle 34 (22.8) 15 (30.0)
Lower 109 (73.2) 34 (68.0)
If lower, involvement of GOJ 60 (40.3) 16 (32.0)
Unknown 1 (0.7) 0 (0.0)
RESULTS




There were 102 versus 97 patients (usual care vs. EBRT) in the modified ITT population with 74 versus
75 patients (usual care vs. EBRT) having complete data at week 12 for the primary end point (Table 8).
The complete-case analysis, which included deaths up to week 12 with complete data as an event,
showed no evidence of a difference in the proportion of patients experiencing a primary event up to
week 12 post stent by trial arm [36/74 (48.6%) vs. 34/75 (45.3%); adjusted odds ratio (OR) 0.82, 95% CI
0.40 to 1.68; p = 0.587]. The sensitivity analysis, treating death by week 12 without prior event as no
event, also showed no evidence of a difference between trial arms [21/74 (28.4%) vs. 21/75 (28.0%);
adjusted OR 1.05, 95% CI 0.49 to 2.25; p = 0.893].
TABLE 7 Baseline characteristics of participants missing vs. not missing primary end-point data (continued )
Characteristic
Complete data up to week 12
(N= 149)
Missing data up to week 12
(N= 50)
Extension across GOJ (if involvement of GOJ), n (%)
Siewert type 1 32 (21.5) 9 (18.0)
Siewert type 2 26 (17.4) 2 (4.0)
Missing 2 (1.3) 5 (10.0)
T stage, n (%)
0 1 (0.7) 0 (0.0)
1 1 (0.7) 1 (2.0)
2 7 (4.7) 4 (8.0)
3 87 (58.4) 28 (56.0)
4 45 (30.2) 15 (30.0)
Unknown 2 (1.3) 2 (4.0)
X 6 (4.0) 0 (0.0)
N stage, n (%)
0 20 (13.4) 7 (14.0)
1 68 (45.6) 24 (48.0)
2 29 (19.5) 11 (22.0)
3 27 (18.1) 5 (10.0)
Unknown 1 (0.7) 2 (4.0)
X 4 (2.7) 1 (2.0)
M stage, n (%)
0 63 (42.3) 24 (48.0)
1 77 (51.7) 22 (44.0)
Unknown 1 (0.7) 2 (4.0)
X 8 (5.4) 2 (4.0)
Overall stage, n (%)
1–3 70 (47.0) 27 (54.0)
4 79 (53.0) 23 (46.0)
GOJ, oesophagogastric junction; PET, positron emission tomography.
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Imputation of missing data under the best- and worst-case scenarios resulted in 90 versus 88 patients
in the denominator for the associated sensitivity analyses. Those with remaining missing data were
missing two or more questionnaires and no deterioration had been confirmed prior to this. There was
no evidence of a difference in the primary end point between trial arms under either the best-case
(p = 0.612) or the worst-case (p = 0.345) scenario.
Per-protocol population
There were 90 versus 82 patients in the per-protocol population with 66 versus 64 (usual care vs. EBRT)
having complete data at week 12 for the primary end point (Table 9). The complete-case analysis, which
included deaths up to week 12 with complete data as an event, showed no evidence of a difference
in the proportion of patients experiencing a primary event up to week 12 post stent by trial arm
[28/66 (42.4%) vs. 26/64 (40.6%); adjusted OR 0.99, 95% CI 0.45 to 2.14; p = 0.972]. The sensitivity
TABLE 8 Analysis of status and primary end point at 12 weeks post stent insertion in the modified ITT population by trial arm
Characteristic
Usual care
(N= 102), n (%)
EBRT
(N= 97), n (%)
Adjusted OR
(95% CI; p-value, n)
Incomplete-case data at week 12
Completely withdrew with no event 6 (5.9) 5 (5.2)
Died with incomplete data and
no event
8 (7.8) 6 (6.2)
Alive at week 12 with incomplete data
and no event
14 (13.7) 11 (11.3)
Reasons for complete withdrawal
Participant choice 3 (2.9) 4 (4.1)
Other 3 (2.9) 1 (1.0)
Informed by CNS on family’s behalf 1 (1.0) 0 (0.0)
Lost to follow-up 1 (1.0) 1 (1.0)
Transferred to another area due
to relocation
1 (1.0) 0 (0.0)
Complete-case data at week 12
Total with complete data 74 (72.5) 75 (77.3)
Died with complete data 20 (19.6) 22 (22.7)
Alive at week 12 with complete data 54 (52.9) 53 (54.6)
Complete-case analysis (death as an event)
Number of primary events or deaths 36 (48.6) 34 (45.3) 0.82 (0.40 to 1.68; 0.587, 149)
Sensitivity analyses
Complete-case analysis (death as non-event)
Number of primary events 21 (28.4) 21 (28.0) 1.05 (0.49 to 2.25; 0.893, 149)
Best case
Total with complete data 90 (88.2) 88 (90.7)
Number of primary events or deaths 40 (44.4) 36 (40.9) 0.85 (0.44 to 1.62; 0.612, 178)
Worst case
Total with complete data 90 (88.2) 88 (90.7)
Number of primary events or deaths 53 (58.9) 46 (52.3) 0.73 (0.38 to 1.40; 0.345, 178)
CNS, clinical nurse specialist.
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analysis, treating death by week 12 without prior event as no event, also showed no evidence of a
difference between trial arms [19/66 (28.8%) vs. 19/64 (29.7%); adjusted OR 1.20, 95% CI 0.53 to 2.71;
p = 0.666]. The complete cases in the per-protocol population all completed full planned radiotherapy.
Imputation of missing data under the best- and worst-case scenarios resulted in 82 versus 76 patients
in the denominator for the associated sensitivity analyses. Those with remaining missing data were
missing two or more questionnaires and no deterioration had been confirmed prior to this. There was
no evidence of a difference in the primary end point between trial arms under either the best-case
(p = 0.910) or the worst-case (p = 0.527) scenario.
Dysphagia deterioration-free survival
Figure 3 shows secondary analysis of the original primary end point of DDFS over all time points. There was
no evidence of a difference between the arms (adjusted HR 0.92; 95% CI 0.68 to 1.26; p = 0.618; n = 199).
Overall, the median time to dysphagia event or death was 14.6 weeks (95% CI 12.1 to 17.4 weeks); median
time to dysphagia event or death was 13.1 weeks (95% CI 10 to 17.9 weeks) and 14.7 weeks (95% CI 12.1
to 17.4 weeks) in the usual-care arm and the EBRT arm, respectively.
TABLE 9 Analysis of status and primary end point at 12 weeks post stent insertion in the per-protocol population by
trial arm
Characteristic Stent (N= 90), n (%)
Stent plus
radiotherapy
(N= 82), n (%)
Adjusted OR
(95% CI; p-value, n)
Incomplete case data at week 12
Completely withdrew with no event 2 (2.2) 3 (3.7)
Died with incomplete data and
no event
8 (8.9) 5 (6.1)
Alive at week 12 with incomplete data
and no event
14 (15.6) 10 (12.2)
Reasons for complete withdrawal
Participant choice 1 (1.1) 2 (2.4)
Other 1 (1.1) 1 (1.2)
Informed by CNS on family’s behalf 1 (1.1) 0 (0.0)
Loss to follow-up 0 (0.0) 1 (1.2)
Complete-case data at week 12
Total with complete data 66 (73.3) 64 (78.0)
Died with complete data 12 (13.3) 14 (17.1)
Alive at week 12 with complete data 54 (60.0) 50 (61.0)
Complete-case analysis (death as an event)
Number of primary events or deaths 28 (42.4) 26 (40.6) 0.99 (0.45 to 2.14; 0.972; 130)
Complete-case analysis (death as non-event)
Number of primary events 19 (28.8) 19 (29.7) 1.20 (0.53 to 2.71; 0.666; 130)
Best case
Total with complete data 82 (91.1) 76 (92.7)
Number of primary events or deaths 32 (39.0) 28 (36.8) 0.96 (0.48 to 1.93; 0.910; 158)
Worst case
Total with complete data 82 (91.1) 76 (92.7)
Number of primary events or deaths 45 (54.9) 37 (48.7) 0.80 (0.41 to 1.58; 0.527; 158)
CNS, clinical nurse specialist.
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Censoring at death with no event resulted in an adjusted HR 0.97 (95% CI 0.59 to 1.60; p = 0.904;
n = 199). Overall, median time to dysphagia event was 41.1 weeks (95% CI 28 weeks – not reached).
Median time to dysphagia event was 41.1 weeks (95% CI 24.1 weeks – not reached) and 30.3 (95% CI
25.4 weeks – not reached) in the usual-care arm and the EBRT arm, respectively.
Secondary outcomes
Overall survival and follow-up
Overall survival and follow-up post stent insertion are shown in Table 10. Very few patients were still
alive at the end of the study. Median follow-up in those still alive was 22.9 weeks (95% CI 4.0 to
41.9 weeks) (n = 16) versus 22.1 weeks (95% CI 8.0 to 34.7 weeks) (n = 15) (see Appendix 3, Figure 22).
There was no evidence of difference in OS: median OS was 19.7 weeks (95% CI 14.4 to 27.7 weeks)
versus 18.9 weeks (95% CI 14.7 to 25.6 weeks) in the usual-care arm versus the EBRT arm, respectively
(adjusted HR 1.06; 95% CI 0.78 to 1.45; two-sided p-value 0.700) (Figure 4).
TABLE 10 Follow-up and OS by trial arm
Characteristic Usual care (N= 102) EBRT (N= 97)
Median follow-up post stent, weeks (95% CI), n 22.9 (4.0 to 41.9), 16 22.1 (8.0 to 34.7), 15
Median overall survival post stent, weeks (95% CI), n 19.7 (14.4 to 27.7), 102 18.9 (14.7 to 25.6), 97
Total deaths, n (%) 86 (84.3) 82 (84.5)
Causes of death, n (%)
Oesophageal cancer 79 (91.9) 72 (87.8)
Stent related 2 (2.3) 2 (2.4)
Radiotherapy related 0 (0.0) 1 (1.2)
Other, please specify 5 (5.8) 7 (8.5)
Acute kidney injury, bladder cancer 0 (0.0) 1 (1.2)
Cardiovascular 1 (1.2) 1 (1.2)
Chest sepsis 2 (2.3) 1 (1.2)
GI bleed 0 (0.0) 1 (1.2)
Neutropenic sepsis 0 (0.0) 1 (1.2)
Pulmonary embolism 0 (0.0) 2 (2.4)




































FIGURE 3 Dysphagia deterioration-free survival post stent by trial arm.
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European Organisation for Research and Treatment of Cancer – Quality of Life Questionnaire
C30 and OG25 questionnaire scales and World Health Organization performance status
The prespecified main subscales or items of interest were global health (Figure 5), odynophagia (Figure 6),
pain/discomfort (OG25) (Figure 7), eating restrictions (Figure 8) and eating in front of others (Figure 9).
There was no evidence of time versus treatment interactions for any of these (p-values all > 0.05).
Appendix 3, Table 30, shows the results of the linear mixed models for the EORTC-QLQ-C30 and OG25
questionnaires scales and WHO performance status. As can be seen, the proportion of missing data
at each time point was balanced across trial arms and increased from ≈ 0% at the first post-stent
assessment to ≈ 25% at week 4, ≈ 40% at week 8, ≈ 55% at week 12 and > 60% at week 16.
There was evidence of time versus treatment interaction for dysphagia (p-value = 0.013), (Figure 10).
It can be seen that at week 4 the median dysphagia was higher in the radiotherapy arm, but by
week 8 scores were the same in both arms. This short-term deterioration was expected hence the
requirement for two successive deteriorations needed in the definition of the primary end point.
There was evidence of time versus treatment interactions for pain as measured by the EORTC QLQ-C30
(p = 0.005) (Figure 11). It can be seen that at weeks 8, 12 and 16 the median pain score was higher in
the radiotherapy arm. There was also evidence of time versus treatment interactions for constipation
(p = 0.009). The mean score at weeks 8, 12 and 16 was higher in the radiotherapy arm, mirroring the

































































FIGURE 5 Mean global health scores and 95% CIs by time and treatment arm.
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FIGURE 8 Mean eating restrictions scores and 95% CIs by time and treatment arm.
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FIGURE 11 Box plots of pain scores (QLQ-C30) by time and treatment arm.
DOI: 10.3310/hta25310 Health Technology Assessment 2021 Vol. 25 No. 31
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Adamson et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
35
There was also evidence of time versus treatment interactions for cognitive functioning (p = 0.007,
with higher median scores at weeks 12 and 16 in the radiotherapy arm), body image (p = 0.011, with
higher median scores at weeks 8 and 16 in the radiotherapy arm), anxiety (p = 0.002, with higher mean
scores at weeks 12 and 16 in the radiotherapy arm) and trouble swallowing saliva (p = 0.025, with
higher median scores at week 16 in the radiotherapy arm). These findings are more difficult to
understand and may be due to chance.
There was no evidence for time–treatment interactions for fatigue (p = 0.522; Figure 12), weight loss
(p = 0.053),WHO performance status (p = 0.565; Appendix 3, Figure 23) or any of the other HRQoL scales.
Upper gastrointestinal-related bleeding events
There was evidence of a difference in time to first upper GI-related bleed event or upper GI-related
hospital admission between trial arms (Figure 13). Adjusted subhazard ratio was 0.52 (95% CI 0.28 to
0.97; p = 0.038, n = 199). Median time to first upper GI-related bleeding event or hospital admission
for bleeding event was 49.0 weeks (95% CI 33.3 to not reached weeks) versus 65.9 weeks (95% CI
52.7 to not reached weeks) in the usual-care arm versus the EBRT arm, respectively. Three participants
versus four participants (usual care vs. EBRT) had anticoagulant treatment within 4 weeks before the
first upper GI-related bleeding event. Table 11 shows the analysis of upper GI-related bleeding events
















































FIGURE 13 Cumulative incidence function plot of time to first upper GI-related bleed event or hospital admission by trial
arm, with death as a competing risk.
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TABLE 11 Upper GI-related bleeding events overall and up to week 16 by trial arm
Characteristic Usual care (N= 102) EBRT (N= 97)
Overall
Number of patients with at least one upper GI-related bleeding event, n (%) 29 (28.4) 16 (16.5)
Absolute risk reduction 0.119
Number needed to treat 8.4
Number of patients experiencing each type of upper GI-related bleeding event, n (%)
Blood transfusion 26 (25.5) 13 (13.4)
Haematemesis 5 (4.9) 6 (6.2)
Upper GI haemorrhage or bleed 8 (7.8) 2 (2.1)
Melaena 4 (3.9) 0 (0.0)
Argon plasma coagulation due to bleed 0 (0.0) 1 (1.0)
Additional radiotherapy due to bleed 1 (1.0) 0 (0.0)
Anaemia due to bleed 4 (3.9) 2 (2.1)
Number of patients with upper GI-related bleeding event who received
antiplatelet drugsa
0 (0.0) 0 (0.0)
Number of patients with upper GI-related bleeding event who received
anticoagulantsb
7 (6.9) 7 (7.2)
Number of patients with upper GI-related bleeding event who received
NSAIDs other than aspirin
4 (3.9) 0 (0.0)
Up to week 16
Number of patients with at least one upper GI-related bleeding event, n (%) 19 (18.6) 10 (10.3)
Absolute risk reduction 0.083
Number needed to treat 12.0
Number of patients experiencing each type of upper GI-related bleeding event, n (%)
Blood transfusion 13 (12.7) 9 (9.3)
Haematemesis 4 (3.9) 3 (3.1)
Upper GI haemorrhage or bleed 6 (5.9) 1 (1.0)
Melaena 3 (2.9) 0 (0.0)
Argon plasma coagulation due to bleed 0 (0.0) 0 (0.0)
Additional radiotherapy due to bleed 0 (0.0) 0 (0.0)
Anaemia due to bleed 2 (2.0) 2 (2.1)
Number of patients with upper GI-related bleeding event who received
antiplatelet drugsa
0 (0.0) 0 (0.0)
Number of patients with upper GI-related bleeding event who received
anticoagulantsb
5 (4.9) 4 (4.1)
Number of patients with upper GI-related bleeding event who received
NSAIDs other than aspirin
2 (2.0) 0 (0.0)
NSAID, non-steroidal anti-inflammatory drug.
a Aspirin or clopidogrel.
b Dalteparin (Fragmin®, Pfizer Inc., New York, NY, USA), enoxaparin, rivaroxaban (Xarelto®, Bayer AG, Leverkusen,
Germany) or other unspecified anticoagulant.
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patients had an upper GI-related bleed event (usual care vs. EBRT). The number needed to treat was
therefore 8.4. Blood transfusion was the most common event (25.5% vs. 13.4%, usual care vs. EBRT),
followed by haematemesis (4.9% vs. 6.2%) and upper GI haemorrhage or bleed (7.8% vs. 2.1%).
No patients in either arm who experienced an upper GI-related bleed event received antiplatelet drugs
at any point over the 52 weeks, but 6.9% versus 7.2% received anticoagulants. A total of 4.9% in the
usual-care arm received non-steroidal anti-inflammatory drugs (NSAIDs) other than aspirin, but none in
the EBRT arm did so.
Up to week 16, 19 patients (18.6%) versus 10 patients (10.3%) had an upper GI-related bleed event
(usual care vs. EBRT). The number needed to treat was therefore 12.0. Blood transfusion was the
most common event (12.7% vs. 9.3%, usual care vs. EBRT), followed by haematemesis (3.9% vs. 3.1%)
and upper GI haemorrhage or bleed (5.9% vs. 1%). No patients in either arm who experienced an upper
GI-related bleed event received antiplatelet drugs at any point over the 16 weeks, but 4.9% versus
4.1% received anticoagulants. Two per cent in the usual-care arm received NSAIDs other than aspirin,
but none in the EBRT arm did so.
A post hoc subgroup analysis was conducted to look for evidence of an interaction between treatment
allocation and tumour length on time to first bleed but none was found (p-value for interaction 0.947;
adjusted for randomisation stratification variables). The treatment effect was consistent in both
subgroups: for baseline tumour length < 6 cm, adjusted subhazard ratio = 0.58 (95% CI 0.24 to 1.38;
p-value 0.216; n = 88); for those patients with baseline tumour length ≥ 6 cm, adjusted subhazard
ratio = 0.60 (95% CI 0.24 to 1.48; p-value 0.265; n = 94).
With or without an upper GI bleed event, antiplatelet and anticoagulant drug administration was
reasonably balanced between trial arms (Table 12). Very few patients received antiplatelet treatment;
however, 16.7% versus 18.6% of patients (usual care vs. EBRT) received anticoagulants. In total,
six patients (5.9%) in the usual-care arm received tranexamic acid versus none in the EBRT arm.
Overall, 38.2% versus 49.5% of patients (usual care vs. EBRT) received opioids.
Dysphagia-related stent complications and reinterventions
There was no evidence of a difference in time to first dysphagia-related stent complication or
reintervention event between trial arms [see Appendix 3, Figure 24; adjusted subhazard ratio 0.79
(95% CI 0.37 to 1.66; p = 0.529; n = 199)]. Median time to first dysphagia-related stent complication
or reintervention event was 45.7 weeks (95% CI 37 to not reached weeks) versus 58.9 weeks (95% CI
36.7 to not reached weeks) (usual care vs. EBRT).
TABLE 12 Antiplatelet and other specified treatments given post stent insertion at any point
Treatment Usual care (N= 102), n (%) EBRT (N= 97), n (%)
Aspirin 1 (1.0) 2 (2.1)
Clopidogrel 0 (0.0) 2 (2.1)
Tranexamic acid 6 (5.9) 0 (0.0)
Anticoagulants 21 (20.6) 18 (18.6)
NSAIDs other than aspirin 7 (6.9) 1 (1.0)
Opioids 39 (38.2) 48 (49.5)
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Additional stent insertion
There was no evidence of a difference in time to first additional stent insertion between trial arms
(adjusted subhazard ratio 0.58, 95% CI 0.23 to 1.46; p = 0.246; n = 199). Median time to first additional
stent insertion was not reached versus 59.7 weeks (95% CI 43.3 to not reached weeks) stent versus
stent plus radiotherapy.
Repeat endoscopy
There was no evidence of a difference in time to first repeat endoscopy between trial arms (see
Appendix 3, Figure 25; adjusted subhazard ratio 1.72, 95% CI 0.86 to 3.47; p = 0.126; n = 199).
Median time to first repeat endoscopy (in weeks) was not reached in either arm.
Overgrowth or undergrowth of stent
There was no evidence of a difference in time to first overgrowth or undergrowth of stent event
between trial arms (see Appendix 3, Figure 26; adjusted subhazard ratio 0.83, 95% CI 0.21 to 3.24;
p = 0.785). Median time to first overgrowth or undergrowth of stent event (in weeks) was not reached
in either arm.
Stent-related pain
There was no evidence of a difference in time to first grade 2+ stent-related pain event between trial
arms (Figure 14; adjusted subhazard ratio 1.27, 95% CI 0.80 to 2.03; p = 0.318; n = 199). Median time to
first stent-related pain event was not reached versus 36.3 weeks (95% CI 20.0 to not reached weeks)
stent versus stent plus radiotherapy.
Toxicity
Figure 15 shows the percentage of patients experiencing each grade 3/4 toxicity by trial arm
after week 1 up to week 16. There was more vomiting in the radiotherapy arm, primarily at week 4
(2.3% vs. 11.9%), and this was also seen at week 4 in the QLQ score (see Appendix 3, Table 30 and
Figure 27). There was also more fatigue in the EBRT arm, particularly at week 12 (4.9% vs. 15.4%),
consistent with the fatigue scores reported on the QLQ-C30 questionnaires at these time points
(see Figure 12 and Appendix 3, Table 30). There was also more nausea, anorexia and stent-related pain
in those receiving radiotherapy, but less anaemia and upper GI haemorrhage.
Three deaths (stent: one fall, one myocardial infarction; stent plus radiotherapy: one multifocal ischaemic






















FIGURE 14 Cumulative incidence function plot of time to first grade 2+ stent-related pain event by trial arm, with death
as a competing risk.
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Additional palliative radiotherapy
In total, 19.6% versus 9.3% (usual care vs. EBRT) of patients received additional palliative radiotherapy
(Table 13). In the usual-care arm, 80% of these received radiotherapy to the oesophagus, compared
with 22.2% in the EBRT arm. The median dose and fractions were 20 Gy in five fractions in the usual-care
arm and 8 Gy in one fraction in the EBRT arm.

























FIGURE 15 Bar chart showing percentage of participants experiencing each grade 3/4 toxicity up to week 16, by trial arm.
TABLE 13 Additional palliative radiotherapy given by trial arm
Characteristic Usual care (N= 102) EBRT (N= 97)
Additional palliative radiotherapy, n (%)
Yes 20 (19.6) 9 (9.3)
No 82 (80.4) 88 (90.7)
If yes, organ/region, n (%)
Oesophagus 16 (80.0) 2 (22.2)
Bilateral sub clavian fossa 1 (5.0) 0 (0.0)
Brain 1 (5.0) 1 (11.1)
Femur 1 (5.0) 0 (0.0)
Gastro-oesophageal junction 1 (5.0) 0 (0.0)
L1–L3 vertebrae and left pelvis 0 (0.0) 1 (11.1)
L4–S1 0 (0.0) 1 (11.1)
Left lung 1 (5.0) 0 (0.0)
Left supraclavicular fossa 0 (0.0) 1 (11.1)
Lumbar spine 0 (0.0) 1 (11.1)
Posterior ribs 0 (0.0) 1 (11.1)
Right hip 1 (5.0) 0 (0.0)
Scapula 0 (0.0) 2 (22.2)
Total dose (Gy), median (IQR), na 20.0 (8.0–30.0), 19 8.0 (8.0–20.0), 9
Total fractions, median (IQR), na 5.0 (3.0–10.0), 19 1.0 (1.0–5.0), 9
a One participant was missing radiotherapy dose and fractions given.
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Post-stent insertion chemotherapy
Table 14 shows post-stent insertion chemotherapy given. The MDT intended to give chemotherapy to
36 out of 102 (35.3%) versus 34 out of 97 (35.1%) patients. Although 29 out of 36 (80.6%) of these
in the usual-care arm were given chemotherapy, less than half of those [15/34 (44.1%)] in the EBRT
arm were given chemotherapy. An additional four versus two patients, for whom the MDT had not
originally intended to give chemotherapy, received chemotherapy post stent.
TABLE 14 Post-stent insertion chemotherapy
Usual care (N= 102) EBRT (N= 97)
MDT intends to give chemotherapy, n (%) 36 (35.3) 34 (35.1)
If yes, did patient receive chemotherapy for oesophageal cancer post stent insertion? n (%)
Yes 29 (80.6) 15 (44.1)
Received chemotherapy for oesophageal cancer post stent insertion, n (%)
Yes 33 (32.4) 17 (16.7)
No 68 (66.7) 79 (77.5)
Missing 1 (1.0) 1 (1.0)
If yes, which?a n (%)
ECF 2 (6.1) 1 (5.9)
Capecitabine 2 (6.1) 0 (0.0)
EOX 13 (39.4) 8 (47.1)
5FU 1 (3.0) 0 (0.0)
Other 31 (93.9) 13 (76.5)
(1) ECX × 3 cycles, (2) docetaxel × 3 cycles and
(3) irinotecan
0 (0.0) 1 (5.9)
Trastuzumab, capecitabine + cisplatin 1 (3.0) 0 (0.0)
CX 4 (12.1) 1 (5.9)
CX+ herceptin 6 (18.2) 2 (11.8)
Capecitabine 2 (6.1) 0 (0.0)
Carboplatin 1 (3.0) 0 (0.0)
Carboplatin+ epirubicin 1 (3.0) 0 (0.0)
Carboplatin+ herceptin 0 (0.0) 2 (11.8)
Carboplatin+ paclitaxel 1 (3.0) 1 (5.9)
Cisplatin 2 (6.1) 1 (5.9)
Docetaxel 4 (12.1) 1 (5.9)
Durvalumab 1 (3.0) 0 (0.0)
ECX 0 (0.0) 1 (5.9)
Epirubicin+ oxaliplatin 1 (3.0) 0 (0.0)
Folfiri 1 (3.0) 0 (0.0)
Herceptin 0 (0.0) 1 (5.9)
Irinotecan 0 (0.0) 1 (5.9)
continued
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TABLE 14 Post-stent insertion chemotherapy (continued )
Usual care (N= 102) EBRT (N= 97)
OxCap 2 (6.1) 0 (0.0)
Oxaliplatin 2 (6.1) 0 (0.0)
Paclitaxel 1 (3.0) 0 (0.0)
Paclitaxel and ramucirumab 1 (3.0) 0 (0.0)
Raltitrexed and oxaliplatin 0 (0.0) 1 (5.9)
Intended number of cycles, median (IQR), n 6.0 (4.0–6.0), 29 6.0 (4.0–6.0), 16
Intended number of cycles missing, n (%) 4 (12.1) 1 (5.9)
Number of cycles given, median (IQR), n 3.0 (2.0–4.0), 33 4.0 (3.0–4.0), 16
Number of cycles given missing, n (%) 0 (0.0) 1 (5.9)
5FU, 5-fluorouracil; CX, capecitabine chemotherapy; ECF, epirubicin, cisplatin, 5-fluorouracil chemotherapy;
ECX, epirubicin, cisplatin, capecitabine chemotherapy; EOX, epirubicin, oxaliplatin, capecitabine chemotherapy.
a Some patents had more than one.
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Chapter 4 Qualitative study
Background
The prognosis for oesophageal cancer is often poor, and most patients present with incurable disease,
with a mean survival of 3–5 months. Cancer Research UK has identified oesophageal cancer as a
priority for clinical research,39 but there is limited literature about the experience of living with the
disease. In qualitative research involving 13 patients,40 the information-seeking patterns and needs
of patients with oesophageal cancer were elicited. Patients outlined the strategies used to manage
uncertainty, such as trial and error and rationalisation, and emphasised the need to consider the whole
family in delivering sufficient information. A recent systematic review41 described a lack of services
designed to meet the needs of people with oesophageal cancer and recommended more bespoke
support for complex cases. In addition, there are complex implications for the patient’s everyday life
and idiosyncratic beliefs with challenges to role and identity. A study with five patients highlighted
these issues through narrative interviews that were analysed using a phenomenological–hermeneutic
approach.42,43
Dysphagia is one of the most distressing manifestations of the disease and the main focus of treatment,
while fatigue challenges activities of everyday life.44 The psychosocial role of food adds a further
dimension to the perceived challenges posed by oesophageal cancer to the mechanics of eating. Palliation
of dysphagia remains the focus of treatment but may result in specialist palliative interventions being
overlooked. Clinical outcomes among 131 patients who underwent palliative interventions highlighted
the palliative limitations of treatments such as SEMSs.45
Qualitative methods were used to explore the views and experiences of patients in this trial. The aim
was to understand how patients understood and experienced the trial itself and what effect the
insertion of a stent had on patients’ QoL. The study particularly explored experiences of patients
who also received radiotherapy. The qualitative data form an essential part of the trial’s evaluation,
provide in-depth patient-centred assessment and support further understanding of the quantitative
trial’s results.
Aims
The qualitative component of the trial had two aims: (1) to explore the acceptability and feasibility
of patients’ recruitment to the trial and (2) to explore participants’ experience of trial interventions.
Patients’ experiences of consent and recruitment, including reasons for declining, were elicited,
as were patients’ motivation to accept randomisation to an intervention that may have included extra
radiotherapy. Recruitment to the qualitative component was optional and required separate consent.
Patients who declined to participate in the trial, but who did consent to the qualitative component, were
offered an interview about their reasons for declining as soon as possible after the approach to participate.
By drawing on the reported experiences of patients, the ROCS qualitative study focused on the
following objectives to:
l explore patients’ motivation for participation in the trial
l explore patients’ perceptions of participation in the trial
l explore reasons for non-consent to the trial
l assess patient experience and perceptions of each trial arm
l identify potential improvements to the recruitment process.
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Information about the optional qualitative study was given to trial participants (and those who declined)
by research nurses at the research sites. Patients were provided with a tear-off slip and a stamped
addressed envelope to return their contact details directly to the qualitative researcher. Patients were
then contacted by the researcher to arrange a time and location for the interview to take place. The
qualitative researcher thoroughly explained the study to the patient, giving them ample opportunity to
ask questions and make an informed decision before signed consent was taken from each participant at
the time of interview. All patients were made aware that they were able to withdraw from the study at
any point, without explanation. Patient companions at the time of interview were also asked for their
consent to record and use their interview data.
Subsequent to the consent process, the interviews were conducted at either the participant’s home or
an alternative quiet location including hospital rooms. Interviews took between 19 and 116 minutes,
with a median time of 68 minutes. For all of the interviews, semistructured topic guides were used to
ensure consistency among participants. The interview guide was adapted following initial interviews to
reflect participants’ concerns and perceptions. Participants were encouraged to discuss their wider
experiences and perceptions in relation to the trial, treatment interventions, or oesophageal cancer
generally. All interviews were audio-recorded and transcribed verbatim.
The interviewers were experienced researchers with backgrounds in occupational therapy and
narrative analysis and sociology. Both interviewers have experience of palliative care research and
conducting interviews concerning sensitive topics.
Data analysis was based on the analysis of 30 longitudinal interviews conducted with 15 patients
over the first 8 weeks of their trial involvement (Table 15). Nine patients were randomised to the





















F, female; M, male.
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EBRT arm (received radiotherapy after stenting) and six to the usual-care arm (no radiotherapy).
All patients were allocated pseudonyms to protect their identity. Each reference to a participant is
followed by a letter, as follows: a, first interview; b, second interview; c, third interview. One patient
declined to participate in the study and two research nurses also participated in interviews.
Data analysis
Interviews were analysed using Braun and Clarke’s framework for thematic analysis.46 Analysis moved
from familiarisation with interviews to initial coding and identifying and defining themes. Coding comprised
two approaches: first, data were coded to elicit specific interpretation around key areas of research study
participation and comparison across the two study arms; and second, a coding framework was developed
around coping and QoL to elicit a rich description of the experience of living with oesophageal cancer.
The coding process was managed using NVivo (QSR International, Warrington, UK) version 11 software
and reflected the interview process, with the interviewer asking specific questions around trial
experience but taking an inductive approach to describe accounts of the everyday experience of patients
and carers. Ten per cent of coded data were checked for agreement by a member of the trial team (AN).
Themes were identified in 16 areas relating to trial experience, and overall coping and QoL when living
with oesophageal cancer (see Table 16). These included symptoms and management, deciding to join
the trial and experience of trial interventions. The next stage of analysis looked at higher-level themes,
exploring what the nature of the strategies and barriers were and how patients constructed their
experience of oesophageal cancer.
Once coding and the development of the themes were completed, two frameworks evolved: one
further developing specific insights around trial experience and the other an interpretive account of
living with oesophageal cancer. Supplementary materials are available in the appendices to illustrate
the depth of data available for each theme.
Results
There was an overlap between the two frameworks, such as the experience of the stent, but the
relationship between coding and themes was central (i.e. stent experience within the trial and stent
within themes of living with oesophageal cancer, e.g. adaption, agency and uncertainty). Table 16
outlines the emergent themes and subthemes.
The following section highlights the experiences of patients and carers regarding their recruitment and
participation in the trial. It outlines participants’ perceptions, including randomisation of each trial arm
and perspectives from non-consenters. In addition, the experiences of participants, including the QLQs
and burdens and benefits of the trial, and researchers’ perspectives are demonstrated.
Recruitment to the trial
Participants spoke at length about their experiences of recruitment to the trial, including their reasons
for participating. Most patients expressed a desire to help others in the future through the research,
implying a sense of altruism:
I can help somebody, someone else, whatever, kids, or something, yeah, that’s how I feel anyway, I said it’s
not for me, for someone down the line.
Usual-care patient, Joan a
It seemed to be not be too much trouble and if it’s to help other people in the future that would be
a bonus.
EBRT patient, May a
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Patients reported that they wanted to give back to the health service: ‘A very tiny payback for an
enormous amount of care I’m about to get’ (usual-care patient, Betty a). Other patients felt that they
would potentially benefit from the trial itself, particularly if they received radiotherapy: ‘I was thinking
radiography part of it might have helped me’ (usual-care patient, Bernard a). For some patients,
participation offered ‘a bit a bit of hope’ (usual-care patient, Bernard b).
Perceptions of trial participation
In the initial stages of the qualitative study (the first 6 months of data collection), the time between
the research nurse approaching the patient about the study and the stent procedure taking place was
very short, and this had a significant impact on the participants’ recall of the recruitment process.
Common across participants’ reflections were feelings of being too rushed:
She [research nurse] came to hospital just before I was having the stent because it was all rushed . . .
I was ready to go to the procedure, so I was kind of [loud bang] mind going to other places.
EBRT patient, Arthur a
Participants also reported feeling very stressed and pressured at the time of receiving the information,
recounting the volume of information at recruitment as being overwhelming and often repetitive:
Patient: It’s just a lot of information to take on board they just.
Carer: was in no state to read it.
EBRT patient, Elsie b
TABLE 16 Themes and subthemes
Frameworks Themes Subthemes
Trial experience Recruitment to trial Decision-making and joining
the trial
Patients’ perceptions of trial Information
Trial understanding
Randomisation Randomisation and equipoise
Experiences of trial (burdens and benefits) Trial experience
Questionnaires
Research practitioner perspective Staff and NHS experience
Living with oesophageal
cancer




Life course (responses to social changes) Coping and QoL
Information
Diet and weight loss
Medical management (responses to physical changes) Diagnosis
Coping and QoL
Diet and weight loss
Medication
Staff and NHS experience
Symptoms and management
Everyday life (responses to psychosocial changes) Coping and QoL
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However, over the course of the research, which incorporated real-time reporting of participant
interview data relating to trial processes at TMG meetings, the research team worked to improve
patients’ experiences of recruitment. Participants reported in later interviews that recruitment was not
overly rushed or confusing and information was given clearly and, typically, multiple times: ‘They gave
me all the paperwork [quite easy] to read and I took it home I read it’ (EBRT patient, Stan a). Participants
were aware that they could ask questions, whom they could ask and how they could contact them:
‘I’ve got all names local hospital telephone numbers and all local hospital’s telephone everybody’s
telephone number’ (EBRT patient, May b).
All participants reported having some comprehension of the study. However, with probing it was evident
that some patients were less clear about the details of the study than others. These points of confusion
included when and for how long research visits would take place: ‘Does she [research nurse] carry on any
length of time?’ (EBRT patient, Camilla a). Participants were at times uncertain about what researchers
wanted to find out from them: ‘What are you learning from me like, you know’ (EBRT patient, Calvin b).
Others felt that better clarification and explanation was required of the questionnaires, as patients
were unclear about the meaning of some of the questions and felt that they were repetitive:
There’s not much difference in their context as a question . . . and there’s not much difference in their
context as an answer, if you know what I mean . . . I think there’s some that you should be able to trim
down you know.
EBRT patient, Calvin b
This information was fed back to the research nurses at the regular investigator meetings and used to
improve discussions with patients around trial design and processes.
Randomisation
Patients often expressed confusion regarding the randomisation process. Several participants struggled
to understand what the different trial arms meant. Uncertainty was expressed regarding whether or
not radiotherapy would be offered regardless of the randomisation outcomes, as patients did not
understand the equipoise of the trial: ‘If I volunteer for it, I think I should go on it’ (EBRT patient,
Stan a). Patients sometimes felt that disease status, general health or prognosis influenced the outcome:
[I] Wondered if I should be having radiotherapy but I’ve been told by other people friends who are doctors
who say that it’s not suitable anyway.
Usual-care patient, Kenneth a
We presumed it was because of the tumour was better to react with the chemo, than radiotherapy
and chemo.
EBRT carer, Elsie a
Having identified these points at an early stage of the qualitative study, research nurses were advised
to increase patients’ comprehension of the potential outcomes of randomisation. Self-reported
understanding subsequently improved, with patients reporting having a good comprehension of the
process of randomisation.
Trial allocation: external beam radiotherapy arm
The EBRT arm was perceived favourably by some patients, who were satisfied with their allocation:
‘I feel pleased that I am getting radiotherapy’ (Emma b). Optimism regarding the possibility of shrinking
or stopping the tumours growing was also reported:
Patient: We’re hoping it would have shrunk the tumour a bit and enable the stent to settle.
Usual-care patient, Kenneth a
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Interviewer: . . . the radiotherapy what do you [think] that it would have [done]?
Carer: . . . stopped it may be growing hey . . . I think what you’re really looking for is a longer life.
EBRT carer, Elsie a
Trial allocation: usual-care arm
Interviews with research nurses highlighted that it was difficult at times to provide patients with the
results of their randomisation allocation, most notably in relation to participants who were randomised
to the usual-care arm of the study. Although particular care was taken to highlight the equipoise of the
study, participants generally favoured the EBRT arm. A number of patients reported feeling ‘a little
disappointed’ at their allocation (EBRT carer, Elsie a).
For some of these patients who received usual care, a general acceptance and rationalisation of the
outcome tended to take place over time, in order for the participant to reposition any initial disappointment
they may have felt: ‘We now feel that it’s positive that I didn’t get selected’ (usual-care patient, Bernard c).
Primary points that usual-care arm patients discussed were not having to deal with the side effects of
radiotherapy, including a potential effect on chemotherapy:
Patient: I feel it’s a positive thing to be honest with you because I know if it had happened, there was
other things that they couldn’t do . . . so you know and I mean I’m quite happy that my treatment is
progressing the way it is.
Carer: . . . not been able to have all your chemo ’cos you wasn’t feeling well.
Usual-care arm, Bernard c
Not having to make additional trips to the hospital were also stated as a positive outcome of
randomisation to the usual-care arm: ‘I’ve heard a few people having to travel so . . . having
radiotherapy there was people going there [hospital] everyday’ (usual-care patient, Janet a).
Patients who declined the trial
This group was difficult to recruit to the qualitative study and only one patient was interviewed.
This patient preferred to make the most of time that they had left; thus, they had a different set of
priorities: ‘Mainly I got enough going on at the moment and I just want didn’t feel up to doing anything
else taking part in that’ (patient declining trial).
Research nurses usefully gave anecdotal reports for the reasons expressed by patients, including
concerns over extra travel, time and family commitments. In addition, nurses acknowledged the burden
of treatment in relation to frailty: ‘2 weeks of daily radiotherapy is quite a commitment, especially for
frail, elderly patients’ (research nurse 1). Concerns were reported about overburdening other family
members who accompanied patients and worries over parking difficulties. One research nurse
(research nurse 2) reflected that both patients who consented straight away were single and the fact
that they did not need to consider others may have been a factor here. Recruitment was also more
successful when researchers met people in person to discuss the study. Nurses did not recruit patients
by telephone: ‘these people seem to be more unwell and haven’t been stented yet’ (research nurse 2).
Experiences of trial assessments
Discussions about the questionnaire completion raised valuable points. Patients enjoyed the research
nurses’ visits, which were perceived as informal opportunities to ask questions and receive information.
Visits sometimes provided therapeutic benefits, providing company and support for patients:
Talking to someone, yes it puts you at your ease . . . you can ask someone if you’re not certain . . . you’re there for
someone to ask questions if they were worried and we got your phone number[s] . . . I’ll probably miss you both.
EBRT patient, Penelope c
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There were instances where the burden or difficulties of the study were notable. Conducting the
questionnaire over the telephone could be confusing: ‘It’s better to come here, then you can explain
it . . . I’ve never been very good on the phone anyway’ (EBRT patient, Peter c). Others commented that
the questionnaires were tedious, repetitive, irrelevant or too long.
Some patients felt that the questionnaires were confusing and required context. They also commented
that the format caused difficulty in matching questions and answers to the same line and tick box:
At the time, there was a lot of irrelevant questions in there . . . It kind of doubles up on itself . . . You know
when you are ticking the boxes and it becomes like one of them things and you start missing boxes,
because actually it’s set out quite bad . . . if it was shaded you say answered that question and then you
go across . . . and tick to box.
EBRT patient, Arthur a
Burdens of the study
Burdens associated with study participation were not directly identified by participants, but several
issues were raised across the interviews. One of these was information overload at the time of consent:
I was going to have my stent [off] and spoke about the trial at the time it seemed a lot to take on board
to make that decision on that very day . . . I wasn’t given much notification initially my thoughts were –
I didn’t want to do that.
EBRT patient, Elsie a
The travel costs and practicalities in getting to hospital, regardless of study arm, were burdens:
It cost me five sixty [£5.60] . . . a real struggle to find a space in the hospital.
Usual-care patient, Bernard b
I just had a letter saying that there was an appointment at half past nine in [hospital], which is impossible
. . . at that time of day.
Usual-care patient, Kenneth a
Time spent at different appointments was significant: ‘You just end up having so many different
appointments don’t you can’t keep up’ (usual-care patient, Janet c). Patients described the physical
impact of radiotherapy treatment including nausea, dizziness and tiredness: ‘I always felt a wee bit
sickish in the morning’ (EBRT patient, Michael b).
Benefits of study participation
Participants reflected on the benefits of trial participation, including access to research nurses
or practitioners:
[Research nurse] gives you a bit more insight . . . because when you see the consultant, he is very fact and
figures . . . and when you see someone like yourselves, you obviously dealt with these people before who
have been in the same position as myself and you get a bit more like . . . normality rather than clinical.
EBRT patient, Arthur a
Patients appreciated the opportunity ‘to actually have some radiotherapy’ (EBRT patient, Elsie b).
Some felt that it increased care including greater monitoring and contact:
Someone keeping tabs to make certain that everything’s alright which you might not necessarily get if you
weren’t part of [it] . . . you’re all so friendly and helpful I can’t give you any criticism at all I think it’s
beneficial full stop.
EBRT patient, Penelope c
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Treatment at clinics was sometimes perceived by patients to be better than they would have received
outside the study: ‘They couldn’t be nicer, can’t do enough for you, it makes such a difference’
(EBRT patient, Elsie c). Some patients felt that interviews provided time to talk and reflect. ‘It’s nice
to talk to you actually’ (EBRT patient, Penelope c).
The research practitioner perspective
Research practitioners reflected on what patients had reported. They perceived the ROCS study to
be challenging and struggled with this: ‘It’s quite a harrowing study’ (research nurse 1). Nurses were
concerned when they perceived patients to be too unwell or too frail: ‘When they are more unwell it is
an awful lot to ask of them . . . it is 15 pages of information sheets’ (research nurse 1). They felt that
informed consent was sometimes conditional: ‘Some patients have said that they’ll consent and then
if they don’t get the radiotherapy they’ll withdraw’ (research nurse 2). Likewise, families played a
significant role in how and why patients participated in the study and were at times difficult to
negotiate: ‘Most of them [patients] are also thinking about their families’ (research nurse 2).
Impact of treatments
This section reports the impact of stent insertion from the usual-care and EBRT arms and the impact
of radiotherapy from the EBRT arm. It outlines the experiences patients reported in terms of
chemotherapy and palliative care, overall.
Impact of the stent
Patients reported varying experiences of having a stent. Improvement in eating was the main positive
outcome, along with improved ability to swallow and less reflux: ‘After the stent put in it was all easier . . .
I take all the proper foods down . . . you know my body weight back up again’ (usual-care patient, Janet a).
Although pain was the most reported negative outcome, fear of blockage, damaging the stent and
uncertainty about cause of discomfort were sources of anxiety for patients. In turn, this affected
patients’ eating habits:
I’ve haven’t really tested it to any extent because I’m only eating [half] of [mashable] of food you know . . .
but I’m scared to try and try and swallow you see.
Usual-care patient, Janet c
In some cases, it was difficult to differentiate between the impact that the stent had and the pain
and discomfort created by the disease itself or the package of treatments including the stent
and chemotherapy:
Patient: I got . . . second stent put in, ‘cos the first one slipped . . . I was in a lot of pain and being sick and
other things so they took me in and . . . they tried pulling it out and things but couldn’t, so they just had
to put another stent on the top. So, once they put that on the other and then the week after that I went
for chemotherapy, which is just like you can imagine it’s like feeling pretty much like rubbish really . . .
Carer: But the stent is working.
Patient: Yeah and I think it’s important to not lose sight of that. I can swallow a lot more easily.
EBRT arm, Emma a
Pain and discomfort around the stent were significant across both trial arms, as were nausea and acid
reflux, particularly immediately after the stent procedure:
I’ve got terrible indigestion . . . Night and day [coughs] . . . It’s like wind, like, wind just very cold around, up
my throat and all around, but I am alright, it eases up sometimes . . . I think it’s worse actually . . . I think
it’s worse than last week.
Usual-care patient, Joan a
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Some patients explicitly compared their symptoms pre and post stent insertion, with most describing
some benefits:
Before the stent went in, I had reflux . . . I know that reflux used to come up like soapy water. Bursting,
you know come up in a bubble. Now since I have had that stent put in, I haven’t had that watery
substance . . . but it clears in extra-long time . . . it really gives me pain, but it doesn’t last . . . as before.
Usual-care patient, Calvin a
Patients were uncertain about the long-term success of the stent and would have liked better follow-up
information and contact with health-care professionals:
When I came out I didn’t know what I was supposed to be taking in the way of medication and I rang my
GP [general practitioner] and I didn’t have a reply then he did reply and he said that he would send a
district nurse . . . but nobody came. I didn’t have any contact with anybody for 5 days . . . and I got all this
medication now and I don’t think some of it is really suitable for me but it’s not for me to decide.
Usual-care patient, Kenneth a
Greater support and advice for patients around diet, eating habits and postural adjustment were
needed, as trial and error was the main strategy for managing the stent:
Then we got this stent in, it was very uncomfortable with the acid and then the hospital they had to give
us stuff, they gave that Gaviscon [® GlaxoSmithKline plc, Brentford, UK] . . . but I didn’t like that I think it’s
awful and then I used it . . . I just seemed to think it stuck there and it’s to me it was awfully gassy but
may be if you persevere with it but when I first come out after getting a stent my brother had that bed,
it’s in the hall there.
EBRT patient, Michael a
Impact of radiotherapy (external beam radiotherapy arm)
Patients who received radiotherapy reported a range of post-therapy negative side effects, which were
more often described than any positive impact. Negative side effects included loss of appetite because
of pain when swallowing. Physical symptoms occurred at varying times post therapy and for different
time spans, and some patients reported feeling worse than before the radiotherapy:
My main concern is not eating . . . at the moment it’s even hard to swallow water because of the pain . . .
Discomfort, that’s probably a better word . . . Last 2 days it really sort of hit me. I was running sick, tired,
couldn’t swallow very well at all worse than what it was before. Even the first week of the radiotherapy I
was walking up to the car park . . . I was doing it on the second week, I was thinking I’m not sure I can do
that now but again I think that’s the radiotherapy doing that . . . so hopefully that will improve.
EBRT patient, Stan a
It was common for patients to generally feel more unwell, tired, dizzy: ‘Nausea [very] nauseous and nae
appetite’ (EBRT patient, Michael b). Despite most patients describing negative side effects of having the
radiotherapy, a few reported a corresponding improvement in longer-term symptoms or general well-being:
I didn’t feel that good, I was tired when I was having the therapy I didn’t want to eat. I lost a lot of
weight but now it’s all over if you like and I’m beginning to get back I’m eating well.
EBRT patient, Stan b
However, some patients were relieved that the radiotherapy had not caused any further deterioration
or side effects:
I thought it was going to make eating a bit more uncomfortable . . . so that kind of didn’t happen which
I was really pleased about.
EBRT patient, Elsie b
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Improvement in physical and mental well-being was described by one patient: ‘It has made an
improvement to my symptoms and also my quality of life’ (EBRT patient, Elsie c).
A lack of knowledge regarding what would happen post therapy was apparent. Participants struggled
with the uncertainty around when normality in their daily lives would be restored:
How long before this hard to swallow and can I possibly start eating properly again I don’t know?
I struggle to eat anyway ‘cos I don’t I never feel hungry is the problem.
EBRT patient, Stan a
Some participants commented on logistical aspects, including the amount of extra travel and long
journeys sometimes necessitated by radiotherapy appointments: ‘I have 8-mile-return journey from
[place name] and 80-mile-return journey from here’ (EBRT patient, Camilla a).
Overall, however, patients felt that the treatment itself, especially compared with chemotherapy,
‘wasn’t long at all’ (EBRT patient, Peter b).
Impact of chemotherapy
The responses to chemotherapy among participants in both arms varied, with more patients in the
EBRT arm undergoing treatment. Reported benefits of chemotherapy were improved ability to swallow
and tumour shrinkage:
I went to the cancer clinic yesterday and they told me that the tumour’s shrunk, so something’s working.
Usual-care patient, Janet a
The wider positive physical and psychological effects of chemotherapy were described by participants.
These constructive experiences were, however, often coupled with concerns around uncertainties
about the future:
I don’t know what’s happened but I’m certainly feeling better than I have felt for a long time and people
are commenting . . . I’m expecting after this next lot of chemo to be feeling better again . . . but I don’t
know how much better . . . I mean a couple of other people have warned me that ‘oh well suddenly it’s
going to hit you and you’re going to go down’ but that hasn’t happened at all so far . . . so I’m hoping it
isn’t going to but maybe it will.
Usual-care patient, Bernard c
Other participants did not tolerate treatment because of unacceptable toxicities, feeling too ill to
continue and feeling worse after chemotherapy than before:
I couldn’t deal with it. It was too much, too toxic. So, then they took me off . . . because chemotherapy can
just be vicious can’t it?
EBRT patient, Stan b
Participants receiving chemotherapy discussed side effects; some compared the impact that different
types of treatments have:
You know you get a reaction after chemo you get everything but I wasn’t expecting that [sickness]. I had
radiotherapy before . . . in my mouth and my neck . . . but not the chemo that was the worst.
Usual-care patient, Janet c
At times patients placed hope around the outcomes of receiving chemotherapy:
I’m really hoping once we start the chemo things are going to change and change for the better . . .
I’ve got to keep looking up because I can’t, I can’t look down.
Usual-care patient, Bernard a
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Participants spoke about the need for further information regarding symptoms:
Patient: . . . my voice is annoying me, I can’t talk . . . you know for some reason, I don’t know why . . .
I told them in the hospital.
Interviewer: And what have they said?
Patient: Er, nothing.
Usual-care patient, Bernard a
Practical implications of chemotherapy involved transport, parking, timing and the impact that it had
on carer employment: ‘I would drop him off and pick him up, ‘cos there’s nowhere to park anyway’
(usual-care carer, Janet c).
Palliative care
Palliative care was framed around either personal awareness of a disease transition, or practical advice,
usually initiated by the carer: ‘I got [Macmillan nurse] phone numbers, yeah I got contact numbers
you know’ (usual-care carer, Janet c). Patients and carers referred to the specific organisations of
Marie Curie (Marie Curie, London, UK), Macmillan (Macmillan Cancer Support, Somerset, UK) and
Tenovus (Tenovus Cancer Care, Cardiff, UK), in addition to discussing hospice and palliative care and
how it may relate to their future medical care. They also provided advice on finances, practical help
and medication:
I saw one of the Macmillan benefits advisors as well and he’s given me other travel costs and um I’ve lost
a lot of weight of course and had to buy a lot of clothes smaller size clothes so, I got clothing money and
travel money from them so that was good.
EBRT patient, May a
Patients framed future disease trajectory around QoL and alleviation of distressing symptoms,
particularly pain:
Because it’s not about the bloody length of your life it’s about what you do with it and you have to be
out of pain and able to move around.
EBRT patient, Emma a
Patients narrated a transition time, where they were evaluating treatment responses and the potential
impact on QoL. Patients still framed any participation in research around benefit to others but
evaluated their own personal situation around maintaining QoL:
Nothing they can do, because I haven’t got the strength to take the treatment, neither the chemo nor the
radiotherapy. So, all they’re doing is, trying to keep it calm and keep at bay . . . it didn’t seem as though it
was going to be a long you know, it wasn’t go to increase life span to a great degree. So, we thought well
why put myself through all that trauma and if I see nothing in the end you know? So uh, that’s what we
are doing . . . I won’t say it’s a waste of time but it’s a waste of time as far as I’m concerned . . . but
whatever I do, somebody in the future may get the benefits, so that’s how we have left it. We are not
bothering to go any further.
Usual-care patient, Calvin b
Palliative medicine itself also at times had an impact on the QoL for patients:
Interviewer: You told me that the oral morphine has made you bit more sleepy, bit confused?
Patient: Yeah well . . .
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Carer: Definitely sleepiness and then confusion . . . Ah but I suppose as a result of being sleepy . . . so his
appetite probably dropped a little as well.
Usual-care arm, Calvin a
Where communication and symptom management were clear, patients were positive about being
adequately supported, despite the paucity of treatment options. Palliative care pathways were
considered useful by patients in dealing with the physical and psychological effects of the disease:
I got a feeling that’s going to come to an end because there’s no point, there’s nothing they can say. I got
the hospice specialist, she’s probably come to take over from them . . . which is what’s happening now.
So, any problems or anything I got now I talk to [hospice nurse], which is better anyway because saves me
going there . . . said if you do get a break through pain then they’ll get it sorted.
EBRT patient, Stan b
Summary of the experiences of each trial arm
Overall, patients described varied experiences after receiving the stent, although most reported some
level of pain or discomfort but improved ability to swallow. Radiotherapy mainly provided negative side
effects including pain, nausea and tiredness, with minimal improvement to QoL. Chemotherapy did
deliver benefits for some patients who were strong enough to receive it, although experiences differed
significantly. These findings highlighted a need for practitioners to provide bespoke, timely and accurate
advice and support relating to all arms of the study. Information such as potential and expected outcomes,
pain management and palliative care were necessary for all patients. Importantly, patients required
ongoing advice and health-care professional contact. The physical, psychological and financial impact of the
extra radiotherapy and chemotherapy needs to be considered in relation to patients, carers and the health
service more generally.
Patients’ experiences of living with oesophageal cancer
Patients were uncertain about the aims of treatment, with the majority of patients unsure about what
would happen next. The long-term impact of stent intervention was unclear, as was how best to
manage the stent in everyday life. Uncertainty affected self-management and access to support.
Patients often responded by using coping strategies such as prioritisation around relationships and
roles, experimentation around symptom management and physical manifestations of the disease,
and rationalisation relating to navigating everyday life.
Responses to social changes
Patients and carers described how they dealt with social changes relating to oesophageal cancer.
They highlighted how their plans for the future were disrupted, with retirement and work uncertainties,
and their valued social roles compromised:
Carer: She [patient] was going to take early retirement as well . . .
Patient: . . . this year we were going to buy a get a new car and go round historic houses and whatever
and do all this decorating, all so it’s all been put on hold.
EBRT arm, Elsie a
Patients described the diminishing of participation in previously valued activities. Daily living, including
hobbies, was affected, with a consequent impact on social life. Marie Curie, Tenovus and Macmillan
were the main external agencies mentioned by patients for providing support and advice on these
matters. Financial and employment worries were expressed, with several participants expressing
relief that they had retired. For some life course challenges, patients spoke of how they were
prioritising relationships and valued activities, with a sense of actively considering what was most
important to them.
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The desire for relative normality and the importance of maintaining their identity, roles and interests
were emphasised, as they expressed the wish to continue to be good neighbours, friends and family
members themselves. Patients described how there was a need to negotiate and prioritise with their
families when dealing with the uncertainties of the disease:
He [son] came and picked me up and I went down there for a few days then he brought me back and
stayed with me for a night . . . I was feeling out of my environment a little bit, being there . . . I don’t know
what it’s going to be like when he goes back . . . he hasn’t even mentioned it yet. I think it’s going to be
when he can see that I have made some, if any, significant improvement . . . So I got a bit of strength,
I can get about and do some things for myself.
Usual-care patient, Calvin b
Participants outlined family and social activities, especially regarding eating, that they valued and
expressed sadness where they were no longer able to take part in them. They described the sources
and also challenges of their support system:
Patient: [Wife’s name] has become, I know she’s the reason I want to beat this, but she’s also become like
my gaoler if you like. She’ll keep on to me, don’t eat so fast, don’t do this do that, and consequently it
seems sometimes like she’s holding me back, although I know that she isn’t . . .
Carer/wife: Yeah but if I don’t do it you get blocked . . . So you know what else can I do? I don’t want to
see you blocked and I don’t want to be rushing you into A&E [accident and emergency].
Usual-care patient, Bernard c
Patients’ feelings of self-consciousness over altered appearance sometimes led to avoidance of social
situations and previously enjoyed activities, reinforcing the sense of a changed self and the impact that
their changing physical self had on others:
I want to go out and I just feel so incredibly skinny and I don’t want people staring at me . . . yeah I do
feel very self-conscious about how thin I am.
EBRT patient Elsie b
The stress placed on family and friends by oesophageal cancer was acknowledged by patients including
feelings of guilt, reinforcing the uncertainty that they felt about their future:
I suppose it’s worrying for all them round about us . . . there’s a lot of people with the same as myself,
that go quicker.
EBRT patient, Michael b
The social aspect of hospital clinics was discussed by patients, where at times they felt supported
by other patients and the knowledge that there were other people undergoing similar experiences:
‘The majority of people I’ve met seem to be as positive as I am and that helps, doesn’t it?’ (usual-care
patient, Bernard c). However, others felt that other patients lacked the capacity to socialise: ‘I don’t
think they want talk to anybody anyway because they’re not well’ (usual-care patient, Janet a).
Patients were uncertain about treatment outcomes and their disease trajectory and prioritised the
need for hope and for a positive manner, even when the prognosis was poor:
I feel that . . . I am coming out . . . on the good side of it now and that you know we’re going to hear . . . in
the coming weeks that something positive has come out of all this and that we’ve actually you know we’re
on the good side of it now and that things are going to get better . . . which is certainly what I’m expecting
to hear and I’m not just saying that I honestly believe it.
Usual-care patient, Bernard c
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Patients stressed the need for a positive and caring approach by clinicians, despite being fully aware of
their terminal prognosis:
We went to see [general practitioner] . . . and he said ‘look’ he said ‘don’t think this is the end of your
world’ he said ‘I get people in here all the time who been told they got cancer and they live for years and
years’ he said ‘you’re not about to die imminently’ so that gave me hope.
Usual-care patient, Bernard a
Patient priorities were primarily concerning personal and professional relationships. Challenges for
patients were in managing the expectations of others and in identifying supportive health-care
professionals who could manage their prognosis realistically but positively.
Responses to physical changes
The overarching theme around clinical management was uncertainty. Patients were unclear about
treatment aims and outcomes, disease trajectories, side effects and symptom management:
I just thought that [feeling sick] was part of the illness . . . I felt that [feeling full up] was part of the
treatment because I don’t know, that’s the trouble and I’ve done a lot of research on it and I can’t find
nothing, apart from saying you’ll feel nauseous, sick.
Usual-care patient, Janet b
Patients felt overwhelmed by the amount of information that they received, the number of
appointments required and the number of different health-care professionals to whom they were
introduced, making it challenging to retain information or know who to contact for specific issues:
‘I get confused with it all . . . there’s so many things . . . too many things going on’ (EBRT patient, Stan b).
Carers and patients often experimented around practical ways of managing information, such as
using diaries to record symptoms and to try to anticipate the likely impact of treatment or trial and
error strategies:
Carer: When the next cycle came down we put it on the same page . . . so we were able to compare what
happened . . . and when [patient] was feeling absolutely terrible I said to her hang on, last time we did
this you felt like that. Well in 3 days you should be picking up . . . Hang on, there’s light at the end of
the tunnel.
EBRT carer, Elsie c
The different communication styles of health-care professionals had an impact on relationships with
patients and carers:
You feel a bit more positive when you see him [doctor]. When you see her [doctor] you don’t . . . and you
know it’s bad but you know it’s not what you want to hear . . . you want to hear some of the positive sides
. . . you got to focus on the positive.
EBRT patient, Elsie b
Patients and carers were uncertain about staff and their roles: ‘Somebody came from out of the blue
one day for a blood test . . . that was about 4 weeks ago, I don’t know why he came’ (usual-care patient,
Janet b). The follow-up process was also unclear for many patients:
I haven’t got an appointment . . . I thought I would have seen him [oncologist/stent consultant] again by
this time but don’t know, I don’t know how he works his system.
Usual-care patient, Betty a
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The role of the research nurse was perceived as multifaceted and research nurses acted as both a
key worker and point of contact for some patients and carers, providing clarification on aspects of
medication and symptoms:
I wouldn’t go the GP [general practitioner] because they haven’t got a clue, I would try [research nurse]
first of all, even if she had to aim me to someone else, because she said phone her up anytime.
EBRT patient, Arthur a
Coping with side effects was complicated by uncertainty over whether disease or treatment was the
cause. This had an impact on the ability of the patient to decide whether or not to seek help. Patients
and carers adapted to changing situations mainly through trial and error. Areas of concern were
primarily pain, nausea, managing poor appetite, nutrition and medication, and the impact that this had
on activities of daily living when patients and carers experimented with retraining habits and making
lifestyle changes.
Pain was a significant issue, and patients found it difficult to establish whether pain was related to
specific activities such as eating or was a short-term consequence of treatment (e.g. the stent
insertion) or a sign of advancing disease:
I’ve got almost like a continual heartburn . . . but I’m guessing it’s the stent probably settling in and my
swallowing’s been fine. It’s just an irritation down my swallowing tube.
Usual-care patient, Bernard a
Patients were unsure about whether or not they should seek help for pain, drawing on previous
experiences and trying to judge possible causes and sometimes opted to simply endure it:
Sometimes it’s been achy there but whether it was the stent or not I really don’t know because I had
aches and pains beforehand . . . it could have been overeating or all sorts of things.
EBRT patient, Penelope b
At the end of the day well, you it’s just there’s not much else you can do but up and get on with it and
give it another day and hope you get through it.
EBRT patient, Emma a
Patients had difficulty interpreting whether pain was directly due to the stent or other factors. At
times, patients expected that the stent would take some time to settle down and described how lack of
clarification had aided confusion:
I would have said the pain was based in my windpipe . . . but alas that turned out to be wrong. Pain was
where the stent was pushing against the growth . . . it hasn’t done the job I think they were hoping . . .
In fact [doctor] is the first one to actually use the word cancerous growth to me.
EBRT patient, Camilla a
Reasons for enduring symptoms such as pain sometimes related to fear of painkiller addiction, not
being certain of how to assess pain severity and waiting for the stent to become more comfortable:
Still terrible, 6 days now, there’s not much change . . . it might calm down tomorrow . . . I want to give it a
week ‘cos then I can ring up one of two nurses that I am dealing with like . . . I am expecting to see some
good change within a week like, ‘cos you can’t rush. They don’t happen overnight like, or two, aahhhgg
[patient in pain].
Usual-care patient, Joan a
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Professional guidance helped in alleviating discomfort at times when patients were having difficulty
judging pain and when it should be treated:
When I first told [research nurse] what the problems I was having, in other words quite severe nausea
and almost inability to eat, she said ‘are you taking pain killers?’ I said ‘no’ . . . she says ‘start taking them
now’ . . . so [laughs] I’m floating in paracetamol now and have been for a week and of course I feel much
better [laughs].
Usual-care patient, Betty a
Patients and carers experimented with how to take medication and expressed difficulties with
swallowing tablets that were too big and correct use of the syringe driver and were worried about side
effects, in particular excessive sleepiness or confusion. The management of pain and the side effects of
medication on everyday life was finely balanced:
I’m getting bad now. I can’t walk very far, not like I used to . . . it’s tiredness more than anything . . . I try
not to, I don’t take that during the day that morphine, because it makes you tired if I go out driving . . . so
I only take it at night.
EBRT patient, Peter b
Tiredness and sleep disturbance caused by pain had a major impact on the ability to carry out
activities, with trial and error experiments around pain management:
It’s lovely when I sleep now. I lay dead flat . . . straight out and it’s lovely. That’s why I love to go on a bed
at night because I can be sat there like this, I can be hurting and I can go to bed . . . hot water might ease
it as well, having a nice hot shower at night . . . I think that eases it a bit.
EBRT patient, Peter b
Participants experimented with various strategies that prioritised maintaining or gaining weight for
health purposes and recovering the enjoyment of eating. Challenges to accomplish these aims included
lack of appetite, boredom with dietary restriction, confusing dietary advice and adapting diet, although
consequences of eating such as regurgitation, pain and nausea also had an impact on motivation to eat:
Even a basic vegetable soup would bloat me . . . it was pretty bad. They couldn’t get the endoscope down,
that’s how bad it was. So, we’re running out of options.
EBRT patient, Emma a
In contrast, good dietetic advice was highly valued and was used by both patients and carers to
adapt meals:
Patient: Food is my medicine, this is what the dietitian told me, which is right.
Carer: She was very good, dietitian from [local hospital] was amazing . . . she gave us a lot more in-depth,
what he could use and what he can eat whereas at the [names other local hospital] they kind of
frightened me a little.
EBRT patient, Arthur a
However, patients expressed frustration if they were unable to see a dietitian or they were given
conflicting or non-specific advice:
Carer: . . . one of the weaknesses up there [hospital] is that the dietitians only work on certain days . . .
which means you never see the same dietitian and some of them are ok they know what’s going on,
the others they just say ‘oh what happened last time?’
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Patient: Yes, they are more generalised aren’t they?
Carer: Yes, and it’s like they got a script.
EBRT arm, Emma a
Strategies for managing diet and weight loss were characterised by trial and error. Participants
described eating smaller meals, eating one big meal, adapting the hospital menu, keeping a food diary,
avoiding gassy drinks, eating early, cutting out sugar, blending food, eating high-calorie food and
boosting their diet with nutritional supplements:
I’ve been off the eating of course but I’m getting more down than I was certainly . . . it’s just whether
you’re in the mood really for eating . . . I’ve been trying toast and egg and beans and stuff, just picking
at stuff.
EBRT patient, May b
Preparation for eating was also important, with patients experimenting to alleviate consequences such
as acid reflux:
I said when’s the right time to take it and he [doctor] said about all day release tablets and [names
medication] and that you get to feel yourself when the right time is.
EBRT patient, Michael b
Patients were uncertain about treatment, disease trajectory and management of symptoms. Carers and
patients experimented with strategies to manage pain, aid sleep and enable eating.
Responses to psychosocial changes
Patients described a variety of responses to their changed psychosocial situations. Central to patients’
experiences was uncertainty, with patients feeling that they could not plan for the future:
Everything seems to be altering all the time, you know what I mean . . . one day is different from the next,
can’t sort of plan anything.
EBRT patient, Peter b
Patients responded by adapting routines, rationalising their situation and accepting their changed
context. Many focused on achievable goals, placing cancer in the context of their overall life.
They often prioritised a positive mindset in which cancer was framed mainly as an obstacle
or challenge:
I’m happy that I can go out every day, quite happy with that. There’s still the illness, well you know you
got cancer . . . you don’t really feel wonderful every day, but no one does. So that’s why I don’t often moan
about it.
Usual-care patient, Janet b
In some cases, coming to terms with a loss of health and the rate at which change had occurred for
patients was highly challenging, resulting in the need to re-evaluate their priorities:
People were saying to me then you’re losing weight, you’re not looking well and then I did decide to go to
the doctor eventually and that was it . . . I can’t believe it’s happened to me so quickly because I was the
one who took people everywhere and did everything, you know.
Usual-care patient, Kenneth a
DOI: 10.3310/hta25310 Health Technology Assessment 2021 Vol. 25 No. 31
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Adamson et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
59
The psychosocial aspect of food was a significant issue for patients and carers, who negotiated the
physical and mechanical challenges of swallowing and stents while trying to retain the social and
pleasurable aspect of eating. Patients described a sense of loss around appetite, mealtimes with others
and food as a comfort:
It’s like a mind thing . . . you’ve got a stent down and you’re scared to eat in case. They warn you of it,
if it chokes or that . . . but I’m getting there. I tried over the weekend a bit of bread and that was
alright . . . and when you’re having the chemo and that you got a different taste and your appetite is
different and your taste. You’re eating things you never used to eat and then you went off things that
you liked . . . I was saying I’m getting back a bit of my appetite now . . . and I try not to eat later on at
night because I think it maybe it lies when I’m sleeping and it gets uncomfortable.
EBRT patient, Michael a
Patients struggled with feelings of guilt over lack of appetite and the ongoing challenge of finding
ways to make food physically and psychologically appetising, in an attempt to mitigate food as source
of distress:
I’m sick and tired of the food that I’ve been eating at home and these bought things, I don’t know
what it is about them. They’re tasteless . . . I tell myself well all you’ve got to do is to cook it yourself
and can’t be bothered . . . I think the main thing is I can’t get out of the habit of . . . feeling guilty about
wasting food.
EBRT patient, Penelope c
The practical support of family members was welcomed, and patients appreciated the alleviation of
pressure around food preparation: ‘My partner is brilliant. She does the food for me . . . because it’s a
pain just to go and do it yourself’ (EBRT patient, Stan b).
When families adapted to the patient, this reinstated the psychosocial aspect, as well as the nutritional
function, of meals:
We all took our time eating. We must have been there over an hour and half wasn’t we? . . . and because
we were all sort of eating at your pace and it was lovely wasn’t it? . . . It was really good.
Usual-care carer, Bernard b
Food could also be a source of contention. For example, some patients reported feeling pressurised by
the strategies of others, such as being given unwanted gifts of food. Others felt pressure to conform to
social expectations:
Patient: So, since the stent . . . I’ve got to try and improve because otherwise you go in that hole . . .
we haven’t actually done a social thing, whereas before we would go for a lot of meals you know with
friends and whatever but obviously since this, we haven’t been doing that you . . . I would go and have a
small dish and they all know now.
Carer: The last time we went we had one between us didn’t we . . . we didn’t want to embarrass him
you know . . .
Patient: Well unfortunately I’ve got two friends who always come down to see me and it’s great you
know and the first thing they do is order food.
Carer: But they are always inviting us and they are always caring and uh, they are lovely but, he just
feels a bit sort of self-conscious because he’s not eating.
EBRT arm, Arthur a
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The psychosocial aspects of oesophageal cancer focused on patients and carers stoically dealing with
the challenges of the disease including living with pain, dealing with the psychosocial aspects of eating
and adapting their daily activities. Although patients and carers were successful in coping with some
aspects, such as finding ways to reduce stent blockage, there was a significant overlay of uncertainty
around when to seek help and who to approach for specific advice. This led to potentially unnecessary
or prolonged discomfort around issues that could be helped by professional advice and guidance.
Patients described oesophageal cancer as obstructing their anticipated life course and accomplishment
of everyday life, as described in Figure 16. A disease-orientated focus via medical management
provided some relief of specific symptoms such as dysphagia, but potentially hindered a more holistic
approach to mediating and managing a terminal prognosis. Patients described these issues in relation
to strategies, uncertainties and challenges. In turn, patients explained responses to social, physical and
psychological changes, which included maintaining or modifying everyday life, dealing with their own
expectations and those of others, and coping with disease symptoms and treatment side effects.
Potential improvements to the recruitment process
The results of the study show that, to improve the recruitment process, patients and carers need an
appropriate amount of time and information to consider their involvement and to give informed
consent. It is important that patients have the opportunity to discuss the study with friends and family
and that patients are provided with contact details of an appropriate person should they wish to ask
further questions. To minimise the burden of time, visits with the qualitative researcher and the
research nurse may be timed to coincide with each other for future appointments.
Confusion over randomisation, particularly the equipoise of the treatments, illustrates that information
should be given multiple times to ensure that the different trial arms are fully explained. Comprehension
of the participant’s status in relation to the study needs to be regularly discussed and clarified.
It is important to discuss potential outcomes and burdens for patients, particularly relating to the value
of radiotherapy when the participant’s health declines. In relation to the QLQs, it is evident that no
single method of data collection will be suitable for all patients. Therefore, it is important that choices





































FIGURE 16 Patients’ experiences of living with oesophageal cancer.
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Discussion
Participants’ accounts of recruitment to the trial itself, as well as their more general experiences of
dealing with oesophageal cancer, highlighted key issues. Patients and carers sought more consistent,
timely and clear guidance on the trial itself, including equipoise of randomisation, longer-term
outcomes, the impact of chemotherapy and radiotherapy, and the levels of contact with practitioners.
Medical issues including stent management, especially blockage,47,48 symptom management, nausea,
pain49 and tiredness were apparent for patients from both trial arms. These physical issues were often
dealt with by patients and carers through processes of experimentation and were usually accompanied
by overlapping social and practical everyday QoL challenges. These included uncertainties around their
sense of purpose and identity, finances, accessing additional support from other agencies and task
management. Personalised care plans with expected time scales and outcomes, could provide some
benefit in these circumstances.
Medical management is limited in oesophageal cancer, and the provision of a stent to relieve swallowing
difficulties is the most common intervention. However, as the study illustrated, stenting does not
address the likely course of the disease and the many symptoms that the patient lives with.
Information around diet,50 pain relief and general medical management needs to be provided
throughout the course of the disease; it is not sufficient just to alleviate specific symptoms relating
to stent provision.51 Patients and carers emphasised the important social, psychosocial and physical
aspects of nutrition and eating.52 Where possible, patients should receive increased ongoing support
with multifaceted eating and diet difficulties from professionals such as nutritionists and counsellors.
Stent insertion is the primary treatment intervention for patients on this clinical pathway and an assumption
that it addresses all issues of food intake and nutrition risks inadvertently obstructing additional treatment
options, including specialist palliative care, that would be timely earlier in the disease course. Patients have
life-limiting disease and expressed the need to address their priorities in relation to their QoL more
holistically.53 Palliative care was viewed as helpful, where provided. A multidisciplinary approach is
recommended, but the patient experience indicated that this was not consistently followed and referrals
to palliative care services could have been made earlier.54
Peer support interventions are recommended for oesophageal cancer patients treated surgically, but
our patient population suggests that it is helpful only if the patient desires peer support, and there was
some ambivalence around its value.
Patients and carers acknowledged the challenges faced by medical staff and services and showed
willingness to rationalise and co-operate even when facing uncertainties. However, patient and carer
insights also highlighted a need for co-ordinated, bespoke, timely advice and information provision55,56
by health services and third-sector services in relation to medical, life course and everyday life issues.
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Chapter 5 Health economics evaluation
Aim
A model-based CUA was undertaken, which reflected the trial follow-up period. This analysis addressed
the secondary trial objective of assessing costs and cost-effectiveness of EBRT in addition to stent
placement to improve participant-reported dysphagia or other dysphagia-related events at 12 weeks
and 12 months following stent insertion in a participant population unable to undergo surgery.
Methods
Prior to commencement of the analysis, a health economic analysis plan was produced, reviewed by
the trial team in line with the statistical analysis plan. The health economics team followed this analysis
plan during the conduct of the economic evaluation without deviation.
A UK NHS and Personal Social Services perspective was adopted in the analysis, in line with NICE
methodological recommendations.57 Health outcomes are expressed in terms of QALYs. No discounting
was applied as the time horizon of the analysis did not exceed 1 year. The analysis undertaken was a
CUA producing incremental cost-effectiveness ratios (ICERs) expressed as cost per QALY gained.
Cost data were analysed in SPSS (IBM Corporation, Armonk, NY, USA) version 26 and Microsoft Excel®
(Microsoft Corporation, Redmond, WA, USA). Outcomes were analysed using Stata decision-analytic
modelling undertaken in Microsoft Excel [using Visual Basics for Applications (VBA)].
Costs included in the health economic analysis
The health economic analysis considered the following costs:
l intervention implementation cost of EBRT
l cost of subsequent health-care resource use (primary, secondary, hospice and social care including
any cancer treatment as well as medications received).
All available cases (for the most complete overview) were used for descriptive purposes. Available cases
were defined as all randomised patients with health-care resource use data for individual time points
(i.e. for calculation of weekly costs for model). Available cases for total health-care resource use
(i.e. for descriptives) were defined as patients with data for all four follow-up points available (to avoid
underestimation of costs between baseline and 12 weeks due to missing data and deaths). All costs are
expressed as 2017/18 Great British pounds, inflated and converted appropriately where required.58
Missing cost data
The problems concerning missing data are particularly relevant to the health economic analysis as
the main outcomes are cumulative measures collected over the trial period. Missing items relating to
health-care service usage may underestimate the total costs while missing outcome data may be
correlated to effects, as those individuals without information may be systematically different from
those for whom all information is observed.59 Therefore, using complete-case assessments and
available cases analysis only could result in meaningful data being excluded. Descriptives and analysis
of costs were based on available cases. For the CUA (based on the modified ITT population), patient-
level mean imputation for all patients alive at each follow-up point was used to account for missing
data. This imputation method was chosen owing to the availability of 14 follow-up observations.
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Considering that most patients had data for at least two follow-up periods, patient-level mean was
considered more accurate than population-level mean. However, for patients without any follow-up
data, population means were imputed. If a patient died, all further health-care costs were left blank for
all follow-up periods after death.
Intervention implementation cost
Patients randomised to the EBRT arm of the ROCS study received EBRT in addition to stent insertion
to improve their ability to swallow. Dose and number of fractions received were collected routinely
as part of the trial. Information regarding the procedure and duration of radiotherapy planning was
obtained from the trial team and clinical experts. Standard, weighted NHS reference costs were applied
to all resource use items.60
Intervention costs considered in the health economic analysis included:
l costs of a standard consultant-led oncology outpatient appointment to discuss the radiotherapy
and likely side effects and to take patient consent
l costs related to planning of EBRT (parallel opposed beams), including CT scan and 2.5 hours of
radiographer time on an outpatient basis to explain the treatment plan and mark the patient
for treatment
l cost of delivery of radiotherapy fractions.
No training costs were considered, as a straightforward, standard radiotherapy approach in keeping
with local practices was used.
In accordance with the protocol,26 we explored different costing methods by microcosting individual
cost items instead of using aggregated NHS reference costs for radiotherapy planning. This was
considered in the deterministic sensitivity analysis.
Cost of subsequent health-care resource use
This included the costs of all health-care resource use accrued between baseline and 12 weeks and
12 months, respectively. Health-care resource use [including primary care consultations, accident and
emergency (A&E) visits, outpatient appointments, inpatient stays, social care contacts, hospice stays
and medications prescribed] was established using a client service receipt inventory (CSRI).61 The CSRI
was adapted for health-care resource use collection in oesophageal cancer patients and administered
at baseline, at the end of weeks 1 and 4 and once every 4 weeks thereafter until the 52-week follow-up.
As long as it was indicated on the CRF whether or not the patient had any health-care contacts by
ticking either ‘Yes’ or ‘No’ to the question ‘Has the patient had contact with any other health-care
provider for any reason in the previous 4 weeks?’ or as long as one or more items in any health-care
consultations section of the CSRI were completed (values of ‘0’ or greater), the CSRI was assumed to
have been fully completed and any missing items were imputed with zeros. If the CRF was marked as
‘not done’ or was otherwise incomplete, data were considered missing.
Each CSRI questionnaire asked for health and social care resource use in the past 4 weeks (except the
week 1 and week 4 CSRIs, which asked for 7 days and 3 weeks, respectively). Therefore, the costs of
the first four follow-up points were summated to calculate the 12-week costs and all 14 post-baseline
time points were added to produce a total cost over the 12-month follow-up period post stent
insertion. CSRI data were cross-checked and supplemented with data on stent complications, blood
transfusion and hospital admission and discharge data as well as information on palliative radiotherapy
and chemotherapy treatments from the main trial CRF. This was necessary to ensure that all health-
care resource use was recorded while avoiding double-counting. Costs were assigned using published
unit costs.60,62,63 All research-related contacts were excluded.
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The health-care costs in primary, secondary and social care for both the EBRT arm and the usual-care
arm in the 12 weeks and 12 months post randomisation were then summated and mean cost
difference per patient (including 95% CI and p-value) calculated using SPSS. Independent-samples
t-tests were used for comparison with a 5% significance level. Bonferroni–Holm sequential corrections
were used to adjust for type I error rate inflation in multiple comparisons.64
Primary care costs
Primary care costs included general practitioner (GP) visits in surgery and home visits (including
telephone consultations), as well as palliative nurse specialist appointments in surgery or the patient’s
home, district nurse visits in surgery and other primary care contacts. Other contacts were costed as
specified (e.g. phlebotomist, dietitian, physiotherapist). When no details on the nature of other contacts
were available, it was assumed to be an interaction with a dietitian as this was the most common other
primary care contact.
All unit costs used for costing primary care resource use can be found in Appendix 4, Table 31.
Secondary care costs
Secondary health-care contacts collected using the CSRI included A&E visits, outpatient consultations,
day hospital visits, palliative nurse specialist appointments in hospital and inpatient stays. Furthermore,
blood transfusions, radiotherapy fractions and chemotherapy cycles were recorded. Numbers of
inpatient days were calculated from recorded hospital admission and discharge dates and compared
with CSRI data. If CRF inpatient data did not match patient-reported CSRI data, the higher number was
used. If hospital stays spanned two follow-up periods (e.g. patient admitted in week 16 and discharged
in week 18), the entire duration of stay was assigned to the admission follow-up period only.
Inpatient stay unit costs were based on a weighted mean across all NHS reference cost entries
for elective and emergency excess bed-days and multiplied by the number of bed-days recorded.
Outpatient visit costs were calculated as the mean consultant-led outpatient appointment, weighted
across all departments.60
Blood transfusions were costed by unit based on published costs65 or as a day case60 where no
information on number of units was available. Palliative radiotherapy was costed by multiplying the
number of fractions recorded by the per fraction cost of £83.06 for same-day radiotherapy admission
or attendance (excluding brachytherapy) taken from NHS reference costs.60 If no information on
fraction number was recorded, the population mean number of fractions in the relevant follow-up
period was used. Chemotherapy treatment costs were established by adding all chemotherapy drug
costs (according to band)60 as well as delivery of oral chemotherapy or simple (for one chemotherapy
drug) and more complex (for two or more drugs) parenteral chemotherapy.60 Where no information
on the regimen used was available, the weighted mean cost of all chemotherapy day case options60
was used. Monoclonal antibody unit costs for immunochemotherapy treatments (e.g. durvalumab,
ramucirumab) were taken from the British National Formulary.63 Only one chemotherapy cycle was
assumed to be administered per 4-week follow-up period.
All unit costs used for costing secondary care resource use can be found in Appendix 4, Table 31.
Social care and hospice costs
Social care costs included district nurse home visits and care assistant visits. District nurse and
carer costs were obtained by multiplying the number of visits with the number of people attending
(one or two) and the unit costs. All unit costs used for costing social care resource use can be found
in Appendix 4, Table 31.
Hospice day cases and inpatient stays were costed using published information,66 inflated to 2018 prices.58
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Medication costs
Up to 20 medication prescriptions were recorded for every living patient in all 14 follow-up periods.
Prescriptions were costed individually using standard unit costs23 for all licensed medications. Costs for
unlicensed medications or other products (e.g. multivitamins, probiotics, udder cream) were obtained
from alternative sources, such as online wholesalers. Where no dose information was available, the
most common dose prescribed was used. Any chemotherapy drugs were excluded to avoid double-
counting. Costs of all medications prescribed were summated to a total medication cost per follow-up
period at an individual patient level.
All medication unit costs used for the economic evaluation are listed in Appendix 4, Table 32.
Total costs
By adding up the implementation costs of EBRT (in the EBRT arm only) and subsequent primary,
secondary, social care, hospice and medication costs for all patients in both trial arms, total mean costs
per patient (including 95% CIs) were calculated to derive the incremental costs of the intervention at
the 12-week and 12-month follow-up compared with usual care.
Health outcomes
The QALYs required for the CUA were derived from EQ-5D-3L responses that were collected once
every 4 weeks from trial participants (as described in Chapter 2). Individual-level utility scores were
obtained at each assessment point using the EQ-5D-3L value set67,68 and summated for the EBRT
and usual-care arms. During this procedure, missing EQ-5D-3L items were replaced with the trial
population mean of each item if at least three items were complete. Where more than two items
were missing, the questionnaire was considered ‘not completed’ and no utility value was calculated.
The CUA used the modified ITT population (n = 199) with missing utility values imputed as the
patient-level mean of all available time points, in the base case. Sensitivity analyses used the complete
cases of the modified ITT population and available cases (without imputation) to test the impact that
missingness had on the analysis results. After the analysis populations were defined and patient-level
mean imputation performed where required, QALYs for each individual patient were calculated according
to an area-under-the-curve approach and linear interpolation, using all time points to estimate overall
QALYs as a combined measure of patients’ QoL and survival over 12 weeks and 12 months.
Some patients were consented prior to stent insertion (n = 75); the remainder were consented after
their stent was inserted (n = 124). This posed a difficulty when assigning any initial values to patient
arms from the clinical data. For this reason, the first clinical assessment and first QoL measure were
week 1 data in the case of the 124 patients who were consented after their stent insertion and
baseline data in the case of the 75 patients who were consented prior to stent insertion.
Model overview
As a means to undertake the health economic analysis in a complex population with high mortality,
a decision-analytic, mathematical model was constructed. Similar models have previously been used
successfully to undertake evaluations in comparable patient populations.68,69 Mathematical models are
built to simulate reality as an efficient way to test the effect of new treatments on the patient population.
A modelling-based approach enables exploration of the cost-effectiveness of a treatment by assessing the
effectiveness and any costs incurred in the process and testing different options and scenarios without
any patient risk. Operational research techniques, and in particular simulation models, have been
employed with much success to optimise the arrangements of different health-care environments.70
A de novo combined decision tree and Markov model was used to assess the cost-effectiveness of the
use of EBRT compared with standard care for patients suffering with end-stage oesophageal cancer
with a time horizon of 12 weeks in the base case as well as 12 months in sensitivity analysis.
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The model, which follows patients through their journey in the cancer pathway, was constructed
using Microsoft Excel with the modelling process coded in VBA. VBA is a computer programming
language attached to Microsoft Excel enabling the user to automate specific procedures to be repeated
thousands of times to attain a degree of variability around the results. This variability is important from
a modelling perspective as not all patients necessarily fit the ‘average’ situation.
Patient population
The model simulates a cohort of 1000 patients based on fully anonymised, directly obtained, patient-level
data collected for patients in the EBRT and comparator arms of the ROCS study.
Model description
A schematic representation of the model structure is depicted in Figure 17. Patients enter the model
at time zero. For the first 2 weeks, patients are assumed to have a stent inserted and receive standard
care, in accordance with the ROCS study, taking into account patients who died in this time period
based on actual trial survival data. The stent insertion and any other treatment received was costed
and patient QoL calculated. At the beginning of week 3, patients are split into the usual-care and EBRT
arms, with the usual-care arm receiving usual care and the EBRT arm receiving usual care plus EBRT,
following the ROCS study protocol. Weekly costs and utilities are calculated. At the end of week 4,
all radiotherapy is assumed to be completed, and patients are assigned to one of three Markov states:
dysphagia worsening, dysphagia stable or death. The patients then move through the model for














FIGURE 17 Schematic of the decision-analytic model constructed to calculate the cost-effectiveness of EBRT.
(a) Decision tree for weeks 0 to 4; and (b) Markov model for weeks 5 to 12.
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survival data from the ROCS study, with costs and utilities calculated weekly. At the end of the
12-week time horizon (4 weeks in decision tree and 8 weeks in the Markov model), all costs and
utilities are totalled for both the EBRT arm and the usual-care arm. An ICER was calculated to
determine cost-effectiveness.
Key model assumptions
Owing to the complexity of cancer treatment and the patient population, the model had to rely on
several simplifications and assumptions, all of which were discussed with and verified by the ROCS
TMG prior to inclusion in the model.
These assumptions include:
l Adverse events were not included as separate states within the model with an associated cost and
utility decrement. This was done to reduce the potential for double-counting as, because of the fact
that HRQoL and health-care resource use data were collected every 4 weeks throughout the trial,
any utility decrements and costs associated with adverse events would be reflected in the actual
trial data.
l If a patient underwent stent reinsertion during the first 12 weeks, this would be accounted for by
the individual costs and utilities calculated in the respective 4-week period.
l Base-case analysis was based on the modified ITT population of 199 patients.
Model inputs
The model required weekly cost and utility data as well as transition probabilities derived from
dysphagia scores and survival. All parameters used in the model were obtained from ROCS study data,
which were analysed on an individual patient level.
Health-care costs
To populate the cost parameters required for the decision-analytic model, costs were converted into
weekly costs. Weekly costs for weeks 1 and 2 were obtained by adding total week 1 costs and
one-third of total week 4 costs and dividing by 2 to get the mean weekly cost. Week 3 and 4 costs
were taken from the week 4 CSRI data divided by 3 (as this questionnaire covered a 3-week period).
Total costs at all other time points up to 12 weeks in the base case were divided by 4 to acquire
weekly costs for both trial arms. After 12 weeks, the model uses mean weekly costs of all further
follow-up points (weeks 13–52) for sensitivity analysis.
Allocation to initial Markov states and transition probabilities
The health economic model required relevant clinical evidence such as dysphagia scores and survival to
calculate transition probabilities between health states.
Dysphagia scores were collected every 4 weeks at the home visit and 2-weekly by telephone in
accordance with the trial protocol.26 Detailed analysis of the dysphagia data can be found in Chapter 2.
Dysphagia is a scale variable ranging from zero (no issues with swallowing) to 100 (severe issues
with swallowing). However, to enable transitions between the health states of stable and worsening
dysphagia, a cut-off point had to be defined for the model. Therefore, if a patient’s dysphagia score
increases by ≥ 11 points, the dysphagia for that patient is defined as ‘worsening’; otherwise a patient
is defined as ‘remaining the same or improving’.
Missing dysphagia scale scores were replaced with the trial population mean of each score if at least
two scores were complete. Where more than one score was missing, the questionnaire was considered
‘not completed’ and no dysphagia score was calculated. When a patient died, the dysphagia score for
the remainder of the data collection period was set to missing.
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As dysphagia scores were collected at 4-week intervals, the data required transformation to enable
the calculation of weekly transition probabilities. It was assumed that a Poisson distribution would be
most likely (i.e. with a constant rate and independent of the time since the last event). This followed
Fleurence and Hollenbeak71 to enable conversion of the probability of an event in the 4-week period to
an instantaneous rate that can then be converted into weekly transition probabilities without loss of
data integrity.
Survival data were analysed by totalling the number of deaths in each 4-week period for each of the
dysphagia categories. This 4-weekly probability was transformed in the same way as the swallowing
probabilities above to obtain weekly probabilities of a patient dying for each of the first 12 weeks in
the base case and subsequently for the remainder of the year for sensitivity analysis.
All transition probabilities used in the model can be found in Appendix 4, Table 34.
Health-related quality-of-life outcomes
Patient-level utilities were calculated every 4 weeks for the different Markov states within the model.
To use utility scores in the Markov model, we calculated utilities for each Markov state at each
particular time point. Although patient mean interpolation was used to populate any missing data while
the patient was alive, when a patient died, a utility score of zero was assumed for that patient for the
remainder of the time horizon. Utilities were calculated based on the individual 4-week follow-up
periods between baseline and week 12 for each of the states in the Markov model. For all time points
beyond 12 weeks, one mean weekly value was calculated for each arm and health state for the
remaining time horizon. This was deemed the most appropriate course of action as no clear pattern in
utility scores from 12 weeks onwards emerged and the sample size diminished rapidly owing to high
mortality in this patient population as time progressed. Although this is a limitation of the model, the
variability is accounted for in probabilistic sensitivity analysis. All utility values used in the model can
be found in Appendix 4, Table 35.
Cost–utility analysis
The model was used to conduct the within-trial CUA to assess the incremental costs per QALY gained as
a result of the use of EBRT. The base case investigated the cost-effectiveness of EBRT at 12 weeks, with
total costs and QALYs based on the modified ITT population (n = 199). Results of the comparative analysis








where C1 and E1 are the costs and effects of the EBRT arm and C0 and E0 are the cost and effects of
the usual-care arm with ΔC and ΔE being the incremental costs and effects of the intervention
compared with the control.
The ICER of a CUA represents the incremental cost per QALY gained. A QALY is a measure that
combines quantity of life (i.e. additional life expectancy) and QoL in one outcome. The cost per QALY
gained is calculated between EBRT and usual-care arms by dividing the difference in costs by the
difference in QALYs. Generally, NICE considers an intervention to be cost-effective if one of the
following applies:57
l The intervention is less costly and more clinically effective than all other relevant alternatives.
In this case, no ICER is calculated as the strategy in question dominates the alternatives.
l The intervention has an ICER of < £20,000 per QALY gained compared with the next best
alternative. This means that an investment of up to £20,000 to achieve an additional QALY is
considered cost-effective.
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However, NICE considers an intervention not to be cost-effective if:
l The intervention is more costly and less clinically effective than all other relevant alternatives.
In this case, no ICER is calculated as the strategy in question is dominated by the alternatives.
l The intervention has an ICER of > £20,000 per QALY gained compared with the next best
alternative, with the maximum threshold increasing depending on the circumstances (e.g. for orphan
drugs or end-of-life interventions).
The ICER resulting from the CUA was compared with the willingness-to-pay threshold of £20,000 per
QALY gained as standardised by NICE. Results are reported as ICERs showing the extra cost of producing
one extra QALY or the extra savings achieved by sacrificing one additional QALY.
Sensitivity analyses
Sensitivity analyses were undertaken to test the robustness of the CUA considering the uncertainty
in input parameters such as costs and outcomes and in different scenarios. Deterministic, univariate
sensitivity analyses changed intervention and health-care costs and outcomes individually within
plausible ranges (using ± 10%, ± 20% and ± 30% of the mean value). Scenario analyses tested different
assumptions and recalculated the ICER (e.g. based on different populations: complete cases, all available
cases). In addition, the time horizon was extended to 12 months to explore longer-term effects of the
intervention. For this, costs and QALYs beyond 12 weeks were based on all available cases, as sample
size was limited after 28 weeks due to high mortality. Considering that, after week 28, sample size in
both arms was small (owing to the high mortality in this patient arm), we also tested different costs
for the post-12-week period in sensitivity analysis (e.g. using weeks 13–16 and weeks 13–28 costs
as proxies for the rest of the year). A summary of all sensitivity analyses undertaken as a part of this
analysis can be found in Appendix 4, Table 33.
Probabilistic sensitivity analysis used non-parametric bootstrapping to address joint parameter uncertainty
and assess the impact on the ICER during 1000 simulations that were undertaken using random sampling
of the distributions of costs and outcomes, with results presented on cost-effectiveness planes and
as cost-effectiveness acceptability curves. The cost-effectiveness plane is a scatterplot of the point
estimates obtained as a result of the 1000 simulations depicted in four quadrants representing the
probability of the intervention being more/less costly and more/less effective than usual care. A cost-
effectiveness acceptability curve is a curve that describes the probability of the intervention being
cost-effective at different willingness-to-pay thresholds based on the probabilistic sensitivity analysis.
Results
Intervention implementation costs
Planning EBRT (oncology appointment, CT scan and radiographer time) was costed as £377.15 based
on the weighted average cost of all external, simple and superficial radiotherapy planning procedures
available in NHS reference costs.60 Cost per fraction delivered was £155.58, calculated as the weighted
mean of all external and superficial radiotherapy delivery costs. The mean number of fractions delivered
per patient was 6.06 [standard deviation (SD) 2.16]. Nineteen patients received 10 fractions, 64 patients
received five fractions and one patient each received four fractions and one fraction, respectively.
No information on the intervention EBRT treatment was available for 23 patients. Based on all available
cases, total mean EBRT intervention cost was £1304.42 (SD £364.99) per patient.
Cost of subsequent health-care resource use
The results reported in this chapter represent mean cost per patient based on all available cases.
Total health-care costs between baseline and 12 weeks were calculated based on data from 51 patients in
the EBRT arm and 61 patients in the usual-care arm who had data available for all four follow-up points
in the 12 weeks post randomisation.
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Primary care costs
A summary of the available primary care costs for the follow-up periods between baseline and
12 weeks can be found in Table 17.
Primary care costs in the EBRT arm were lower in weeks 2–8 and higher in weeks 9–12 than in the
usual-care arm. Notably, EBRT patients had more GP home visits throughout the 12-week follow-up
period. However, none of the differences reached statistical significance.





n (SD) Difference; 95% CI p-value
Total primary care costs between baseline and 12 weeks (all four follow-up points available)
Sample size 51 61 n/a n/a
GP visits at home 103.74 (222.83) 41.73 (41.73) 62.01; –2.96 to 126.99 0.061
GP visits at surgery 49.87 (51.10) 59.61 (76.14) –9.75; –34.54 to 15.05 0.438
Palliative nurse specialist visits
at home
129.19 (207.03) 126.37 (207.57) 2.82; –75.14 to 80.78 0.943
Palliative nurse specialist visits at surgery 0.73 (5.18) 1.82 (8.07) –1.09; –3.69 to 1.50 0.406
District nurse visits at surgery 1.69 (7.81) 0.20 (1.58) 1.49; –0.54 to 3.52 0.148
Other contacts 30.17 (57.28) 17.71 (33.78) 12.46; –4.82 to 29.75 0.156
Total cost of primary care use
per patient
315.39 (397.12) 247.44 (261.83) 67.95; –61.18 to 197.08 0.298
Primary care costs between baseline and 1 week
Sample size 100 100 n/a n/a
GP visits at home 13.88 (42.20) 11.28 (43.85) 2.60; –9.40 to 14.60 0.669
GP visits at surgery 8.60 (19.06) 9.35 (17.93) –0.75; –5.91 to 4.41 0.775
Palliative nurse specialist visits at home 9.38 (29.96) 13.54 (52.67) –4.17; –16.12 to 7.78 0.492
Palliative nurse specialist visits
at surgery
0.00 (0.00) 0.74 (5.21) –0.74; –1.77 to 0.29 0.157
District nurse visits at surgery 0.00 (0.00) 0.12 (1.23) –0.12; –0.37 to 0.12 0.319
Other contacts 10.02 (47.23) 3.79 (18.47) 6.23; –3.77 to 16.24 0.220
Total cost of primary care use
per patient
41.88 (73.91) 38.82 (84.68) 3.06; –19.11 to 25.22 0.786
Primary care costs in weeks 2 to 4
Sample size 91 92 n/a n/a
GP visits at home 25.73 (59.94) 21.68 (58.40) 4.05; –13.21 to 21.31 0.644
GP visits at surgery 11.92 (26.08) 19.11 (39.01) –7.19; –16.88 to 2.50 0.145
Palliative nurse specialist visits
at home
33.20 (90.39) 46.42 (93.13) –13.23; –40.00 to 13.55 0.331
Palliative nurse specialist visits
at surgery
0.00 (0.00) 0.40 (3.86) –0.40; –1.20 to 0.40 0.321
District nurse visits at surgery 0.00 (0.00) 0.13 (1.29) –0.13; –0.40 to 0.13 0.321
Other contacts 6.64 (23.55) 6.81 (26.62) –0.17; –7.50 to 7.16 0.963
Total cost of primary care use
per patient
77.49 (129.61) 94.56 (132.66) –17.07; –55.33 to 21.19 0.380
continued
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The total primary care costs between baseline and week 12 for all patients who provided data for all
four follow-up points amounted to £315.39 (SD £397.12) per patient in the EBRT arm and £247.44
(SD £261.83) per patient in the usual-care arm. The mean difference of £67.95 (95% CI –£61.18 to
£197.08) in favour of the usual-care arm was not statistically significant (p = 0.298).
Secondary care costs
A summary of the available secondary care costs for the follow-up periods between baseline and
12 weeks can be found in Table 18. It should be noted that total costs do not match individual item
costs as data were obtained from two different data sets with different numbers of available cases.
Secondary care costs in the EBRT arm were slightly higher between baseline and week 8 but lower
between weeks 9 and 12 than for usual-care arm patients (p = 0.015, not statistically significant after
Bonferroni–Holm correction for multiple comparison). This lower cost was mainly due to reduced
inpatient stay, blood transfusion and chemotherapy costs compared with the usual-care arm.
Total secondary care costs between baseline and the 12-week follow-up point per patient with available
data for all four follow-up periods amounted to £3623.23 (SD £4437.86) in the EBRT arm and £4917.96
(SD £4803.16) in the usual-care arm. The mean difference of –£1294.73 (95% CI –£3039.72 to £450.26)
was not statistically significant (p = 0.144).






n (SD) Difference; 95% CI p-value
Primary care costs in weeks 5 to 8
Sample size 79 83 n/a n/a
GP visits at home 27.45 (80.44) 19.85 (51.27) 7.59; –13.23 to 28.42 0.473
GP visits at surgery 12.31 (24.49) 14.42 (30.81) –2.11; –10.77 to 6.55 0.631
Palliative nurse specialist visits
at home
40.88 (100.66) 70.28 (142.86) –29.41; –67.93 to 9.11 0.134
Palliative nurse specialist visits
at surgery
0.47 (4.16) 0.45 (4.06) 0.02; –1.25 to 1.30 0.972
District nurse visits at surgery 0.00 (0.00) 0.15 (1.35) –0.15; –0.45 to 0.15 0.331
Other contacts 10.68 (38.50) 7.89 (22.97) 2.79; –6.99 to 12.58 0.574
Total cost of primary care use
per patient
91.78 (138.76) 113.04 (175.31) –21.26; –70.47 to 27.96 0.395
Primary care costs in weeks 9 to 12
Sample size 55 62 n/a n/a
GP visits at home 39.42 (123.59) 13.08 (34.61) 26.35; –6.07 to 58.77 0.110
GP visits at surgery 14.28 (25.44) 10.39 (27.78) 3.89; –5.91 to 13.68 0.434
Palliative nurse specialist visits at home 49.72 (91.77) 31.92 (74.47) 17.79; –12.68 to 48.26 0.250
Palliative nurse specialist visits
at surgery
0.00 (0.00) 0.00 (0.00) 0.00 n/a
District nurse visits at surgery 1.57 (7.53) 0.00 (0.00) 1.57; –0.32 to 3.46 0.103
Other contacts 6.08 (21.90) 3.54 (14.71) 2.54; –4.23 to 9.30 0.459
Total cost of primary care use per
patient (SD)
111.07 (175.79) 58.93 (89.02) 52.14; –0.15 to 104.42 0.051
n/a, not applicable.
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TABLE 18 Cost of secondary care resources (£) used in the 12-week period post randomisation based on all available cases
Health-care resource EBRT arm, n (SD)
Usual-care arm,
n (SD) Difference; 95% CI p-value
Total secondary care costs between baseline and 12 weeks (all four follow-up points available)
Sample size 51 61 n/a n/a
A&E visits 70.45 (111.24) 91.04 (173.91) –20.59; –76.52 to 35.34 0.467
Outpatient visits 568.36 (522.29) 449.13 (437.02) 119.23; –60.38 to 298.84 0.191
Palliative nurse visits
at hospital
18.14 (44.01) 19.41 (57.56) –1.27; –20.77 to 18.22 0.897
Day surgery visits 378.03 (527.23) 236.20 (448.04) 141.83; –40.78 to 324.44 0.127
Inpatient stays 1832.33 (3654.49) 2659.16 (4511.55) –826.83; –2385.06 to 731.40 0.295
Blood transfusions 41.53 (167.80) 107.57 (262.07) –66.03; –150.33 to 18.27 0.123
Palliative radiotherapy n = 6 n = 19 0.00 n/a
0.00 (0.00) 0.00 (0.00)
Chemotherapy n = 6 n = 19 258.33; –1585.56 to 2102.21 0.775
3114.60 (3027.96) 2856.27 (1443.07)
Total cost of secondary care
use per patient
3623.23 (4437.86) 4917.96 (4803.16) –1294.73; 3039.72 to 450.26 0.144
Secondary care costs between baseline and 1 week
Sample size 100 100 n/a n/a
A&E visits 38.30 (84.93) 22.50 (60.49) 15.79; –4.77 to 36.35 0.131
Outpatient visits 123.47 (188.09) 133.40 (210.16) –9.92; –65.54 to 45.69 0.725
Palliative nurse visits at
hospital
6.66 (21.28) 6.29 (24.13) 0.37; –5.98 to 6.71 0.909
Day surgery visits 149.94 (319.75) 111.80 (337.97) 38.14; –53.61 to 129.89 0.413
Inpatient stays 573.38 (1106.45) 452.67 (907.57) 120.71; –161.49 to 402.92 0.400
Blood transfusions 9.04 (64.90) 0.00 (0.00) 9.04; –3.76 to 21.84 0.165
Palliative radiotherapy n = 101 n = 99 0.00 n/a
0.00 (0.00) 0.00 (0.00)
Chemotherapy n = 101 n = 99 51.03; –147.36 to 249.42 0.613
136.68 (948.40) 85.65 (323.29)
Total cost of secondary care
use per patient
n = 101 n = 100 217.10; –148.93 to 583.13 0.244
1028.56 (1549.20) 811.46 (1027.52)
Secondary care costs in weeks 2 to 4
Sample size 91 92 n/a n/a
A&E visits 16.93 (61.90) 17.17 (68.00) –0.23; –19.21 to 18.74 0.981
Outpatient visits 201.76 (366.00) 65.48 (96.08) 136.28; 58.41 to 214.15 0.001a
Palliative nurse visits at
hospital
10.16 (43.45) 8.04 (23.80) 2.12; –8.08 to 12.33 0.682
Day surgery visits 114.02 (453.41) 36.46 (163.78) 77.56; –21.70 to 176.79 0.125
Inpatient stays 744.05 (2421.60) 549.65 (1683.39) 194.40; –413.39 to 802.18 0.529
Blood transfusions 23.18 (101.98) 22.93 (104.61) 0.25; –29.89 to 30.39 0.987
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TABLE 18 Cost of secondary care resources (£) used in the 12-week period post randomisation based on all available
cases (continued )
Health-care resource EBRT arm, n (SD)
Usual-care arm,
n (SD) Difference; 95% CI p-value
Palliative radiotherapy n = 32 n= 45 15.57; –6.46 to 37.61 0.163
15.57 (74.40) 0.00 (0.00)
Chemotherapy n = 32 n= 45 –91.18; –415.05 to 232.75 0.577
366.55 (833.80) 457.73 (593.92)
Total cost of secondary care
use per patient
1244.48 (2472.70) 923.62 (1816.24) 320.86; –311.50 to 953.21 0.318
Secondary care costs in weeks 5 to 8
Sample size 79 83 n/a n/a
A&E visits 19.99 (62.46) 17.28 (62.14) 2.71; –16.63 to 22.05 0.782
Outpatient visits 112.57 (234.99) 93.32 (175.58) 19.25; –44.91 to 83.41 0.554
Palliative nurse visits at
hospital
5.62 (23.76) 7.13 (39.81) –1.51; –11.75 to 8.72 0.771
Day surgery visits 75.15 (254.72) 26.82 (139.35) 48.33; –14.97 to 111.63 0.134
Inpatient stays 1101.05 (2444.29) 720.49 (1794.11) 380.56; –282.48 to 1034.60 0.259
Blood transfusions 31.50 (153.36) 21.16 (110.49) 10.34; –30.99 to 51.66 0.622
Palliative radiotherapy n = 37 n= 48 –28.38; –63.73 to 6.95 0.114
4.49 (19.04) 32.88 (106.64)
Chemotherapy n = 37 n= 48 –275.04; –573.93 to 23.84 0.071
370.95 (772.90) 645.99 (612.90)
Total cost of secondary care
use per patient
1521.72 (2587.36) 1278.81 (2051.69) 242.91; –479.83 to 965.65 0.508
Secondary care costs in weeks 9 to 12
Sample size 55 62 n/a n/a
A&E visits 19.14 (57.05) 21.65 (58.51) –2.51; –23.73 to 18.71 0.815
Outpatient visits 91.28 (139.02) 101.80 (196.76) –10.52; –73.65 to 52.62 0.742
Palliative nurse visits at
hospital
4.04 (18.39) 3.58 (17.35) 0.46; –6.09 to 7.00 0.891
Day surgery visits 28.88 (140.52) 45.24 (163.80) –16.36; –72.10 to 39.89 0.566
Inpatient stays 359.43 (1520.19) 964.53 (2192.82) –605.10; –1304.70 to 94.51 0.089
Blood transfusions 0.00 (0.00) 66.11 (198.79) –66.11; –119.23 to –12.99 0.015b
Palliative radiotherapy n = 24 n= 42 –4.45; –49.51 to 40.61 0.844
17.30 (84.77) 21.75 (89.98)
Chemotherapy n = 24 n= 42 –105.26; –437.21 to 226.68 0.529
513.12 (684.89) 618.38 (628.56)
Total cost of secondary care
use per patient
734.22 (1714.83) 1636.55 (2175.52) –902.32; –1.626 to –178.54 0.015b
n/a, not applicable.
a This result remained statistically significant after Bonferroni–Holm correction for multiple comparisons of secondary
care costs.
b This result was no longer statistically significant after Bonferroni–Holm correction for multiple comparisons of
secondary care costs.
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Hospice and social care costs
A summary of the available hospice and social care costs for the follow-up periods between baseline
and 12 weeks is presented in Table 19.
TABLE 19 Cost of hospice and social care resources (£) used in the 12-week period post randomisation based on all
available cases
Health-care resource EBRT arm, n (SD) Usual-care arm, n (SD) Difference; 95% CI p-value
Total hospice and social care costs between baseline and 12 weeks (all four follow-up points available)
Sample size 51 61 n/a n/a
Hospice days 25.89 (145.28) 178.57 (835.74) –152.68; –387.68 to 82.32 0.201
District nurse home visits 180.96 (524.86) 94.56 (310.08) 86.40; –72.09 to 244.90 0.282
Carer visits 220.24 (1281.88) 2.66 (12.76) 217.58; –107.41 to 542.57 0.187
Total cost of social care use
per patient
401.20 (1360.64) 97.22 (309.52) 303.98; –51.51 to 659.47 0.093
Hospice and social care costs between baseline and 1 week
Sample size 100 100 n/a n/a
Hospice days 0.00 (0.00) 26.41 (264.06) –26.41; –78.48 to 25.67 0.319
District nurse home visits 23.46 (162.68) 5.38 (35.01) 18.07; –14.74 to 50.89 0.279
Carer visits 45.36 (336.72) 8.18 (76.12) 37.18; –31.23 to 105.59 0.285
Total cost of social care use
per patient
68.82 (389.61) 13.48 (82.91) 55.33; –23.22 to 133.89 0.166
Hospice and social care costs in weeks 2 to 4
Sample size 91 92 n/a n/a
Hospice days 16.32 (115.54) 82.52 (467.76) –66.20; –165.83 to 33.44 0.192
District nurse home visits 79.87 (398.65) 33.44 (180.21) 46.43; –43.65 to 136.51 0.311
Carer visits 34.42 (197.10) 51.39 (331.35) –16.97; –96.49 to 62.55 0.674
Total cost of social care use
per patient
114.28 (506.77) 85.38 (469.73) 28.90; –113.61 to 171.41 0.690
Hospice and social care costs in weeks 5 to 8
Sample size 79 83 n/a n/a
Hospice days 133.70 (529.26) 99.42 (407.49) 34.28; –111.87 to 180.43 0.644
District nurse home visits 76.91 (342.12) 98.68 (389.45) –21.78; –135.74 to 92.19 0.706
Carer visits 118.94 (702.98) 10.41 (83.68) 108.53; –44.97 to 262.02 0.165
Total cost of social care use
per patient
195.85 (815.02) 109.09 (403.83) 86.75; –111.67 to 284.89 0.389
Hospice and social care costs in weeks 9 to 12
Sample size 55 62 n/a n/a
Hospice days 15.00 (91.35) 13.31 (86.09) 1.69; –30.81 to 34.20 0.918
District nurse home visits 170.60 (665.80) 19.23 (88.83) 151.37; –17.70 to 320.44 0.079
Carer visits 74.62 (417.70) 1.74 (10.79) 72.88; –32.18 to 177.94 0.172
Total cost of social care use
per patient
245.22 (772.10) 20.97 (89.10) 224.25; 28.67 to 419.83 0.025a
n/a, not applicable.
a This result was no longer statistically significant after Bonferroni–Holm correction for multiple comparisons of social
care costs.
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Total hospice costs (including day cases and inpatient days) between baseline and the 12-week follow-up
point per patient who contributed data to all four follow-up points amounted to £25.89 (SD £145.28)
in the EBRT arm and £178.57 (SD £835.75) in the usual-care arm. The mean difference of –£152.68
(95% CI –£387.68 to £82.32) was not statistically significant (p = 0.201).
Social care costs were higher in the EBRT arm at all follow-up points with higher costs between 9 and
12 weeks (p = 0.025; difference not significant after Bonferroni–Holm correction for multiple comparison).
Total per patient social care costs (including district nurse home visits and carer visits) in the 12-week
follow-up period amounted to £401.20 (SD = £1360.64) in the EBRT arm and £97.22 (SD = £309.52) in
the usual-care arm. The mean difference of £303.98 (95% CI –£51.51 to £659.47) was not statistically
significant (p = 0.093).
Medication costs
A summary of the available medication costs for the follow-up periods between baseline and 12 weeks
is presented in Table 20.
Medication costs were slightly lower in the EBRT arm than in the usual-care arm, but no evidence of
significant differences was found.
Total per patient medication costs in the 12-week follow-up period amounted to £187.76 (SD £166.35)
in the EBRT arm and £257.83 (SD £197.28) in the usual-care arm. The mean difference of –£70.07
(95% CI –£139.21 to –£0.93) reached statistical significance at the 0.05 level (p = 0.047).
TABLE 20 Medication cost (£) used in the 12-week period post randomisation based on all available cases
Health-care resource EBRT arm, n (SD) Usual-care arm, n (SD) Difference; 95% CI p-value
Medication costs between baseline and 12 weeks (all four follow-up points available)
Sample size 51 61 n/a n/a
Total cost of medication use
per patient
187.76 (166.35) 257.83 (197.28) –70.07; –139.21 to –0.93 0.047
Medication costs between baseline and 1 week
Sample size 100 100 n/a n/a
Total cost of medication use
per patient
40.09 (63.68) 48.24 (56.26) –8.15; –24.91 to 8.60 0.339
Medication costs in weeks 2 to 4
Sample size 91 92 n/a n/a
Total cost of medication use
per patient
43.05 (56.22) 51.15 (78.75) –8.11; –28.08 to 11.87 0.424
Medication costs in weeks 5 to 8
Sample size 79 83 n/a n/a
Total cost of medication use
per patient
74.74 (110.22) 74.56 (76.10) 0.18; –29.09 to 29.45 0.990
Medication costs in weeks 9 to 12
Sample size 55 62 n/a n/a
Total cost of medication use
per patient
60.96 (70.32) 79.14 (84.83) –18.18; –46.93 to 10.57 0.213
n/a, not applicable.
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Total health-care costs
Total health-care costs (based on available cases) in the 12-week follow-up period included the cost of
all primary, secondary and social care, and any medications prescribed (Table 21). Patients in the EBRT
arm had higher health-care costs than those in the usual-care arm in the first 8 weeks after baseline.
Between 8 and 12 weeks, total health-care costs were lower in the EBRT arm. None of the differences
was statistically significant.
If we considered only patients with data for all four follow-up periods in the first 12 weeks following
randomisation, patients in the EBRT arm accrued mean per patient health-care costs of £4553.47
(SD £4746.01), compared with £5699.02 (SD £5024.49) in the usual-care arm. The incremental
cost of EBRT was –£1145.55 (95% CI –£2988.00 to £696.90). The lower cost was mainly caused by
lower inpatient and chemotherapy costs in the weeks 9–12 time period, but the difference was not
statistically significant (p = 0.221).
After adding the intervention implementation costs for all patients who had data for all four follow-up
periods in the 12 weeks from baseline, patients in the EBRT arm accrued a mean cost of £5854.10
(SD £4768.79), compared with £5699.02 (SD £5024.49) in the usual-care arm. The difference of
£155.08 (95% CI –£1691.15 to £2001.31) was not statistically significant (p = 0.868).
Total costs of the modified intention-to-treat population
Consistent with the statistical analysis, the CUA was based on the modified ITT population (n = 199).
This included 97 patients in the EBRT arm and 102 patients in the usual-care arm. Because not all cost
data were recorded at all time points for every patient, the population mean for every parameter at
individual follow-up points was used for imputation of missing data.
A breakdown of all costs in the modified ITT population can be found in Table 22. In the 12-week
follow-up period, costs of secondary and social care were higher in the EBRT arm whereas primary
care, hospice and medication costs were slightly lower (Figure 18). The higher costs mainly occurred in
TABLE 21 Total health-care cost (£) used in the 12-week period post randomisation based on all available cases
Health-care resource EBRT arm, n (SD)
Usual-care arm,
n (SD) Difference; 95% CI p-value
Total health-care costs between baseline and 1 week
Sample size 101 100 n/a n/a
Total cost of health-care use
per patient
1177.85 (1660.00) 938.41 (1094.15) 239.44; –152.03 to 630.91 0.229
Total health-care costs in weeks 2 to 4
Sample size 91 92 n/a n/a
Total cost of health-care use
per patient
1495.62 (2625.95) 1237.24 (1951.38) 258.38; –415.95 to 932.72 0.451
Total health-care costs in weeks 5 to 8
Sample size 79 83 n/a n/a
Total cost of health-care use
per patient
2017.80 (2710.67) 1674.93 (2066.76) 342.86; –402.87 to 1088.60 0.365
Total health-care costs in weeks 9 to 12
Sample size 55 62 n/a n/a
Total cost of health-care use
per patient
1166.47 (1902.23) 1808.90 (2206.20) –642.43; –1401.57 to 116.72 0.094
n/a, not applicable.
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TABLE 22 Cost of health-care resources (£) used in the 12-week period post randomisation based on patients included
in the modified ITT population
Health-care resource EBRT arm, n (SD)
Usual-care arm,
n (SD) Difference; 95% CI p-value
Health-care costs between baseline and 1 week
Sample size 97 102 n/a n/a
Primary care 52.82 (87.19) 41.08 (84.08) 11.74; –12.20 to 35.67 0.335
Secondary care 1070.00 (1621.15) 838.74 (1057.42) 231.26; –149.55 to 612.08 0.233
Hospice care 0.00 (0.00) 27.23 (261.39) –27.23; –79.57 to 25.12 0.306
Social care 77.29 (398.14) 14.64 (82.14) 62.65; –16.80 to 142.10 0.122
Medication 41.51 (66.40) 48.85 (55.01) –7.34; –24.35 to 9.67 0.396
Total cost of health-care use
per patient
1241.62 (1741.88) 970.54 (1120.28) 271.09; –136.33 to 678.50 0.191
Health-care costs in weeks 2–4
Sample size 90 92 n/a n/a
Primary care 99.41 (197.39) 110.75 (165.58) –11.34; –64.58 to 41.91 0.675
Secondary care 1080.91 (2119.35) 915.50 (1816.67) 165.41; –411.53 to 742.36 0.572
Hospice care 17.12 (116.23) 83.67 (467.62) –66.55; –166.72 to 33.61 0.192
Social care 134.92 (528.08) 87.69 (469.56) 47.23; –98.85 to 193.32 0.524
Medication 42.92 (55.54) 52.72 (78.29) –9.79; –29.69 to 10.10 0.333
Total cost of health-care use
per patient
1375.28 (2343.80) 1250.32 (1962.63) 124.96; –506.80 to 756.73 0.697
Health-care costs in weeks 5–8
Sample size 83 86 n/a n/a
Primary care 102.86 (165.67) 148.84 (324.27) –45.99; –124.62 to 32.65 0.250
Secondary care 1549.66 (2571.33) 1241.40 (2028.24) 308.26; –393.75 to 1010.27 0.387
Hospice care 127.26 (516.99) 98.76 (400.39) 28.50; –111.65 to 168.65 0.689
Social care 190.11 (795.85) 103.51 (395.17) 86.60; –103.22 to 276.43 0.369
Medication 72.54 (108.02) 73.35 (74.73) –0.81; –28.94 to 27.32 0.955
Total cost of health-care use
per patient
2042.44 (2710.97) 1665.87 (2078.36) 376.57; –355.49 to 1180.63 0.311
Health-care costs in weeks 9–12
Sample size 67 74 n/a n/a
Primary care 112.32 (170.89) 64.69 (90.53) 47.63; 2.68 to 92.57 0.038a
Secondary care 897.68 (1740.03) 1464.16 (2041.91) –566.48; –1201.51 to 68.55 0.080
Hospice care 37.77 (165.10) 11.54 (78.83) 26.23; –16.21 to 68.68 0.224
Social care 246.15 (718.81) 22.60 (84.03) 223.54; 57.15 to 389.94 0.009b
Medication 62.41 (69.61) 72.97 (80.02) –10.56; –35.65 to 14.53 0.407
Total cost of health-care use
per patient
1356.33 (1968.01) 1635.97 (2069.81) –279.63; –953.86 to 394.60 0.414
HEALTH ECONOMICS EVALUATION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
78
the first 8 weeks and could not be offset by lower costs, especially for secondary care, in weeks 9–12.
Total mean health-care cost (including primary, secondary, hospice and social care, as well as medication
costs) in the modified ITT population therefore amounted to £5202.16 (SD £5613.63) in the EBRT
arm and £4667.73 (SD £4719.99) in the usual-care arm with a mean difference of £534.43
(95% CI –£912.86 to £1981.73; p = 0.467) in favour of the usual-care arm.
Mean EBRT intervention costs were £1297.34 (SD £296.38) in the modified ITT population. Therefore,
total mean cost for this population (including all health-care costs and intervention costs) was £6499.50
(SD £5593.65) in the EBRT arm. The mean difference of £1831.77 (95% CI £387.43 to £3276.11)
favouring usual-care treatment was statistically significant (p = 0.013).
TABLE 22 Cost of health-care resources (£) used in the 12-week period post randomisation based on patients included
in the modified ITT population (continued )
Health-care resource EBRT arm, n (SD)
Usual-care arm,
n (SD) Difference; 95% CI p-value
Total health-care costs between baseline and week 12
Sample size 97 102 n/a n/a
Primary care 310.65 (400.09) 312.01 (410.02) –1.36; –114.69 to 111.97 0.981
Secondary care 4018.96 (5000.51) 3756.21 (4410.26) 262.75; –1053.76 to 1579.26 0.694
Hospice care 150.86 (605.37) 193.67 (746.57) –42.80; –233.39 to 147.78 0.658
Social care 535.17 (1552.36) 195.61 (621.18) 339.57; 11.95 to 667.19 0.042a
Medication 186.52 (186.82) 210.24 (183.42) –23.72; –75.49 to 28.04 0.367
Total cost of health-care use
per patient
5202.16 (5613.63) 4667.73 (4719.99) 534.43; –912.86 to 1981.73 0.467
n/a, not applicable.
a This result was no longer statistically significant after Bonferroni–Holm correction for multiple comparisons of total
health-care costs.





















FIGURE 18 Mean cost differences between EBRT and usual-care patients in the modified ITT population in the 12-week
follow-up period.
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Total cost at 12 months
Total health-care costs at 52 weeks were based on all available cases who contributed at least one
health-care resource use data set at one follow-up point within the 1-year trial period. This included
104 people in the EBRT arm and 102 in the usual-care arm. The total 12-month health-care costs in
this population were £7440.43 (SD £7643.21) in the EBRT arm and £9087.14 (SD £8890.75) in the
usual-care arm. The mean difference of –£1646.70 (95% CI –£3922.89 to £629.49) was not statistically
significant (p = 0.155). Adding the implementation cost of EBRT on an individual patient level decreases
the cost difference to –£568.05 (95% CI –£2858.80 to £1722.71; p = 0.625).
Figure 19 illustrates the changes in health-care costs over time. It is apparent from the graph that the
difference in costs between the two trial arms is mainly attributed to the follow-up points from 28
weeks onwards, when health-care costs were consistently lower in the EBRT arm, especially in weeks
45–52. However, none of these cost differences reached statistical significance, and sample sizes had
fallen below 25 patients per trial arm. When considering health-care costs (including intervention cost)
between baseline and 28 weeks only (with more representative sample sizes), patients in the EBRT
arm (n = 104) accrued £8092.74 (SD £7768.58), compared with £7443.79 (SD £7169.20) in the usual-
care arm (n = 102), with a mean incremental cost of EBRT patients of £648.95 (95% CI –£1405.64 to
£2703.54; p = 0.534). The cost savings in the EBRT arm, based on the 12-month follow-up period,
should therefore be interpreted with caution. However, between weeks 9 and 16, patients in the EBRT
arm (n = 57) had lower health-care costs (£2382.48, SD £3429.09) than the usual-care arm (n = 66)
(£3325.41, SD £3234.21). The mean difference of –£942.93 (95% CI –£2133.51 to £247.64) may be
attributed to a short-term effect of the intervention on the need for health care in this period but was
not statistically significant (p = 0.119).
Although the annual costs reported above represent the mean costs over 1 year for a palliative
population with poor prognosis, they underestimate costs for patients with longer survival. We
therefore calculated mean annual costs for five EBRT patients and 11 usual-care patients who were
still alive at the 52-week follow-up point and completed the CSRI questionnaire. Based on the small
sample size of 16 patients in the ROCS study population at 52 weeks, the mean annual health-care
























FIGURE 19 Total health-care costs (excluding intervention costs) in EBRT and usual-care arms over 52 weeks’ follow-up
(based on available cases).
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Weekly costs used in the model
Costs were converted into weekly costs based on the modified ITT population for the 12-week time
horizon and based on available cases for costs between weeks 13 and 52 for the 1-year horizon used
as part of sensitivity analysis. Weekly costs used in the model can be found in Table 23.
Dysphagia and survival
At week 5, patients are split into dysphagia categories by treatment for the Markov model (see
Appendix 4, Table 34). Initially, the proportion of patients whose ability to swallow improves or
remains the same is higher in the EBRT arm than in the usual-care arm (0.77 and 0.76 respectively).
The probability of death is higher in the usual-care arm (p = 0.11) than in the EBRT arm (p = 0.06).
Considering patients beginning in the ‘ability to swallow improved’ state, the probability that
patients in the EBRT arm remain in that state for the next cycle decreases each month, beginning
at 0.92 for weeks 5–8, then increasing to 0.90 for weeks 9–12 and to 0.82 for weeks 13 onwards;
the corresponding figures for the usual-care arm are 0.91, 0.91 and 0.88, respectively. Similarly,
the pattern repeats for patients beginning in a worsening state of dysphagia, with probabilities for
improving their dysphagia decreasing over time. The probability of death increased every month in
both arms for most time points (see Appendix 4, Table 34). In the usual-care arm, the probability of
dying decreased in weeks 9–12 among those whose ability to swallow improved. However, this
anomaly could be due to a diminishing sample size and sample variation.
Health-related quality of life and quality-adjusted life-years
No significant differences in QALYs between the EBRT arm and the usual-care arm were found at
baseline (p = 0.1345). This picture remains the same at 12 weeks and 12 months, with no significant
differences in the instantaneous utility score between the EBRT arm and the usual-care arm (p = 0.460
and p = 0.294 for 12 weeks and 12 months, respectively). Table 24 summarises the QALY gains by arm
over the 12-week and 12-month follow-up periods.
TABLE 23 Weekly cost of health-care resources (£) used to populate the decision-analytic model
Time period EBRT arm Usual-care arm
Weeks 1 and 2 770.02 770.02
Weeks 3 and 4 (HRU) 458.43 416.77
Weeks 3 and 4 (EBRT) 648.67 0.00
Weeks 5 to 8 510.61 416.47
Weeks 9 to 12 339.08 408.99
Weeks 12 onwards 163.99 240.77
HRU, health-care resource use.
TABLE 24 Summary of the QALY gains in the 12-week and 12-month follow-up periods
Time horizon Allocation Mean SD Minimum Median Maximum IQR
12 weeks EBRT 0.1602 0.0831 –0.0172 0.1794 0.3077 0.1516
Usual care 0.1485 0.0861 –0.0382 0.1510 0.3077 0.1447
12 months EBRT 0.2529 0.2092 –0.0382 0.2023 0.9533 –
Usual care 0.3004 0.2471 –0.0603 0.2189 0.8969 0.3767
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The changes in transition probabilities over time according to which state of the Markov model the
patients begin in are illustrated in Appendix 4, Figures 28 and 29.
Correlation analysis conducted as part of the model validation process found a negative correlation
that exists between dysphagia and EQ-5D-3L score. At 12 weeks, by running Spearman’s rank tests,
there is a highly significant moderate negative correlation for both the EBRT arm and the usual-care
arm (ρ = –0.4410; p = 0.0031 and ρ = –0.4319; p = 0.0.0054, respectively). This conclusion follows
intuition showing that poor ability to swallow negatively affects QoL for both the EBRT and
usual-care patients.
Cost–utility analysis
Based on the incremental cost of stent insertion and EBRT compared with stent insertion alone, the
base case ICER is –£549,200 per QALY gained at the 12-week follow-up. This means that EBRT is
more costly and less effective than the usual-care treatment and thus dominated by usual care.
Table 25 summarises the incremental results for the deterministic base-case CUA. The difference in
QALYs between the arms is minimal over the 12 weeks (1.3919). However, the costs for the EBRT arm
are over £750,000 higher (for 500 simulated patients in the EBRT arm), resulting in a large negative ICER.
Sensitivity analyses
No change to the base-case conclusion was found in the one-way sensitivity analyses conducted. EBRT
was dominated, and thus found not to be a cost-effective treatment for end-stage oesophageal cancer,
in all one-way sensitivity analyses (Table 26). Scenario analysis showed that extending the analysis to a
12-month time horizon does not have an impact on the conclusion as EBRT remains dominated in all cases.
Figure 20 displays the probabilistic sensitivity analysis results. In all 1000 iterations, EBRT was found
to be more costly than usual care (with all points in the north-east and north-west quadrants of the
cost-effectiveness plane). Overall, the probability that EBRT is cost-effective at the willingness-to-pay
threshold of £20,000 per QALY gained is 1.4% (Figure 21). If we extend the time horizon to 12 months,
this probability increases to 10.5%.
Discussion
This chapter describes the methods and results of the health economic evaluation undertaken as part of
the ROCS study, providing a thorough and transparent account of the economic analysis, with potential
for the economic model to be adapted in future trials and studies and to inform decision-making. To our
knowledge, this represents the first reported economic analysis of the cost-effectiveness of the addition
of EBRT in patients with advanced oesophageal cancer undergoing stent placement compared with
stent placement alone, based on one of the largest reported intervention trials involving stents.
TABLE 25 Results of the CUA for 1000 simulated patients (including 500 patients in each of the two trial arms)
Characteristic Usual care EBRT Difference
Total cost £2,313,998 £3,078,427 £764,429
Total QALYs 55.32 53.93 –1.3919
ICER (cost per QALY gained) Dominated (–£549,200)
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TABLE 26 Results of the one-way sensitivity analyses
SA-ID Parameter Change
ICER
12 weeks 12 months
Base case n/a n/a Dominated Dominated
SA1 Costs –10% Dominated Dominated
SA2 Costs –20% Dominated Dominated
SA3 Costs –30% Dominated Dominated
SA4 Costs +10% Dominated Dominated
SA5 Costs +20% Dominated Dominated
SA6 Costs +30% Dominated Dominated
SA7 Costs Intervention cost microcosted Dominated Dominated
SA8 Utilities –10% Dominated Dominated
SA9 Utilities –20% Dominated Dominated
SA10 Utilities –30% Dominated Dominated
SA11 Utilities +10% Dominated Dominated
SA12 Utilities +20% Dominated Dominated
SA13 Utilities +30% Dominated Dominated
SA14 All parameters Complete cases used Dominated Dominated
SA15 All parameters All available cases used Dominated Dominated
SA16 All parameters post 12 weeks Weeks 13–16 used Dominated Dominated
SA17 All parameters post 12 weeks Weeks 13–28 used Dominated Dominated


















FIGURE 20 Cost-effectiveness plane illustrating the distribution of incremental cost per QALY gained over 1000 analysis
iterations following parameter resampling within predefined ranges and distributions based on a simulation cohort of
1000 patients.
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The ROCS study enabled the collection of detailed patient-level resource use and clinical and health
utilities reflecting interventions that replicate current practice in the UK NHS sites. This provided a
comprehensive assessment of costs and health utilities, capturing in-depth data on intervention and
subsequent use of health and personal social care resources over the course of the follow-up period.
The data collection of economic outcomes benefited from the attention that the ROCS study design
paid to capturing precise and regular resource use information from patients and including reasons for
missing data. These individual patient-level data were used to undertake a CUA, employing economic
modelling as the vehicle for analysis. The construction of a complex model, populated entirely with
trial data, allowed a thorough examination of the costs and consequences of EBRT in addition to stent
placement in the context of routine clinical practice with careful attention paid to managing the challenges
of undertaking an economic evaluation in a palliative population with limited prognosis.
External beam radiotherapy is an expected up-front intervention cost, which represented an additional
£1304 per patient in addition to stent insertion. As a result, the combined intervention was more
expensive than stent placement alone. Despite lower health-care costs of £943 in the EBRT arm
between weeks 9 and 16, which may be attributed to a short-term effect of the intervention on the
need for health care in this period, little difference in health resource use and associated costs was
evidenced across both arms in the first 12 weeks. At 12 months, potential savings were noted in
subsequent health and social care costs in the EBRT arm, which offset the EBRT costs and resulted
in savings of £568 per patient still alive at 52 weeks. These savings were mainly attributed to the
follow-up points from 28 weeks onwards, at which time health-care costs were consistently lower in
the EBRT arm, especially in weeks 45–52. However, none of these cost differences reached statistical
significance, and sample sizes had fallen below 25 patients per trial arm. Furthermore, between
baseline and 28 weeks, with more representative sample sizes, patients in the EBRT arm accrued a
mean incremental cost of £648. The cost savings in the EBRT arm based on the 12-month follow-up
period should therefore be interpreted with caution.
When health outcomes were assessed, there were no statistically significant differences in health
utilities and survival between arms, which reflects the findings from the primary and secondary
clinical and QoL outcomes of the ROCS study. Although the clinical analysis observed significantly
fewer bleeding events in the ERBT arm over the time horizon, this did not result in any significant
differences in costs associated with admissions or interventions in the EBRT arm. However, given the
potential for EBRT to reduce bleeding in selected patients and a significantly lower cost for blood
transfusions in the EBRT arm between weeks 9 and 12, further examination of the association of
bleeding risk and impact on resource use and costs is warranted. Based on the QALYs generated from

























FIGURE 21 Cost-effectiveness acceptability curve depicting the probability of EBRT being cost-effective at different
willingness-to-pay thresholds based on 1000 iterations for a simulated cohort of 1000 patients.
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The base-case analysis (12-week time horizon) found that EBRT is not a cost-effective treatment at a
willingness-to-pay threshold of £20,000 per QALY gained when used in addition to stent placement in
an advanced oesophageal cancer population. The findings remain robust when tested in a range of
sensitivity analyses and the conclusion did not change when a 12-month time horizon was considered.
Although there are no directly comparable economic evaluations to the ROCS study population, the
findings from the ROCS study can be placed in the wider context of palliative interventions in advanced
oesophageal cancer, although the economic evidence base is limited. Such studies have considered the
potential for upfront intervention costs to be offset by reducing the need for further (re-)interventions.
However, prior studies72,73 have been constrained by limitations such as capturing initial interventions
costs only and lack of corresponding health utilities. Although limited in providing a ‘single trial’
estimation of data inputs, the ROCS study data have provided detailed assessment of costs and
outcomes related to a range of different health states associated with the patient pathway following
EBRT in addition to stenting and stenting alone. The 12-month time horizon is likely to have captured
all relevant costs and health consequences, with longer-term extrapolation unlikely to affect the
findings (i.e. given that the ROCS study population reflects the wider clinical population, this could
be considered appropriate in capturing a lifetime horizon for this population).
A recent costing study72 discussed the direct medical costs to the Canadian health-care system.
Although this compared costs across cancer stages and treatment, radiotherapy was a predictor of
higher net costs. This was also observed in an Australian study of resource use and costs in oesophageal
cancer.73 Thien et al.72 highlighted the importance of capturing phase-specific costs to estimate the
cumulative costs over the patient pathway. The ROCS study data set provides detailed assessment of
health and social care resource use during the ROCS study treatment pathways, which in turn could
enable further assessment of the costs associated with the management of people with advanced
oesophageal cancer.
There are several important caveats to the economic evaluation. The focus on an NHS/Personal Social
Services perspective will not have captured the impact on patients, family and society. The CUA was
based on the EQ-5D-3L. Although this reflects appropriate methods for national decision-making,57
the inherent insensitivity of the generic EQ-5D questionnaire may not have reflected the more precise
estimates of HRQoL changes, captured by the other patient-reported measures used in the trial.
However, the findings from the EQ-5D-3L derived utilities are comparable to the clinical measures
of HRQoL in that no differences were observed in QoL outcomes. The trade-off between costs and
benefits focused on the interventions tested in the ROCS study and may not fully reflect the other
potential treatment options such as specialist palliative care. No regard has been made as to whether
EBRT would be cost-effective taking into account any specific decision criteria (e.g. in relation to
end-of-life care). Although it is ultimately the jurisdiction of decision-makers to appraise the evidence
from the ROCS study, given that there is no survival advantage shown, it is unlikely that formal
consideration of such criteria would alter the conclusion.
In conclusion, the addition of EBRT to stent placement is not a cost-effective option, at a willingness-
to-pay threshold of £20,000 per QALY gained, in the management of patients with advanced
oesophageal cancer.
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Chapter 6 Discussion and conclusions
The most common intervention for relief of severe dysphagia in advanced oesophageal cancer isinsertion of a SEMS. Although this provides rapid relief, it is associated with deteriorations in
quality of life and increased reintervention rates over time, with average stent patency reported as
11–12 weeks.10,20,21 Systematic reviews8,9 have highlighted the need for studies that test interventions in
combination with SEMS to improve dysphagia outcomes and for such studies to include robust health
economic and qualitative evaluation of participant experiences.
Any combined intervention should not have too great an impact on other aspects of quality of life and,
to be useful, should be readily available reasonably close to home for a frail patient population. Such
availability will be dependent on the expertise and infrastructure available locally. EBRT is a treatment
modality that is widely available across the UK and accounts for over 95% of all radiotherapy given.18
It is commonly used as a palliative oncological treatment for oesophageal cancer symptoms. This
contrasts starkly with the lack of infrastructure and expertise for palliative oesophageal brachytherapy.17
Therefore, EBRT represents a readily available modality for combination with SEMS to improve palliation
in the setting of advanced oesophageal cancer in the UK. Given its wide availability internationally, it also
represents a viable option in middle- and low-income countries, which account for > 80% of oesophageal
cancer incidence and deaths.2
The ROCS study is the first large-scale prospective, pragmatic RCT to test the impact of combining
palliative EBRT with stent insertion versus stent insertion alone on dysphagia, quality of life and
bleeding. Its mixed-methodological approach has allowed a robust multiperspective analysis of efficacy.
Summary of key findings
This study clearly shows that EBRT did not improve the proportion of patients with a stent who
experienced recurrent dysphagia up to and including 12 weeks. The median overall survival of 19 weeks
confirmed that the participant population accurately reflects the wider clinical population of these
patients.3 Only 31 patients were alive at the end of the study, with a median follow-up of those still
alive of 22.9 weeks (n = 16) versus 22.1 (n = 15). Nonetheless, the majority of the recruited patients
had a performance status (PS) of 2 or better, and thus were among the fitter patients with this disease,
so our results may underestimate burdens to those with poorer PS.
The trial was powered on 82 patients per arm to reduce the proportion of recurrent dysphagia events
from 40% to 20% at week 12 (80% power, 5% alpha two-sided). Our complete-case analysis revealed
an average event rate across arms of 46%, similar to that predicted.
Our modified ITT population had 102 (usual care) and 97 (EBRT plus stent) patients per arm, with
74 versus 75 complete data sets up to week 12. Sensitivity analysis by imputing for missing data under
best- and worst-case scenarios resulted in 90 versus 88 patients in the denominator. The robustness of
the primary outcome result was confirmed across all of these data sets as well as a per-protocol data
set. Whether or not death was treated as an event did not alter the primary outcome.
Secondary sensitivity analysis of DDFS again showed no difference.
For those undergoing EBRT, the qualitative data set importantly uncovered trade-offs in terms of
fatigue, pain and burden associated with travel to the radiotherapy sessions. Similarly, QoL data
showed a trend towards increased fatigue in the radiotherapy arm, and fatigue was noticeably more
frequently described as a grade 3+ toxicity in the radiotherapy arm although this finding was not
statistically significant.
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It is noteworthy that, although there was no difference in other QoL outcomes between arms, global
HRQoL scores were low across the study population. Eating restriction scores improved from baseline,
reflecting SEMS insertion, but never returned to normal and eating remained a significant issue over
time. These outcomes reflect the challenges that patients described in the qualitative study of their
lived experiences of eating restrictions, concerns over nutrition and diet, and a trial and error approach
to combating these, with important implications for practice.
The health economic evaluation of complete cases did not demonstrate a significant difference in
combined health and social care costs between arms at 12 weeks, and cost–utility analysis of the full
ITT arm confirmed that EBRT was a less cost-effective approach than stent insertion alone.
At 12 months, potential savings were noted in subsequent health and social care costs in the EBRT arm,
which offset the intervention costs and resulted in savings of £568 per patient still alive at 52 weeks.
These savings were mainly attributed to the period after 28 weeks, when health-care costs were
consistently lower in the EBRT arm. However, none of the differences reached statistical significance,
and sample sizes had fallen below 25 patients per arm. So few patients survive for 1 year in this
situation that it is not appropriate to propose radiotherapy on this basis.
Radiotherapy is often offered to try to help palliate bleeding, although there are no prospective studies
to show that it is effective for this. Although there was no evidence of a difference between arms for
the primary outcome, those in the radiotherapy arm had significantly fewer bleeding events. Up to
week 16, in the usual-care arm 19 (18.6%) patients had a bleeding-related event compared with 10
(10.3%) patients in the EBRT arm, giving a number needed to treat of 12. The effect persisted and
increased over time: at 52 weeks, 29 (28.4%) patients in the usual-care arm, compared with 16 (16.5%)
patients in the radiotherapy arm, had an event, giving a number needed to treat of eight. These are the
first prospective randomised data on radiotherapy for palliation of upper GI cancer bleeding risk that
we are aware of.
There were no differences between arms in antiplatelet or anticoagulant use. We did not capture data
on visual descriptions of tumour at endoscopy, but there was no association between tumour length
and bleeding risk.
These data suggest that, for those patients with good performance status deemed at higher risk of
bleeding at initial endoscopy, prophylactic radiotherapy may reduce later bleeding risk and associated
admissions/interventions. The health economic data, for example, showed lower health-care costs in
the EBRT arm between weeks 9 and 12, associated in particular with lower blood transfusion costs.
Patients in the EBRT arm were also much less likely to undergo subsequent palliative radiotherapy to
the oesophagus. In the usual-care arm, 20 patients had subsequent palliative radiotherapy (overall
median dose was 20 Gy in five fractions), in 16 (80%) cases to the oesophagus; in the EBRT arm, nine
(9.3%) patients had additional radiotherapy, with only two of these receiving further oesophageal
radiotherapy. It would, however, be expected that clinicians are more reluctant to repeat radiotherapy
treatment in the EBRT patients because of the risk of exceeding normal tissue tolerance.
Patients’ and carers’ descriptions of living with advanced oesophageal cancer and dysphagia revealed
ongoing challenges with eating despite stent placement. The ROCS study clearly illustrated that the
technical intervention of stenting does not address the multidimensional eating concerns and symptoms
that the patient lives with. Information around diet, pain relief and general medical management through
the course of the disease was often missing, with patients having to adopt a trial and error approach to
their daily life, and gradually adopting a process of ‘reframing hope’ to address their quality of life rather
than survival. Both patients and carers emphasised the important social, psychosocial and physical
aspects of nutrition and eating, as well as the need for holistic support in dealing with uncertainty.
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Strengths and limitations
The ROCS study successfully recruited to its revised target of 220 patients, making it one of the
largest reported intervention studies involving stents for advanced oesophageal cancer. Recruitment in
this population is extremely challenging,10,32 and specific design elements were important in helping
recruitment and reducing the risk of missing data.
Additional research nurse time and training to allow for data capture to take place in the patient’s
home ensured that CRF returns were high, and were able to describe reasons for missing data. CRF
analysis confirmed that patients requested support from the research nurse on approximately 50% of
occasions to complete questionnaires, highlighting the importance of the nurse’s presence in capturing
robust data and the frailty of this patient population.
Regular face-to-face meetings of the research nurse teams allowed sharing of good practice as well as
rapid feedback of emerging qualitative data to support approaches to information-giving, consent and
follow-up. The meetings produced practical solutions that informed protocol amendments and changes
to process such as timing of randomisation, changes to CRF design, and the timing and content of
‘between-visit’ telephone calls.
The ROCS study also specifically addressed the identified gaps in qualitative and health economic
outcomes consistently called for.7–9 The trial had a comprehensive assessment of HRQoL issues with
both generic and disease-specific components and a patient-reported HRQoL primary outcome.
The embedded qualitative study acted as a ‘study within a study’ to help improve trial processes and
resulted in improvements such as timing of randomisation, options for follow-up and study description
to help understanding of equipoise. It also captured the perceived trade-offs of the radiotherapy
intervention in terms of additional burden. The qualitative data also described the experience across
both trial arms of living with advanced oesophageal cancer, and it was possible to correlate findings
in relation to symptoms such as fatigue across quantitative QoL and toxicity data.
The attention paid to capturing precise and regular resource use information from patients, including
reasons for missing data, provided a rich data set for comprehensive assessment of costs and health
utilities. The construction of a complex model, populated entirely with trial data, allowed a thorough
examination of the costs and consequences of EBRT in addition to stent insertion in the context of
routine clinical practice.
The study was originally powered to detect a difference in time to event of 4 weeks, from 12 to
16 weeks. During the course of the study, it became clear that it would not be possible to reach the
recruitment target and that missing data increased significantly beyond 12 weeks, reflecting the frailty
of the patient population. On the advice of the IDMC, and with independent TSC and funder support,
we therefore revised the primary outcome to a binary outcome of differences in proportions of
recurrent dysphagia at 12 weeks. Although it is possible that this affected the ability of the study to
detect a true effect for EBRT, we believe that the consistency of the results across the sensitivity
analyses is robust, including the secondary analysis of DDFS. In addition, the event rate in the
study reflected that used in the power calculation. Careful attention to data capture meant that,
of a required population of 164, our modified ITT population of 199 yielded 149 complete data sets
to week 12, and 178 data sets when using a sensitivity analysis of best- and worst-case scenario
appropriate to the data set.
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Implications for health-care practice
l Patients with advanced oesophageal cancer requiring SEMSs to improve dysphagia will not benefit
further from the addition of concurrent palliative EBRT and are likely to find the trade-offs of
fatigue and additional hospital visits too burdensome. For those with a longer prognosis and who
are considered to have an increased risk of tumour bleeding, concurrent EBRT may reduce the risk
of bleeding and associated interventions. However, when offering patients this intervention,
information about the impact that it can have on QoL and trade-offs would be important in
informing decision-making.
l Insertion of a stent for dysphagia does not address the experience of patients in relation to eating
concerns, symptoms and adapting to uncertainty. Patients and carers require timely and ongoing
support from multidisciplinary professionals on the important psychosocial and physical aspects of
nutrition and eating. Patients also require help in negotiating uncertainty and the reframing of hope
towards quality of life rather than survival.
l A significant proportion of the patients who took part in the ROCS study were planned to have
systemic anticancer treatment despite very limited prognosis and with wide variation across the
UK in regimen used. The study confirms the need for greater consistency in the assessment of
suitability for systemic treatment, being mindful of the trade-offs between survival advantage and
burdens of treatment. The wide variation in the type of regimen used reflects the current clinical
uncertainty about the most effective palliative chemotherapy approach.
Implications for future research
l Future studies are required to assess other interventions that may usefully be combined with a
SEMS to improve the patient’s ability to swallow. Such studies may benefit from insights gained
during the ROCS study on trial conduct in this setting. Specifically, we recommend investment in
additional research practitioner time and training to capture follow-up data in the home setting,
randomisation after stent insertion to allow more time for patient identification and trial
consideration and regular meeting up of multisite research practitioners to consider barriers and
share best practice as trial processes that can all improve trial conduct. Embedded qualitative
methods can also ensure that intervention combinations are robustly assessed in terms of patient
experience and perceptions of trade-offs between treatment benefits and burdens.
l The ROCS study has highlighted significant unmet supportive and palliative care needs of patients
with advanced oesophageal cancer, including multifaceted aspects of eating and nutrition. Further
research is required to assess the benefits of early (at time of diagnosis) palliative interventions
and to specify the effective domains of multidisciplinary supportive care. In particular, research is
required on the types of nutritional support that will best address the practical challenges and
psychosocial distress around eating and nutritional intake for both patients and carers.
l The ROCS study has also identified how oesophageal cancer patients and their carers adapt their
expectations over time and engage in their own process of ‘reframing hope’. Further research
would be useful to define how this is best supported, and how the concept of reframing hope
may influence treatment discussions and subsequent choices.
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Royal Glamorgan Hospital, Cwm Taff Morgannwg University Health Board Dr Paul Shaw 7
Weston Super Mare Hospital, Weston Area Health Trust Dr Serena Hilman 7
Worthing Hospital, Western Sussex Hospitals NHS Foundation Trust Dr Angus Robinson/
Dr Elizabeth Selvaduri
6
Conquest Hospital Hastings, East Sussex Healthcare NHS Trust Dr Angus Robinson 5
Royal Sussex Hospital Brighton, East Sussex Healthcare NHS Trust Dr Angus Robinson 4
University Hospital Southampton Foundation Trust Dr Andrew Bateman 3
George Eliot Hospital NHS Trust Dr Martin Scott-Brown 3
Kent and Canterbury Hospital, East Kent Hospitals NHS Foundation Trust Dr Mathilda Cominos 3
King’s Mill Hospital, Sherwood Forest Hospitals NHS Foundation Trust Dr Eleanor James 3
Doncaster and Bassetlaw Hospitals Hospitals NHS Foundation Trust Dr Jonathan Wadsley 3
Southend University Hospital Hospitals NHS Foundation Trust Dr Olivia Chan/
Dr David Tsang
3
Royal Gwent Hospital, Aneurin Bevan University Health Board Professor Ashraf Rasheed 2
James Cook Hospital, South Tees Hospitals NHS Foundation Trust Dr Nick Wadd 2
Total 220
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Appendix 2 Quality-of-life questionnaires
Reproduced from The EORTC Quality of Life Group.74 Any person wishing to use EORTC measuresmust contact the EORTC Quality of Life Department. Details available at https://www.qol.eortc.org/
questionnaires.
ENGLISH 
EORTC QLQ-C30 (version 3)
We are interested in some things about you and your health. Please answer all of the questions yourself by circling the 
number that best applies to you. There are no "right" or "wrong" answers. The information that you provide will 
remain strictly confidential.
Please fill in your initials:
Your birthdate (Day, Month, Year):
Today's date (Day, Month, Year): 31 
__________________________________________________________________________________________
Not at A Quite Very
All Little a Bit Much
1. Do you have any trouble doing strenuous activities, 
like carrying a heavy shopping bag or a suitcase? 1 2 3 4 
2. Do you have any trouble taking a long walk? 1 2 3 4 
3. Do you have any trouble taking a short walk outside of the house? 1 2 3 4 
4. Do you need to stay in bed or a chair during the day? 1 2 3 4 
5. Do you need help with eating, dressing, washing 
 yourself or using the toilet? 1 2 3 4 
During the past week: Not at A Quite Very
All Little a Bit Much
6. Were you limited in doing either your work or other daily activities? 1 2 3 4 
7. Were you limited in pursuing your hobbies or other 
leisure time activities? 1 2 3 4 
8. Were you short of breath? 1 2 3 4 
9. Have you had pain? 1 2 3 4 
10. Did you need to rest? 1 2 3 4 
11. Have you had trouble sleeping? 1 2 3 4 
12. Have you felt weak? 1 2 3 4 
13. Have you lacked appetite? 1 2 3 4 
14. Have you felt nauseated? 1 2 3 4 
15. Have you vomited? 1 2 3 4 
16. Have you been constipated? 1 2 3 4 
Please go on to the next page
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ENGLISH 
© Copyright 1995 EORTC Quality of Life Group. All rights reserved. Version 3.0 
During the past week: Not at A Quite Very
All Little a Bit Much
17. Have you had diarrhea? 1 2 3 4 
18. Were you tired? 1 2 3 4 
19. Did pain interfere with your daily activities? 1 2 3 4 
20. Have you had difficulty in concentrating on things, 
like reading a newspaper or watching television? 1 2 3 4 
21. Did you feel tense? 1 2 3 4 
22. Did you worry? 1 2 3 4 
23. Did you feel irritable? 1 2 3 4 
24. Did you feel depressed? 1 2 3 4 
25. Have you had difficulty remembering things? 1 2 3 4 
26. Has your physical condition or medical treatment 
interfered with your family life? 1 2 3 4 
27. Has your physical condition or medical treatment
interfered with your social activities? 1 2 3 4 
28. Has your physical condition or medical treatment
caused you financial difficulties? 1 2 3 4 
For the following questions please circle the number between 1 and 7 that 
best applies to you
29. How would you rate your overall health during the past week? 
1 2 3 4 5 6 7 
 Very poor Excellent
30. How would you rate your overall quality of life during the past week? 
1 2 3 4 5 6 7 
 Very poor Excellent
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Appendix 3 Main results additional tables
and figures
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TABLE 28 Quality-of-life questionnaire-C30 return and missing reason by trial arm
Time point














































































































































































































86 16 3 (18.8) 2 (66.7) 0 (0.0) 3 (23.1) 0 (0.0) 0 (0.0) 10 (76.9) 85 12 5 (41.7) 2 (40.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 7 (100.0)


















































































































































































































































































































































TABLE 29 Baseline prior and intended chemotherapy for participants missing vs. not missing primary end-point data
Chemotherapy
Complete data up to
week 12a (N= 149)
Missing data up to
week 12a (N= 50)
Previous chemotherapy given
None 118 (79.2) 43 (86.0)
EOX 11 (7.4) 2 (4.0)
ECX 6 (4.0) 1 (2.0)
Cisplatin + capecitabine 4 (2.7) 0 (0.0)
CX; OxCap 2 (1.3) 0 (0.0)
OxCap 1 (0.7) 1 (2.0)
Carboplatin + capecitabine + epirubicin 0 (0.0) 1 (2.0)
Carboplatin + paclitaxel 1 (0.7) 0 (0.0)
Cisplatin; 5FU 1 (0.7) 0 (0.0)
Cisplatin + epirubicin 1 (0.7) 0 (0.0)
CX 1 (0.7) 0 (2.0)
CX + herceptin; docetaxel 1 (0.7) 0 (0.0)
Docetaxel; irinotecan 1 (0.7) 0 (0.0)
ECF 0 (0.0) 1 (2.0)
ECX neoadjuvant; EOX 0 (0.0) 1 (2.0)
EOX; docetaxel 1 (0.7) 0 (0.0)
If had prior chemotherapy, intended number of cycles – median (IQR), n 6.0 (3.0–6.0), 29 3.0 (3.0–8.0), 7
Number of prior chemotherapy cycles given – median (IQR), n 4.0 (3.0–6.0), 31 3.0 (1.0–3.0), 7
MDT intended chemotherapy after stent?
Yes 52 (34.9) 18 (36.0)
No 97 (65.1) 32 (64.0)
CX, capecitabine chemotherapy; ECF, epirubicin, cisplatin, 5-fluorouracil chemotherapy; ECX, epirubicin, cisplatin,
capecitabine chemotherapy; EOX, epirubicin, oxaliplatin, capecitabine chemotherapy.
a n (%) unless otherwise indicated.
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Usual care EBRT Time Treatment
Mean (95% CI), n or
median (IQR), n
Mean (95% CI), n or
median (IQR), n
Adjusted mean
difference (95% CI)a p-value
Adjusted mean
difference (95% CI)a p-value
EORTC-QLQ-C30/QLQ OG25 facet
Global health (mean)
Baseline 49.4 (44.2 to 54.4), 99 40.2 (35.1 to 45.2), 95 0.12 (–0.25 to 0.49) 0.516 –1.99 (–6.59 to 2.62) 0.398 0.660
Week 4 49.4 (44.5 to 54.4), 77 43.0 (36.5 to 49.5), 73
Week 8 51.8 (45.3 to 58.3), 57 47.1 (40.4 to 53.7), 56
Week 12 54.6 (46.8 to 62.4), 41 51.4 (45.0 to 57.9), 46
Week 16 53.7 (46.7 to 60.7), 34 49.0 (41.5 to 56.5), 37
Odynophagia (median)
Baseline 16.7 (0–50), 101 33.3 (16.7–66.7), 95 –0.65 (–1.06 to –0.23) 0.002 2.69 (–2.52 to 7.91) 0.311 0.694
Week 4 16.7 (0–33.3), 77 16.7 (0–50), 74
Week 8 16.7 (0–33.3), 58 16.7 (0–33.3), 59
Week 12 16.7 (0–33.3), 43 16.7 (0–50), 46
Week 16 16.7 (0–33.3), 34 16.7 (0–33.3), 35
Dysphagia (median)
Baseline 33.3 (16.6–44.4), 102 33.3 (22.2–66.7), 97 –0.75(–1.12 to –0.38) < 0.001 4.21 (–0.56 to 8.98) 0.084 0.013
Week 4 11.1 (0–33.3), 78 22.2 (11.1–44.4), 75
Week 8 11.1 (0–33.3), 60 11.1 (11.1–33.3), 62
Week 12 11.1 (0–33.3), 46 11.1 (0–33.3), 49
























































































































































































































































































































































Usual care EBRT Time Treatment
Mean (95% CI), n or
median (IQR), n
Mean (95% CI), n or
median (IQR), n
Adjusted mean
difference (95% CI)a p-value
Adjusted mean
difference (95% CI)a p-value
Pain/discomfort OG25 (median)
Baseline 16.7 (0–33.3), 102 16.7 (0–50), 94 –0.15 (–0.58 to 0.29) 0.514 2.08 (–3.50 to 7.66) 0.466 0.579
Week 4 16.7 (0–33.3), 77 25 (0–33.3), 74
Week 8 16.7 (0–33.3), 59 33.3 (0–50), 59
Week 12 16.7 (0–33.3), 44 33.3 (0–66.7), 46
Week 16 16.7 (0–33.3), 34 33.3 (0–33.3), 35
Eating restriction (mean)
Baseline 52.9 (46.9 to 58.9), 102 56.3 (50.6 to 61.9), 95 –0.45 (–0.87 to –0.02) 0.040 1.86 (–3.73 to 7.47) 0.513 0.555
Week 4 44 (37.2 to 50.8), 75 47.8 (40.4 to 55.2), 69
Week 8 38.6 (31.6 to 45.6), 59 48.2 (40.3 to 56.1), 57
Week 12 38.8 (30.4 to 47.1), 40 42.6 (33.3 to 51.8), 46
Week 16 40.8 (31.4 to 50.2), 40 42.5 (33.3 to 51.6), 42
Eating in front of others (median)
Baseline 0 (0–33.3), 98 0 (0–66.7), 95 –0.37 (–0.86 to 0.12) 0.138 1.51 (–4.47 to 7.49) 0.622 0.117
Week 4 0 (0–33.3), 74 0 (0–33.3), 73
Week 8 0 (0–33.3), 58 0 (0–33.3), 58
Week 12 0 (0–33.3), 42 33.3 (0–66.7), 45




































Usual care EBRT Time Treatment
Mean (95% CI), n or
median (IQR), n
Mean (95% CI), n or
median (IQR), n
Adjusted mean
difference (95% CI)a p-value
Adjusted mean
difference (95% CI)a p-value
Physical functioning (median)
Baseline 26.7 (8.3–53.3), 102 33.3 (13.3–53.3), 95 0.68 (0.34 to1.03) < 0.001 1.22 (–3.40 to 5.84) 0.604 0.643
Week 4 26.7 (13.3–53.3), 77 40 (13.3–60), 73
Week 8 33.3 (20–46.7), 59 40 (13.3–60), 57
Week 12 33.3 (13.3–46.7), 41 33.3 (20–53.3), 46
Week 16 33.3 (13.3–53.3), 30 33.3 (20–58.3), 34
Role functioning (mean)
Baseline 44.6 (37.4 to 51.8), 102 48.6 (41.5 to 55.7), 95 0.41 (–0.09 to 0.91) 0.110 2.49 (–4.09 to 9.06) 0.459 0.750
Week 4 45.5 (37.5 to 53.6), 75 50 (42.0 to 58.0), 68
Week 8 43.7 (34.5 to 52.8), 58 51.9 (42.7 to 61.0), 54
Week 12 38.6 (27.6 to 49.6), 38 47.1 (37.1 to 57.1), 46
Week 16 44.9 (33.6 to 56.3), 36 47.1 (36.1 to 58.2), 41
Emotional functioning (median)
Baseline 25 (8.3–41.7), 99 25 (0–50), 95 –0.26 (–0.59 to 0.06) 0.114 0.50 (–3.65 to 4.64) 0.815 0.225
Week 4 25 (8.3–41.7), 77 25 (8.3–58.3), 73
Week 8 25 (0–33.3), 58 20.8 (8.3–41.7), 56
Week 12 16.7 (8.3–33.3), 41 25 (8.3–33.3), 46
























































































































































































































































































































































Usual care EBRT Time Treatment
Mean (95% CI), n or
median (IQR), n
Mean (95% CI), n or
median (IQR), n
Adjusted mean
difference (95% CI)a p-value
Adjusted mean
difference (95% CI)a p-value
Cognitive functioning (median)
Baseline 16.7 (0–33.3), 99 16.7 (0–50), 95 –0.14 (–0.47 to 0.18) 0.392 –0.35 (–4.64 to 3.94) 0.874 0.007
Week 4 16.7 (0–33.3), 77 16.7 (0–50), 73
Week 8 16.7 (0–33.3), 58 16.7 (0–41.7), 56
Week 12 0 (0–16.7), 41 16.7 (0–33.3), 46
Week 16 0 (0–16.7), 30 25 (0–50), 34
Social functioning (median)
Baseline 33.3 (0–66.7), 99 33.3 (0.66.7), 95 0.62 (0.15 to 1.09) 0.010 2.43 (–3.84 to 8.71) 0.447 0.351
Week 4 33.3 (0–66.7), 77 33.3 (0.66.7), 73
Week 8 33.3 (0.66.7), 57 33.3 (8.3–66.7), 56
Week 12 33.3 (0–50), 41 33.3 (16.7–66.7), 46
Week 16 33.3 (0–66.7), 30 33.3 (16.7–66.7), 34
Fatigue (median)
Baseline 44.4 (22.2–77.8), 102 55.6 (33.3–77.8), 95 0.37 (–0.02 to 0.77) 0.065 3.50 (–1.68 to 8.68) 0.186 0.522
Week 4 44.4 (33.3–66.7), 77 66.7 (33.3–88.9), 73
Week 8 44.4 (33.3–66.7), 59 44.4 (33.3–77.8), 57
Week 12 44.4 (22.2–66.7), 41 55.6 (33.3–66.7), 46




































Usual care EBRT Time Treatment
Mean (95% CI), n or
median (IQR), n
Mean (95% CI), n or
median (IQR), n
Adjusted mean
difference (95% CI)a p-value
Adjusted mean
difference (95% CI)a p-value
Nausea/vomiting (median)
Baseline 16.7 (0–50), 102 33.3 (16.7–66.7), 95 –0.54 (–0.98 to –0.10) 0.017 5.60 (0.11 to 11.08) 0.046 0.195
Week 4 16.7 (0–33.3), 77 33.3 (0–50), 73
Week 8 16.7 (0–33.3), 59 16.7 (0–33.3), 57
Week 12 16.7 (0–33.3), 41 16.7 (0–33.3), 46
Week 16 0 (0–33.3), 30 16.7 (0–33.3), 34
Pain C30 (median)
Baseline 33.3 (16.7–66.7), 102 50 (16.7–66.7), 95 –0.56 (–1.01 to –0.11) 0.015 2.39 (–3.25 to 8.03) 0.406 0.005
Week 4 33.3 (16.7–50), 77 33.3 (16.7–66.7), 73
Week 8 16.7 (0–33.3), 58 33.3 (16.7–66.7), 57
Week 12 16.7 (0–50), 41 33.3 (16.7–66.7), 46
Week 16 16.7 (0–50), 30 50 (16.7–83.3), 34
Dyspnoea (median)
Baseline 33.3 (0–33.3), 102 33.3 (0–66.7), 94 0.17 (–0.25 to 0.59) 0.427 2.50 (–3.03 to 8.02) 0.376 0.169
Week 4 33.3 (0–33.3), 77 33.3 (0–66.7), 73
Week 8 33.3 (0–33.3), 59 33.3 (0–33.3), 57
Week 12 33.3 (0–33.3), 41 33.3 (0–66.7), 46
























































































































































































































































































































































Usual care EBRT Time Treatment
Mean (95% CI), n or
median (IQR), n
Mean (95% CI), n or
median (IQR), n
Adjusted mean
difference (95% CI)a p-value
Adjusted mean
difference (95% CI)a p-value
Insomnia (mean)
Baseline 37.6 (30.8 to 44.4), 102 44.2 (36.7 to 51.7), 95 –0.70 (–1.21 to –0.18) 0.009 6.76 (–0.10 to 13.42) 0.047 0.688
Week 4 32.9 (25.2 to 40.6), 74 42.3 (32.7 to 51.8), 67
Week 8 25.9 (17.6 to 34.1), 58 36.4 (26.4 to 46.5), 54
Week 12 21.6 (11.4 to 31.8), 37 31.9 (21.8 to 41.9), 45
Week 16 29.6 (18.9 to 40.3), 36 37.5 (25.6 to 49.4), 40
Appetite loss (mean)
Baseline 50.8 (43.6 to 58.0), 101 62.8 (55.4 to 70.2), 94 –0.30 (–0.90 to 0.30) 0.560 6.42 (–1.18 to 14.02) 0.098 0.612
Week 4 52.9 (45.1 to 60.7), 75 55.9 (46.6 to 65.2), 68
Week 8 37.9 (29.0 to 46.8), 58 55.8 (46.4 to 65.1), 55
Week 12 45.9 (33.0 to 58.9), 37 47.8 (36.9 to 58.8), 46
Week 16 41.7 (31.1 to 52.2), 36 49.6 (38.8 to 60.4), 41
Constipation (mean)
Baseline 42.4 (35.9 to 48.9), 99 41.1 (34.2 to 47.9), 95 –0.95 (–1.49 to –0.41) 0.003 –4.33 (–10.78 to 2.12) 0.240 0.009
Week 4 48.0 (40.3 to 55.7), 75 44.1 (35.1 to 53.1), 68
Week 8 30.4 (22.5 to 38.3), 57 35.8 (27.2 to 44.4), 54
Week 12 22.8 (13.6 to 32.0), 38 37.7 (28.7 to 46.7), 46




































Usual care EBRT Time Treatment
Mean (95% CI), n or
median (IQR), n
Mean (95% CI), n or
median (IQR), n
Adjusted mean
difference (95% CI)a p-value
Adjusted mean
difference (95% CI)a p-value
Diarrhoea (median)
Baseline 0 (0–0), 98 0 (0–33.3), 95 0.15 (–0.28 to 0.59) 0.493 2.81 (–2.27 to 7.89) 0.279 0.147
Week 4 0 (0–0), 77 0 (0–33.3), 72
Week 8 0 (0–33.3), 57 0 (0–0), 56
Week 12 0 (0–33.3), 41 0 (0–0), 45
Week 16 0 (0–0), 30 0 (0–33.3), 34
Financial difficulties (median)
Baseline 0 (0–0), 99 0 (0–33.3), 94 –0.15 (–0.47 to 0.17) 0.400 –0.27 (–4.46 to 3.91) 0.899 0.445
Week 4 0 (0–0), 76 0 (0–0), 73
Week 8 0 (0–0), 56 0 (0–0), 56
Week 12 0 (0–0), 41 0 (0–0), 46
Week 16 0 (0–0), 29 0 (0–33.3), 34
Body image (median)
Baseline 0 (0–33.3), 101 0 (0–66.7), 94 –0.15 (–0.66 to 0.36) 0.920 –2.23 (–8.66 to 4.20) 0.496 0.011
Week 4 0 (0–33.3), 75 0 (0–33.3), 74
Week 8 0 (0–33.3), 59 33.3 (0–66.7), 59
Week 12 0 (0–33.3), 44 0 (0–66.7), 45
























































































































































































































































































































































Usual care EBRT Time Treatment
Mean (95% CI), n or
median (IQR), n
Mean (95% CI), n or
median (IQR), n
Adjusted mean
difference (95% CI)a p-value
Adjusted mean
difference (95% CI)a p-value
Reflux (median)
Baseline 33.3 (0–50), 102 33.3 (0–66.7), 95 –0.55 (–0.96 to –0.15) 0.007 0.72 (–4.47 to 5.92) 0.785 0.825
Week 4 16.7 (0–33.3), 77 33.3 (0–50), 74
Week 8 16.7 (0–50), 59 16.7 (0–33.3), 59
Week 12 16.7 (0–50), 44 16.7 (0–50), 46
Week 16 8.33 (0–33.3), 34 33.3 (0–50), 35
Anxiety (mean)
Baseline 55.4 (49.2 to 61.6), 102 51.2 (44.6 to 57.9), 95 –0.91 (–1.32 to –0.50) < 0.001 –2.87 (–8.45 to 2.71) 0.313 0.002
Week 4 49.6 (42.4 to 56.7), 75 47.6 (39.3 to 55.9), 69
Week 8 45.5 (38.1 to 52.8), 59 44.2 (36.1 to 52.2), 57
Week 12 38.8 (29.4 to 48.1), 40 49.3 (40.1 to 58.4), 46
Week 16 40 (30.5 to 49.5), 40 46.8 (35.9 to 57.8), 42
Dry mouth (median)
Baseline 33.3 (0–66.7), 100 33.3 (0–66.7), 95 –0.58 (–1.08 to 0.09) 0.022 0.64 (–5.61 to 6.89) 0.840 0.816
Week 4 33.3 (0–66.7), 77 33.3 (0–66.7), 74
Week 8 0 (0–33.3), 59 33.3 (0–66.7), 59
Week 12 16.7 (0–33.3), 44 33.3 (0–33.3), 43




































Usual care EBRT Time Treatment
Mean (95% CI), n or
median (IQR), n
Mean (95% CI), n or
median (IQR), n
Adjusted mean
difference (95% CI)a p-value
Adjusted mean
difference (95% CI)a p-value
Trouble with taste (median)
Baseline 0 (0–33.3), 101 33.3 (0–66.7), 95 0.44 (–0.05 to 0.94) 0.079 1.08 (–5.39 to 7.55) 0.744 0.547
Week 4 0 (0–66.7), 76 0 (0–66.7), 73
Week 8 0 (0–33.3), 59 0 (0–66.7), 59
Week 12 16.7 (0–50), 44 33.3 (0–33.3), 46
Week 16 0 (0–33.3), 33 33.3 (0–66.7), 34
Trouble swallowing saliva (median)
Baseline 0 (0–33.3), 102 0 (0–33.3), 95 –0.79 (–1.22 to –0.36) < 0.001 –1.84 (–7.31 to 3.63) 0.511 0.025
Week 4 0 (0–33.3), 76 0 (0–33.3), 74
Week 8 0 (0–33.3), 59 0 (0–33.3), 59
Week 12 0 (0–33.3), 44 0 (0–33.3), 46
Week 16 0 (0–0), 34 0 (0–33.3), 35
Choked when swallowing (median)
Baseline 0 (0–33.3), 102 0 (0–33.3), 95 –0.49 (–0.86 to 0.11) 0.011 –0.74 (–5.29 to 3.80) 0.749 0.321
Week 4 0 (0–0), 77 0 (0–33.3), 74
Week 8 0 (0–0), 59 0 (0–33.3), 59
Week 12 0 (0–0), 44 0 (0–0), 46
























































































































































































































































































































































Usual care EBRT Time Treatment
Mean (95% CI), n or
median (IQR), n
Mean (95% CI), n or
median (IQR), n
Adjusted mean
difference (95% CI)a p-value
Adjusted mean
difference (95% CI)a p-value
Trouble with coughing (median)
Baseline 33.3 (0–33.3), 101 33.3 (0–33.3), 95 –0.28 (–0.71 to 0.15) 0.202 –0.62 (–5.94 to 4.70) 0.820 0.370
Week 4 33.3 (0–33.3), 77 33.3 (0–33.3), 74
Week 8 33.3 (0–33.3), 59 33.3 (0–33.3), 57
Week 12 33.3 (0–33.3), 43 33.3 (0–33.3), 46
Week 16 33.3 (0–33.3), 34 33.3 (0–33.3), 34
Trouble talking (median)
Baseline 0 (0–0), 99 0 (0–33.3), 94 0.00 (–0.33 to 0.33) 0.990 0.56 (–3.55 to 4.67) 0.790 0.487
Week 4 0 (0–0), 75 0 (0–33.3), 74
Week 8 0 (0–0), 59 0 (0–0), 58
Week 12 0 (0–0), 44 0 (0–0), 45
Week 16 0 (0–0), 34 0 (0–33.3), 35
Weight loss (mean)
Baseline 40.6 (33.2 to 48.0), 101 41.8 (34.0 to 49.5), 95 –0.56 (–1.06 to 0.05) 0.030 –1.01 (–7.71 to 5.69) 0.767 0.053
Week 4 43.7 (35.3 to 52.1), 74 45.4 (36.6 to 54.2), 69
Week 8 32.8 (23.9 to 41.7), 59 36.3 (27.6 to 45.0), 56
Week 12 30.0 (18.7 to 41.3), 40 42.8 (33.3 to 52.2), 46




































Usual care EBRT Time Treatment
Mean (95% CI), n or
median (IQR), n
Mean (95% CI), n or
median (IQR), n
Adjusted mean
difference (95% CI)a p-value
Adjusted mean
difference (95% CI)a p-value
Hair loss (median)
Baseline 0 (0–0), 17 0 (0–33.3), 21 0.10 (–0.58 to 0.77) 0.781 0.61 (–7.98 to 9.20) 0.889 0.160
Week 4 0 (0–0), 13 0 (0–16.7), 16
Week 8 0 (0–33.3), 15 0 (0–33.3), 11
Week 12 33.3 (0–33.3), 10 16.7 (0–33.3), 12
Week 16 0 (0–0), 11 0 (0–33.3), 8
WHO performance status (mean)
Baseline 1.30 (1.16 to 1.45), 102 1.32 (1.19 to 1.45), 97 0.03 (0.02 to 0.04) < 0.001 0.06 (–0.09 to 0.20) 0.457 0.565
Week 4 1.47 (1.30 to 1.64), 76 1.61 (1.44 to 1.79), 75
Week 8 1.57 (1.34 to 1.80), 63 1.73 (1.52 to 1.95), 60
Week 12 1.44 (1.21 to 1.67), 48 1.55 (1.35 to 1.75), 49
Week 16 1.52 (1.27 to 1.77), 42 1.77 (1.55 to 2.00), 44
a A negative difference indicates that the mean score decreases over time or is lower in the treatment arm; a positive difference indicates the mean score increases over time or is
































































































































































































































































































































































































































FIGURE 24 Cumulative incidence function plot of time to first dysphagia-related stent complication or reintervention by
trial arm, with death as a competing risk.
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FIGURE 27 Box plots of nausea/vomiting scores by time and treatment arm.
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Appendix 4 Health economic evaluation
additional tables and figures
TABLE 31 Unit costs of health-care resources included in costing for health economic evaluation
Resource
Currency
code/HRG Unit cost (£) Notes
Primary care
GP consultation at surgery n/a 37.40a 9.22 minutes’ duration, including direct care staff and
qualifications
GP consultation at home n/a 86.73a GP home visit (9.22 minutes) + 20-minute travel time
(indirect, £148 per hour)
GP consultation by
telephone
n/a 15.10a 4 minutes’ duration
Palliative nurse specialist
at surgery
n/a 37.00a Band 6; 30-minute visit assumed (£74 per hour)
Palliative nurse specialist
at home
N21AF 104.17b Specialist nursing, palliative/respite care, adult, face to face
District nurse consultation
at surgery
n/a 12.33a Band 6; 10-minute visit (£74 per hour)
Dietitian A03 85.76b Community Health Services
Podiatrist A09A-A09F 43.39b Weighted across all options
Practice nurse consultation
at surgery
n/a 7.00a £42.00 per hour (including qualifications), 10-minute
appointment assumed
Physiotherapist A08A1 57.26b Physiotherapist, adult, one to one
Occupational therapist A06A1 81.31b Occupational therapist, adult, one to one
Social worker in surgery n/a 28.00a £60/hour; £84 per hour of client-related work; 20-minute
visit assumed
Phlebotomist n/a 5.09a Including £1.93b (weighted average blood test cost)
Health visitor N03F 52.97b Health visitor, other clinical intervention
Pharmacist n/a 7.33a £44 per hour; 10 minutes assumed
Secondary care




n/a 144.90b Weighted across all discharged A&E entries (patient dead
on arrival excluded)
Inpatient day (all) n/a 494.22b Weighted across all elective and emergency excess
bed-days (paediatrics excluded)
Inpatient day (elective) n/a 431.11b Weighted across all elective excess bed-days
(paediatrics excluded)




n/a 143.44b Weighted across all consultant-led outpatient visits
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TABLE 31 Unit costs of health-care resources included in costing for health economic evaluation (continued )
Resource
Currency
code/HRG Unit cost (£) Notes
Outpatient appointment
(oncologist)
n/a 182.45b Weighted for first and follow-up attendance
Outpatient appointment
(general surgeon)
n/a 149.24b Weighted for first and follow-up attendance
Day hospital n/a 742.09b Weighted across all day case entries
Specialist nurse in hospital n/a 37.00a Band 6; £111 per hour patient contact; 20-minute
appointment assumed
Procedures and imaging
Stenting n/a 877.09b Based on endoscopic insertion of luminal stent
(weighted for all options)
Blood transfusion
(day case)
SA44A 499.00b Single plasma exchange or other intravenous blood
transfusion, aged ≥ 19 years
Blood transfusion
(per unit)




329.74b Weighted across all relevant options
CT scan RD20A-RD28Z 103.95b Weighted for all options in a number of areas
Oesophageal biopsy FE21Z 476.19b Diagnostic endoscopic upper gastrointestinal tract
procedures with biopsy, aged ≥ 19 years
Radiotherapy SC96Z 83.06b Same day radiotherapy admission or attendance
(excluding brachytherapy)
Chemotherapy (per cycle)
Chemotherapy as day case
(unspecified)
n/a 1099.77b Includes drug procurement and delivery (weighted across
all day case options)
5-FU chemotherapy n/a 1445.49b Includes procurement of two drugs (bands 5 and 6)
and delivery
Carboplatin chemotherapy n/a 654.41b Includes procurement of one drug (band 6) and delivery
Carboplatin/capecitabine
chemotherapy




n/a 468.79b Includes procurement of one drug (band 1) and oral
delivery
CAP chemotherapy n/a 1550.48b Includes procurement of three drugs (bands 2, 5 and 6)
and delivery
Cisplatin chemotherapy n/a 815.88b Includes procurement of one drug (band 5) and delivery
Cisplatin/capecitabine
chemotherapy
n/a 1121.71b Includes procurement of two drugs (bands 1 and 5)
and delivery
Docetaxel chemotherapy n/a 654.41b Includes procurement of one drug (band 6) and delivery
Durvalumab chemotherapy n/a 5427.48b,d Includes procurement and delivery every 2 weeks
ECF chemotherapy n/a 1711.94b Includes procurement of three drugs (bands 2, 5 and 5)
and delivery
ECX chemotherapy n/a 1449.64b Includes procurement of three drugs (bands 1, 2 and 5)
and delivery
EOX chemotherapy n/a 1159.65b Includes procurement of three drugs (bands 1, 2 and 3)
and delivery
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TABLE 31 Unit costs of health-care resources included in costing for health economic evaluation (continued )
Resource
Currency
code/HRG Unit cost (£) Notes
Epirubicin/oxaliplatin
chemotherapy
n/a 853.82b Includes procurement of two drugs (bands 2 and 3)
and delivery
HCX chemotherapy n/a 1449.64b Includes procurement of three drugs (bands 1, 2 and 5)
and delivery
Irinotecan chemotherapy n/a 654.41b Includes procurement of one drug (band 6) and delivery
Oxaliplatin chemotherapy n/a 525.89b Includes procurement of one drug (band 3) and delivery
Oxaliplatin/capecitabine
chemotherapy




n/a 982.34b Includes procurement of two drugs (bands 2 and 6) and
delivery
Paclitaxel/ramucirumab n/a 5823.41b,d Includes procurement of two drugs (band 2 and
ramucirumab) and delivery at day 1 and ramucirumab and
single delivery on day 15
Raltitrexed/oxaliplatin
chemotherapy








N02AF 38.45b District nurse, adult, face to face
Care assistant n/a 27.00a £27 per hour; 1 hour assumed (based on home care
worker, face to face)
Social worker n/a 48.00a £60 per hour; £84 per hour of client-related work;
20-minute visit; 20-minute travel assumed
Hospice day n/a 165.04e Per day, inflated to 2018 prices
ECF, epirubicin, cisplatin, 5-fluorouracil; ECX, epirubicin, cisplatin, capecitabine; EOX, epirubicin, oxaliplatin, capecitabine;
HCX, herceptin, cisplatin, capecitabine; n/a, not applicable.
Sources:
a Unit Costs of Health and Social Care 2018.62
b NHS Reference Costs 2017 to 2018.60
c Costing Statement: Blood Transfusion.65
d British National Formulary 2019.63
e McBride et al.66
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TABLE 32 Unit costs of medications included in costing for health economic evaluation
Medication type Dose Pack size Unit cost
Accrete D3 1.5 g/400 units 60 £2.95
Acidophilus extra 10 billion 60 £19.95a
Aclidinium bromide/formoterol (Duaklir Genuair) 340/12 µg 60 puffs £32.50
Actrapid Insulin 100 units/ml 10 ml £15.68
Adcal-D3 Dissolve 750mg/200 unit 112 £2.95
Adcal-D3 Dissolve 1500mg/400 unit 56 £5.99
Akynzeo 300mg/0.5 mg 1 £69.00
Alendronic acid 70mg 4 £0.86
Alfentanil infection 5 mg/ml 10 £21.95
Allopurinol 100 mg 28 £1.72
Allopurinol 300 mg 28 £6.35
Alprazolam (Xanax) 0.5 mg 60 £6.09
Amiodarone 100mg 28 £1.63
Amiodarone 200mg 28 £2.91
Amitriptyline 10mg 28 £1.01
Amitriptyline 25mg 28 £0.72
Amlodipine 5 mg 28 £0.71
Amlodipine 10mg 28 £0.71
Amoxicillin 250 mg 21 £1.05
Amoxicillin 500 mg 21 £1.08
Amoxicillin oral suspension 50mg/ml 100ml £1.26
Amoxicillin IV 1 g 10 £10.96
Anastrozole 1 mg 28 £1.84
Antacid and oxetacaine suspension 10mg/5 ml 150ml £19.00
Apixaban 5mg 56 £53.20
Aprepitant 80 mg 2 £31.61
Aprepitant 125 mg 5 £79.03
Aspirin 75 mg 28 £0.71
Aspirin dispersable 75mg 28 £0.77
Atenolol 25 mg 28 £0.57
Atenolol 50 mg 28 £0.63
Atorvastatin 10 mg 28 £0.69
Atorvastatin 20 mg 28 £0.81
Atorvastatin 40 mg 28 £0.98
Atorvastatin 80 mg 28 £1.65
Atropine sulfate injection 300 µg 1 £7.29
Atropine sulfate injection 500 µg 1 £13.00
Azithromycin 500mg 3 £1.09
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TABLE 32 Unit costs of medications included in costing for health economic evaluation (continued )
Medication type Dose Pack size Unit cost
Baclofen 10mg 84 £1.54
Beconase nasal spray £4.00
Beclomethasone nasal spray 50 µg/puff 200 puffs £3.02
Beclomethasone/formoterol (Fostair) inhaler 100 µg/6 µg 120 puffs £29.32
Beclomethasone/formoterol (Fostair) inhaler 200 µg/6 µg 120 puffs £29.32
Betahistine dihydrochloride 8 mg 84 £1.16
Betamethasone (Betnovate) cream 0.10% 30 g £1.61
Bendroflumethiazide 2.5 mg 28 £0.54
Benzydamine hydrochloride spray 0.15% 30ml £4.02
Benzydamine hydrochloride mouthwash 0.15% 300ml £6.95
Benzylpenicillin sodium 1.2 g 25 £109.49
Bimatoprost eye drops 100 µg/ml 3 ml £11.71
Biotene Oralbalance gel 50 g £4.46
Bisacodyl 5 mg 60 £5.39
Bisacodyl suppository 10mg 12 £3.53
Bisoprolol fumarate 1.25 mg 28 £0.76
Bisoprolol fumarate 2.5 mg 28 £0.69
Bisoprolol fumarate 3.75 mg 28 £0.93
Bisoprolol fumarate 5 mg 28 £0.68
Bisoprolol fumarate 10mg 28 £0.75
Bonjela choline salicylate 87mg/1 g 15 g £2.91
Brinzolamide eye drops 10mg/ml 5 ml £2.00
Budesonide 3 mg 100 £75.05
Buprenorphine transdermal patch 5 µg/h 4 £17.60
Buprenorphine transdermal patch 10 µg/h 4 £31.55
Buprenorphine transdermal patch 15 µg/h 4 £49.15
Buprenorphine transdermal patch (Butec) 20 µg/h 4 £57.46
Buprenorphine transdermal patch 35 µg/h 4 £15.80
Buscopan (hyoscine butylbromide) 10 mg 56 £3.00
Buscopan IV 20mg 10 £2.92
Calceos chewable (colecaliferol) 500 mg/400 units 60 £4.24
Calcichew D3 Forte 60 £4.24
Calcipotriol topical 50 µg/1 g 30 g £6.64
Calmurid cream 100 g £5.75
Calogen extra 200ml £4.98
Camellose sodium (optive) eye drops 1% 30 £3.00
Candesartan cilexetil 4 mg 28 £0.54
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TABLE 32 Unit costs of medications included in costing for health economic evaluation (continued )
Medication type Dose Pack size Unit cost
Candesartan cilexetil 8 mg 28 £4.72
Candesartan cilexetil 16 mg 28 £1.78
Carbamazepine 100mg 84 £2.07
Carbocisteine 375mg 120 £4.60
Carbocisteine oral solution 250mg/5 ml 300ml £9.49
Carbomer 980 0.2% eye gel 2 mg/g 10 g £2.80
Carvedilol 6.25 mg 28 £0.97
Carvedilol 25 mg 28 £1.17
Cefalexin 500mg 21 £2.15
Cetirizine 10mg 30 £0.86
Cetraben ointment 125 g £3.49
Chloramphenicol 0.5% eye drops 5 mg/ml 10 ml £2.96
Chlorhexidine gluconate mouthwash 0.20% 300ml £4.18
Chlorphenamine maleate 4 mg 28 £0.76
Chlorphenamine maleate (Piriton) 4 mg 30 £2.06
Chlorphenamine maleate injection 10mg/1 ml 5 £22.49
Cinnarizine 15mg 84 £5.05
Ciprofloxacin 500mg 10 £0.91
Citalopram 10mg 28 £0.89
Citalopram 20mg 28 £0.88
Clarithromycin 250mg 14 £1.29
Clarithromycin 500mg 14 £2.10
Clarithromycin oral suspension 250mg/5 ml 70ml £6.07
Clarithromycin IV 500mg 1 £9.45
Clenil Modutile (beclomethasone inhaler) 100 µg/puff 200 £7.42
Clexane (enoxaparin sodium) IV 40mg/0.4 ml 10 £30.27
Clexane (enoxaparin sodium) IV 100mg/ml 10 £72.30
Clexane (enoxaparin sodium) IV 120mg/0.8 ml 10 £87.93
Clexane (enoxaparin sodium) IV 150mg/1 ml 10 £99.91
Clopidogrel 75 mg 28 £1.40
Clotrimazole 1% cream 10mg/g 30 g £2.89
Co-Amilofruse 5/40 mg 28 £5.29
Co-amociclav 250/125 mg 21 £1.79
Co-amociclav 500/125 mg 21 £2.31
Co-amociclav (Augmentin) injection 1.2 g powder 10 £10.60
Co-codamol 8/500 mg 30 £0.81
Co-codamol 15/500 mg 100 £4.12
Co-codamol 30/500 mg 100 £3.63
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TABLE 32 Unit costs of medications included in costing for health economic evaluation (continued )
Medication type Dose Pack size Unit cost
Co-codamol effervescent tablets 30/500mg 100 £7.19
Co-danthramer 25mg/200 mg/5 ml 300ml £180.00
Co-danthrusate 12mg/1 ml 200ml £202.50
Codeine linctus 3 mg/1 ml 200ml £1.90
Codeine phosphate 15mg 28 £0.83
Codeine phosphate 30mg 28 £0.93
Codeine phosphate 60mg 28 £1.82
Co-dydramol (dihydrocodeine/paracetamol) 500/7.46 mg 32 £4.52
Colchicine 500 µg 100 £8.70
Colestyramine 4 g 50 £10.76
Complan shakes 57 g 4 sachets £2.80
Coracten XL (nifedipine) 60 mg 28 £7.34
Co-trimoxazole 80/400mg 28 £2.01
Co-trimoxazole IV infusion 960mg 10 £35.00
Covonia cough mixture (pholcodine) 5 mg/5 ml 150ml £3.30
Cyclizine 50mg 100 £6.81
Cyclizine injection 50mg/ml 5 £17.02
Dalteparin 2500 units/0.2 ml 10 £18.58
Dalteparin (Fragmin) 5000 units/0.2 ml 10 £28.23
Dalteparin (Fragmin) 7500 units/0.3 ml 10 £42.34
Dalteparin 12,500 units/0.5 ml 5 £35.29
Dalteparin (Fragmin) 15,000 units/0.6 ml 5 £42.34
Desunin 800 (colecalciferol) 800 units 30 £3.60
Dexamethasone 500 µg 28 £10.27
Dexamethasone 2mg 50 £30.01
Dexamethasone 4mg 50 £60.01
Dexamethasone 8mg 30 £72.00
Dexamethasone oral solution 2 mg/5 ml 150ml £42.30
Dexamethasone for injection 3.3 mg/1 ml 10 £23.21
Dexamethasone for injection 6.6 mg/2 ml 10 £22.00
Dexamethasone for injection 3.8 mg/1 ml 10 £20.00
Diamorphine hydrochloride 5 mg 5 £13.76
Diamorphine hydrochloride 10mg 5 £16.76
Diamorphine hydrochloride 30mg 5 £16.14
Diazepam 2mg 28 £0.71
Diazepam 5mg 28 £0.61
Diclofenac sodium (Voltarol) gel 1.16% 100 g £4.63
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TABLE 32 Unit costs of medications included in costing for health economic evaluation (continued )
Medication type Dose Pack size Unit cost
Difflam (benzydamine hydrochloride) 1.5 mg/ml 300ml £6.50
Diffundox XL (tamsulosin hydrochloride) 400 µg 30 £3.87
Digoxin 62.5 µg 28 £1.39
Digoxin 125 µg 28 £1.40
Digoxin 250 µg 28 £1.44
Dihydrocodeine tartrate 30mg 28 £0.94
Dihydrocodeine tartrate 60mg 56 £5.20
Diltiazem hydrochloride 60mg 90 £7.96
Diltiazem hydrochloride 120mg 56 £7.15
Docusate sodium oral solution 50mg/5 ml 300ml £9.19
Docusate sodium 100mg 30 £2.09
Domperidone 10mg 30 £0.94
Domperidone oral suspension 1mg/ml 200ml £23.60
Dorzolamide eye drops 20mg/ml 5 ml £2.38
Dorzolamide/timolol eye drops 20 and 5 mg/ml 5 ml £2.04
Doxazosin 2 mg 28 £0.86
Doxazosin 4 mg 28 £1.00
Doxazosin 8 mg 28 £1.92
Doxycycline 50mg 28 £1.21
Doxycycline 100mg 8 £0.91
E45 cream 100 g £4.28
Elantan LA25 (isosorbide mononitrate) 25 mg 28 £3.40
Emollient cream (Dermol) 1 mg 100 g £2.86
Enalapril 10 mg 28 £1.81
Enoxaparin 20mg/0.2 ml 10 £20.86
Enoxaparin 40mg/0.4 ml 10 £30.37
Enoxaparin 80mg/0.8 ml 10 £55.13
Enoxaparin 100mg/ml 10 £72.30
Ensure Supplement 250ml £2.39
Epimax cream 500 g £2.49
Epirubicin hydrochloride infusion 100mg/50 ml 1 £201.76
Ertapenem injection 1 g 10 £31.65
Erythromycin 250mg 28 £1.40
Esomeprazole 20mg 28 £2.28
Esomeprazole 40mg 28 £2.27
Exanatide 10 µg/0.04 ml 1 £81.89
Ezetimibe 10mg 28 £2.17
Felodipine 5 mg 28 £4.21
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TABLE 32 Unit costs of medications included in costing for health economic evaluation (continued )
Medication type Dose Pack size Unit cost
Felodipine 10mg 28 £5.66
Fentanyl patch 12 µg 5 £12.59
Fentanyl patch 25 µg 5 £17.99
Fentanyl patch 37.5 µg 5 £15.46
Fentanyl patch 50 µg 5 £33.66
Fentanyl patch 75 µg 5 £46.99
Fentanyl patch 100 µg 5 £57.86
Ferric carboxymaltose (Ferinject) 500 mg 5 £405.88
Ferric carboxymaltose (Ferinject) 1000 mg/20 ml 1 £154.23
Ferrous fumarate 210mg 84 £3.50
Ferrous fumarate 140mg/5 ml 200ml £0.72
Ferrous gluconate 300mg 28 £1.00
Ferrous sulphate 200mg 28 £1.06
Fexofenadine hydrochloride 120mg 30 £2.05
Filgrastim 30million units/ml 5 £263.52
Filgrastim £304.59
Finasteride 5 mg 28 £1.18
Fluconazole 50mg 7 £0.72
Fluconazole 200mg 7 £3.92
Fluconazole oral suspension 50mg/5 ml 35ml £25.50
Fluconazole IV 200mg/100 ml 5 £19.45
Fludrocortisone acetate 100 µg 30 £13.60
Fluoxetine 20mg 30 £0.93
Fluoxetine 40mg 30 £1.80
Fluticasone 50 µg 120 £6.53
Fluticasone (Flixotide Accuhaler) 250 µg 60 puffs £25.51
Fluticasone fuorate nasal spray (Avamys) 27.5 µg 120 puffs £6.44
Fluticasone/vilanterol (Relvar Ellipta) inhaler 92 µg/22 µg 30 doses £22.00
Folic acid 5 mg 28 £0.73
Forceval vitamins 30 £9.92
Formoterol Easyhaler 12 µg 120 £23.75
Fortijuce 200ml £2.02
Fortisip Compact 500ml £5.32
Fortisip Standard 200ml £1.12
Fostair NEXTHaler 100/6 µg 120 puffs £29.32
Fresubin Energy 200ml £1.40
Fultium D3 oral solution 3000 units/ml 100 ml £144.00
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TABLE 32 Unit costs of medications included in costing for health economic evaluation (continued )
Medication type Dose Pack size Unit cost
Fultium D3 capsules 800 units 30 £3.60
Furosemide IV 20mg/2 ml 10 £13.42
Furosemide tablets 20 mg 28 £1.48
Furosemide tablets 40 mg 28 £2.09
Furosemide 20mg/5 ml 150ml £14.81
Gabapentin 300mg 100 £3.15
Gaviscon Advance 5ml 500ml £5.12
Gentamicin IV 360mg/120 ml 20 £174.07
Gliclazide 40mg 28 £1.53
Gliclazide 80mg 28 £0.82
Glycerol suppository 4 g 12 £1.16
Glyceryl trinitrate transdermal patch 5 mg/24 hours 28 £12.77
Glyceryl trinitrate spray 400 µg/dose 200 £3.83
Haloperidol 500 µg 28 £29.88
Haloperidol 1.5 mg 28 £14.81
Haloperidol injection 5 mg/1 ml 10 £35.00
Hexetidine (Gelclair) 200 ml £2.92
Humalog (insulin lispro) 100 units/ml 10 ml £16.61
Humulin M3 insulin 100 units/ml 1 £15.68
Hydrocortisone injection 100mg/ml 5 £10.60
Hydroxocobalamin injection 1 mg/1 ml 5 £10.60
Hydroxychloroquine 200mg 60 £3.70
Hylo Tear 0.10% 10ml £8.50
Hyoscine butylbromide tablet 10 mg 56 £3.00
Hyoscine butylbromide injection 20mg/ml 10 £2.92
Hyoscine hydrobromide patch 1mg/72 hours 2 £12.87
Hypovase (prazosin) 500 µg 60 £2.69
Ibuprofen 200mg 16 £1.18
Ibuprofen 400mg 24 £0.91
Ibuprofen 10% gel (Fenbid Forte) 100 g £4.00
Ibuprofen oral suspension 100mg/5 ml 100 £1.49
Indoramin 25mg 84 £60.26
Influenza vaccine Prefilled 1 £8.00
Inositol nicotinate 1 g 50 £13.12b
Ipratropium bromide (Atrovent inhaler) 20 µg/puff 200 £5.56
Irbesartan 300mg 28 £2.77
Iron dextran infusion 500mg/10 ml 2 £79.70
Isosorbide mononitrate 10mg 56 £1.07
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TABLE 32 Unit costs of medications included in costing for health economic evaluation (continued )
Medication type Dose Pack size Unit cost
Isosorbide mononitrate 40mg 56 £1.30
Isotard 25XL (iIsosorbide mononitrate) 25 mg 28 £6.75
Isotard 50XL (isosorbide mononitrate) 50 mg 28 £6.75
Isotard 60XL (isosorbide mononitrate) 60 mg 28 £10.50
Ispaghula Husk Granules (Fybogel) 3.5 g 30 £2.83
Ivabradine 2.5 mg 56 £91.75
Januvia (sitagliptin) 100 mg 28 £33.26
Ketorolac trometamol 0.5% eye drops 5 mg/ml 5 ml £3.57
Lacidipine 2 mg 28 £2.64
Lacidipine 4 mg 28 £2.57
Lacri-lube eye ointment 3.5 g £3.01
Lactulose oral solution 3.1–3.7 g/5 ml 500ml £2.40
Lactulose oral solution (sachets) 10 g/15 ml 10 £2.51
Lansoprazole 15mg 28 £0.76
Lansoprazole 30mg 28 £1.01
Lansoprazole orodispersible 15 mg 28 £3.12
Latanoprost eye drops 50 µg/ml 2.5 ml £7.92
Laxido oral powder 30 £3.84
Lercanidipine hydrochloride 20mg 28 £3.83
Letrozole 2.5 mg 14 £0.95
Levemir insulin detemir 100 units/ml 5 £42.00
Levomepromazine 25mg 84 £20.26
Levomepromazine IV 25mg/ml 10 £20.13
Levonorgestrel/ethinylestradiol 150 µg/30 µg 63 £2.82
Levothyroxine 12.5 µg 28 £1.78
Levothyroxine 25 µg 28 £1.63
Levothyroxine 50 µg 28 £1.03
Levothyroxine 75 µg 28 £2.73
Levothyroxine 100 µg 28 £1.03
Levothyroxine oral solution 25 µg/5 ml 100ml £94.99
Levothyroxine oral solution 125 µg/5 ml 100ml £185.00
Lisinopril 2.5 mg 28 £0.80
Lisinopril 5 mg 28 £0.80
Lisinopril 10 mg 28 £0.80
Lisinopril 20 mg 28 £0.88
Loperamide hydrochloride 2 mg 30 £1.83
Loratadine 10mg 30 £0.88
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TABLE 32 Unit costs of medications included in costing for health economic evaluation (continued )
Medication type Dose Pack size Unit cost
Lorazepam 500mg 28 £12.00
Lorazepam 1mg 28 £3.38
Losartan 50mg 28 £2.07
Losartan 100mg 28 £1.95
Lumigan 0.1% eye drops (bimatoprost) 100 µg/ml 3 ml £11.71
Macrogol 3350 powder 85 g/l 28 £29.85
Magnesium aspartate powder 243mg 10 £8.95
Magnesium Hydroxide 79mg/ml 500ml £5.31
Mebeverine 200mg 60 £9.22
Meropenem IV 500mg 10 £88.90
Meropenem IV 1 g 10 £206.28
Metformin (Sukkarto SR) 500 mg 56 £2.38
Metformin (Glucient SR, Glucophage SR) 500mg 56 £4.00
Metformin (Glucient SR) 1 g 56 £6.40
Metformin (oral solution) 500 mg/5 ml 150ml £6.80
Metoclopramide hydrochloride 10mg 28 £0.61
Metoclopramide hydrochloride oral solution 5 mg/5 ml 150ml £19.77
Metoclopramide hydrochloride IV 10mg/2 ml 10 £2.65
Methotrexate 2.5 mg 28 £1.77
Metronidazole 400mg 21 £5.47
Metronidazole IV 500mg/100 ml 20 £63.86
Microlax enema 5ml 12 £4.87
Midazolam injection 2 mg/2 ml 10 £6.00
Midazolam 5mg/5 ml 10 £9.63
Midazolam injection 10mg/2 ml 10 £6.43
Mirabegron 50mg 30 £29.00
Mirtazapine 15mg 28 £1.23
Mirtazapine 30mg 28 £7.28
Misoprostol (Cytotec) 200 mg 60 £10.03
Montelukast 10 mg 28 £1.17
Morphine (Sevredol) 10 mg 56 £5.31
Morphine (Sevredol) 20 mg 56 £10.61
Morphine sulphate oral solution 10mg/5 ml 300ml £5.32
Morphine sulphate injection 1 mg/1 ml 10 £31.90
Morphine sulphate Injection 5 mg/5 ml 10 £44.00
Morphine sulphate Injection 10mg/ml 10 £11.13
Morphine sulphate Injection 15mg/ml 10 £10.74
Morphine sulphate injection 20mg/ml 10 £68.95
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TABLE 32 Unit costs of medications included in costing for health economic evaluation (continued )
Medication type Dose Pack size Unit cost
Morphine sulphate infusion 50mg/50 ml 1 £5.78
Movicol Ready to Take 13.7 g 30 sachets £7.72
MST Continus 5 mg 60 £3.29
MST Continus 10mg 60 £5.20
MST Continus 15mg 60 £9.10
MST Continus 30mg 60 £12.47
MST Continus 60mg 60 £24.32
MST Continuous 100mg 60 £38.50
MST Continus modified-release granules 20 mg 30 sachets £24.58
Mucodyne (carbocisteine) 250 mg/5 ml 300ml £8.55
Multivitamin (Centrum assumed) £8.33a
Mupirocin cream 2% 20mg/1g 15 g £5.26
MXL capsules 90 mg 28 £22.04
Nebivolol 5 mg 28 £4.37
Nefopam hydrochloride 30mg 90 £7.77
Nicorandil 5 mg 60 £4.29
Nicotine Inhalator 15 mg 4 £4.87
Nicotine patch 7mg 7 £9.12
Nifedipine 10mg 56 £7.34
Nitrofurantoin 50mg 28 £8.21
Nitrofurantoin (Macrobid) 100 mg 14 £9.50
NovoMix 30 (biphasic insulin aspart) 100 units/ml 5 £29.89
Nutrison concentrated 500ml £5.87
Nystatin 100,000 units/ml 30 ml £2.03
Olmesartan 20mg 28 £1.52
Omeprazole 10mg 28 £0.82
Omeprazole 20mg 28 £0.83
Omeprazole 40mg 28 £2.24
Omeprazole infusion 40mg 5 £26.00
Ondansetrone 4mg 10 £9.94
Ondansetrone 8mg 10 £10.31
Ondansetrone oral solution 4 mg/5 ml 50ml £38.10
Ondansetrone injection 4 mg/2 ml 5 £29.97
Ondansetrone injection 8 mg/4 ml 5 £15.00
Oramorph 10mg/5 ml 300ml £5.32
Oramorph 20mg/ml 120ml £19.50
Oxazepam 10mg 28 £7.68
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TABLE 32 Unit costs of medications included in costing for health economic evaluation (continued )
Medication type Dose Pack size Unit cost
Oxybutynin hydrochloride 2.5 mg 56 £2.17
Oxycodone hydrochloride tablets 10 mg 56 £25.04
Oxycodon hydrochloride (OxyNorm) capsules 5 mg 56 £11.43
Oxycodon hydrochloride (OxyNorm) capsules 10 mg 56 £22.86
Oxycodone hydrochloride (OxyNorm) capsules 20 mg 56 £45.71
Oxycodone hydrochloride (OxyNorm) oral solution 5 mg/5 ml 250 £9.71
Oxycodone hydrochloride prolonged release 15mg 56 £19.06
Oxycodone hydrochloride modified release 5 mg 28 £12.52
Oxycodone hydrochloride modified release 10mg 56 £25.04
Oxycodone hydrochloride modified release 15mg 56 £38.12
Oxycodone hydrochloride modified release 20mg 56 £50.08
Oxycodone hydrochloride modified release 30mg 56 £76.23
Oxycodone hydrochloride modified release 40mg 56 £100.19
Oxycodone hydrochloride injection 20mg/2 ml 5 £16.00
Pabrinex 5 ml and 2 ml 20 £22.53
Palonosetron 500 µg 1 £55.89
Pancreatine (Creon) 25,000 units 100 £28.25
Pantoprazole 40mg 28 £1.06
Paracetamol 250 mg/5 ml 100ml £1.75
Paracetamol 500 mg 100 £1.81
Paracetamol 1 g 100 £2.49
Paracetamol orodispersible 250mg 24 £4.12
Paracetamol soluble 500mg 100 £6.80
Paracetamol soluble 1 g 50 £6.59
Paracetamol oral solution 250mg/5 ml 200ml £4.40
Paracetamol oral solution 500mg/5 ml 200ml £18.00
Paracetamol infusion 1 g/100 ml 10 £12.00
Parenteral nutrition supplement Infusion 1 £3.55
Paroxetine 30mg 30 £1.79
Peppermint oil capsules 0.2 ml 84 £7.04
Peptac Liquid 500ml £1.95
Perindopril erbumine 2mg 30 £2.04
Perindopril erbumine 8mg 30 £2.53
Phenytoin 300mg 28 £9.11
Phorpain 5% ibuprofen gel 50 mg/g 100 g £2.26
Phosphate Sandoz 1.93 6g 100 £19.39
Pizotifen 500 µg 28 £1.02
Potassium chloride 600mg 100 £13.12b
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TABLE 32 Unit costs of medications included in costing for health economic evaluation (continued )
Medication type Dose Pack size Unit cost
Pramipexole 0.088 mg 30 £5.18
Prednisolone 1mg 28 £0.63
Prednisolone 5mg 28 £0.74
Prednisolone 10mg 28 £1.77
Pregabalin 25 mg 56 £2.79
Pregabalin 50 mg 84 £3.25
Pregabalin 75 mg 56 £3.25
Pregabalin 100mg 84 £4.27
Pregabalin 150mg 56 £3.67
Pregabalin 300mg 56 £5.55
Probiotic tabletsb 60 £9.49†
Pro-Cal Shot 720ml 1 £15.26
Prochlorperazine 5 mg 28 £0.73
Prochlorperazine oral solution 5 mg/5 ml 100ml £3.34
Propranolol hydrochloride 40mg 28 £2.05
Propranolol hydrochloride 80mg 56 £2.98
Propranolol hydrochloride oral solution 10mg/5 ml 150ml £28.45
ProSource Plus 30ml 100 £149.08
Prostap SR DCS (leuprorelin acetate) 3.75 mg 1 £75.24
Prostap 3 DCS (leuprorelin acetate) 11.25 mg 1 £225.72
Quinine bisulphate 300mg 28 £2.78
Qvar 50 Inhaler (beclometasone) 50 µg/puff 200 puffs £3.70
Ramipril 1.25 mg 28 £1.93
Ramipril 2.5 mg 28 £4.24
Ramipril 5 mg 28 £4.63
Ramipril 10 mg 28 £5.12
Ramipril oral solution 2.5 mg/5 ml 150ml £96.00
Ranitidine 75mg 12 £2.80
Ranitidine 150mg 60 £1.07
Ranitidine 300mg 30 £1.08
Ranitidine 75mg/5 ml 300ml £6.39
Ranitidine injection 50mg/2 ml 5 £4.40
Rivaroxaban 10mg 30 £54.00
Rivaroxaban 15mg 28 £50.40
Rivaroxaban 20mg 28 £50.40
Rolapitant 90 mg 2 £47.42
Rosuvastatin 10 mg 28 £1.41
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TABLE 32 Unit costs of medications included in costing for health economic evaluation (continued )
Medication type Dose Pack size Unit cost
Rosuvastatin 20 mg 28 £2.01
Salbutamol 5 mg/2.5 ml 20 £3.90
Salbutamol Easyhaler 100 µg 200 puffs £3.31
Salbutamol Easyhaler 200 µg 200 puffs £6.63
Salbutamol Airomir Autohaler 100 µg 200 puffs £6.02
Sando K potassium 600/400 mg 100 £9.95
Sativex oromucosal spray (cannabis extract) 270 £375.00
Scandishake 85 g 6 £15.54
Secura cream 3.25 oz £6.60a
Seebri Breezhaler (glycopyrronium) 44 µg 30 £27.50
Senna 7.5 mg 60 £2.01
Senna (Senokot MaxStrength tablets) 15 mg 48 £5.69
Senna (Senokot) 7.5 mg/5 ml 500ml £4.76
Seretide 250 Evohaler 25/250 µg 120 £29.32
Seretide 250 Accuhaler 50/250 µg 60 £35.00
Sertraline 50mg 28 £0.82
Sertraline 100mg 28 £1.08
Simeticone (Maalox) 250 ml £2.91
Simvastatin 10 mg 28 £0.90
Simvastatin 20 mg 28 £0.75
Simvastatin 40 mg 28 £0.87
Sodium acid phosphate/sodium phosphate enema 1 £3.98
Sodium bicarbonate 500mg 56 £1.47
Sodium chloride 0.009 1 l £3.59
Sodium chloride with glucose 5%/0.45% 500ml £2.34
Sodium chloride (nebuliser solution) 4 ml 60 £24.30
Sodium chloride nebuliser liquid 2.5 ml 20 £4.36
Sodium picosulfate 5 mg/5 ml 300ml £7.10
Solifenacin succinate 5 mg 30 £27.62
Solpadeine (co-codamol) 500 mg/12.8 mg 20 £3.61
Solpadol (co-codamol) 30/500 mg 30 £1.09
Spatone 560ml 28 £12.00a
Spironolactone 25mg 28 £1.05
Sucralfate (unlicensed) 1 g 100 £31.71c
Sulfasalazine 500mg 112 £8.12
Sulfasalazine 250mg/5 ml 500ml £44.51
Symbicort 100/6 Turbohaler 100/6 µg 120 puffs £28.00
Symbicort 200/6 Turbohaler 200/6 µg 120 puffs £28.00
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TABLE 32 Unit costs of medications included in costing for health economic evaluation (continued )
Medication type Dose Pack size Unit cost
Tamsulosin hydrochloride 400 µg 30 £10.47
Tazocin IV 4 g/0.5 g 1 £15.17
Teicoplanin 200mg 1 £3.93
Teicoplanin 400mg 1 £7.32
Temazepam 10mg 28 £3.00
Testosterone (Testogel) 50 mg/5 g 30 £31.11
Terbinafine 250mg 14 £1.20
Terbutaline 500 µg 120 puffs £8.30
Theophylline (Uniphylline Continus) 400 mg 56 £5.65
Thiamine 50mg 100 £3.99
Thiamine 100mg 100 £5.74
Ticagrelor 90 mg 56 £54.60
Timolol maleate (Timoptol 0.5%) 5 mg/ml 5 ml £3.12
Tinzaparin sodium 3500 units/0.35 ml 10 £27.71
Tinzaparin sodium 10,000 units/0.5 ml 10 £59.50
Tinzaparin sodium 12,000 units/0.6 ml 10 £71.40
Tiotropium (Braltus) inhaler 10 µg/dose 30 £25.80
Tiotropium (Spritiva Respimat) inhaler 2.5 µg/dose 60 £23.00
Tiotropium bromide (Spiriva) 18 µg 30 £33.50
Tramadol hydrochloride (Zydol) 50 mg 60 £4.60
Tramadol hydrochloride Injection 100mg/2 ml 5 £4.00
Tranexamic acid 500mg 60 £5.42
Tranexamic acid injection 500mg/5 ml 10 £15.47
Travadan (travoprost) eye drops 40 µg/ml 2.5 ml £3.24
Trazodone hydrochloride 100mg/5 ml 120 £185.45
Trimethoprim 200mg 14 £0.89
Udder cream 340 g £8.89a
Ultibro Breezhaler (glycopyrronium/indacaterol) 85 mg/43 mg 30 £32.50
Uniphyllin Continus 200mg 56 £2.96
Uniphyllin Continus 400mg 56 £5.65
Urea moisturising cream 50mg/1 g 500 £14.99
Ursodeoxycholic acid 300mg 60 £55.08
Venlafaxine 75mg 56 £3.40
Ventolin Evohaler (salbumatol) 100 µg/puff 200 puffs £1.50
Ventolin Accuhaler (salbumatol) 200 µg/puff 60 puffs £3.60
Viscopaste bandage 7.5 cm × 6m 1 £3.78
Vitamin B compound 15/1/1 mg 28 £26.63
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TABLE 32 Unit costs of medications included in costing for health economic evaluation (continued )
Medication type Dose Pack size Unit cost
Vitamin K (menadiol phosphate) 5 mg 100 £204.49
Warfarin sodium 500 µg 28 £1.34
Warfarin sodium 1mg 28 £0.67
Warfarin sodium 3mg 28 £0.74
Warfarin sodium 5mg 28 £0.78
Xerotin (mucilage) 100 ml £6.86
Zimovane (zopiclone) 7.5 mg 28 £0.87
Zolpidem tartrate 10mg 28 £0.92
Zomorph 10mg 60 £3.47
Zomorph 30mg 60 £8.30
Zomorph 60mg 60 £16.20
Zopiclone 3.75 mg 28 £0.88
Zopiclone 7.5 mg 28 £0.87
Zoton FasTab (Lansoprazole) 15 mg 28 £2.90
Zoton FasTab (Lansoprazole) 30 mg 28 £4.26
Source: British National Formulary 201963 (unless otherwise indicated).
a Amazon.co.uk (10 August 2019).
b www.hollandandbarrett.com/shop/ (accessed 3 September 2019).
c www.pharmacychecker.com/sucralfate/ (accessed 16 September 2019; converted from US$45.50).















SA14 All parameters Complete cases used
SA15 All parameters All available cases used
SA16 All parameters post 12 weeks Weeks 13 to 16 used
SA17 All parameters post 12 weeks Weeks 13 to 28 used
ID, identifier; SA, sensitivity analysis.
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TABLE 34 Transition probabilities used in the model based on actual trial dysphagia and survival data
Model stage Arm Parameter Used
Weeks 1 and 2 Both Probability of death 0.01
Total = 199
Weeks 3 and 4 EBRT Probability of death 0.03
Usual
care
Probability of death 0.05
Total = 193
Entering Markov cycles EBRT Probability of starting in ‘ability to swallow improved’ stage 0.77
Probability of starting in ‘progression/not improved’ stage 0.16




Probability of starting in ‘ability to swallow improved’ stage 0.76
Probability of starting in ‘progression/not improved’ stage 0.13
Probability of death 0.11
Total = 91
Markov: ability to swallow
improved – weeks 4 to 8
EBRT Probability of remaining in ability to swallow improved 0.92
Probability of progression of dysphagia (move to progressive state) 0.06




Probability of remaining in ability to swallow improved 0.91
Probability of progression of dysphagia (move to progressive state) 0.06
Probability of death (move to absorbing state) 0.03
Total = 61
Markov: dysphagia
progression – weeks 4 to 8
EBRT Probability of improvement (move to improved ability to swallow state) 0.34
Probability of remaining in progressive state 0.63




Probability of improvement (move to improved ability to swallow state) 0.21
Probability of remaining in progressive state 0.75
Probability of death (move to absorbing state) 0.04
Total = 19
Markov: ability to swallow
improved – weeks 8 to 12
EBRT Probability of remaining in ability to swallow improved 0.90
Probability of progression of dysphagia (move to progressive state) 0.05




Probability of remaining in ability to swallow improved 0.91
Probability of progression of dysphagia (move to progressive state) 0.06
Probability of death (move to absorbing state) 0.03
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TABLE 34 Transition probabilities used in the model based on actual trial dysphagia and survival data (continued )




weeks 8 to 12
EBRT Probability of improvement (move to improved ability to swallow state) 0.20
Probability of remaining in progressive state 0.70




Probability of improvement (move to improved ability to swallow state) 0.15
Probability of remaining in progressive state 0.78
Probability of death (move to absorbing state) 0.07
Total = 18
Markov: ability to swallow
improved – weeks 12
onward
EBRT Probability of remaining in ability to swallow improved 0.82
Probability of progression of dysphagia (move to progressive state) 0.08
Probability of death (move to absorbing state) 0.09
Usual
care
Probability of remaining in ability to swallow improved 0.88
Probability of progression of dysphagia (move to progressive state) 0.06
Probability of death (move to absorbing state) 0.06
Markov: dysphagia
progression – weeks 12
onward
EBRT Probability of improvement (move to improved ability to swallow state) 0.11
Probability of remaining in progressive state 0.79
Probability of death (move to absorbing state) 0.09
Usual
care
Probability of improvement (move to improved ability to swallow state) 0.15
Probability of remaining in progressive state 0.73
Probability of death (move to absorbing state) 0.12
TABLE 35 Utility values used in the model based on trial data
Model stage Arm Mean SD n
Weeks 1 and 2 Both 0.6141 0.2831 199
Weeks 3 and 4 EBRT 0.5610 0.3214 91
Usual care 0.5860 0.3020 91
Markov: ability to swallow improved – weeks 5 to 8 EBRT 0.6090 0.2957 75
Usual care 0.6006 0.2896 78
Markov: dysphagia progression – weeks 5 to 8 EBRT 0.3359 0.3505 16
Usual care 0.4980 0.3688 13
Markov: ability to swallow improved – weeks 9 to 12 EBRT 0.5439 0.3149 65
Usual care 0.6602 0.2437 61
Markov: dysphagia progression – weeks 9 to 12 EBRT 0.4624 0.3090 17
Usual care 0.5230 0.3160 19
Markov: ability to swallow improved – weeks 13 onwards EBRT 0.6264 0.2634 148
Usual care 0.6659 0.1718 220
Markov: dysphagia progression – weeks 13 onwards EBRT 0.5674 0.3226 72
Usual care 0.6239 0.1924 65
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Second week of transition
FIGURE 28 Comparing the transition probabilities for patients who begin in a worsening or improving state of dysphagia

























Second week of transition
FIGURE 29 Comparing the transition probabilities for patients who begin in a worsening or improving state of dysphagia
and the different probabilities for the next state: usual care.
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